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Abstract 
 
Low levels of survival motor neuron (SMN) protein cause the autosomal recessive 
neurodegenerative disease spinal muscular atrophy (SMA), through mechanisms that 
are poorly defined. SMN protein is ubiquitously expressed, however the major 
pathological hallmarks of SMA are focused on the neuromuscular system, including 
a loss of lower motor neurons in the ventral horn of the spinal cord and atrophy of 
skeletal muscle. At present there is no cure for SMA. Most research to date has 
focused on examining how low levels of SMN lead to pathological changes in motor 
neurons, therefore the contribution of other tissues, for example muscle, remains 
unclear. In this thesis I have used proteomic techniques to identify intrinsic 
molecular changes in muscle of SMA mice that contribute to neuromuscular 
pathology in SMA. I demonstrate significant disruption to the molecular composition 
of skeletal muscle in pre-symptomatic SMA mice, in the absence of any detectable 
degenerative changes in lower motor neurons and with a molecular profile distinct 
from that of denervated muscle. Functional cluster analysis of proteomics data and 
phospho-histone H2AX labelling of DNA damage revealed increased activity of cell 
death pathways in SMA muscle. In addition robust up-regulation of VDAC2 and 
down-regulation of parvalbumin was confirmed in two mouse models of SMA as 
well as in patient muscle biopsies. Thus intrinsic pathology of skeletal muscle is an 
important event in SMA. I then used proteomics to identify individual proteins in 
skeletal muscle of SMA that report directly on disease status. Two proteins, GRP75 
and calreticulin, showed increased expression levels over time in different muscles as 
well as in skin samples, a more accessible tissue for biopsies in patients. Preliminary 
results suggest that GRP75 and calreticulin can be detected and measured in SMA 
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patient muscle biopsies. These results show that proteomics provides a powerful 
platform for biomarker identification in SMA, revealing GRP75 and calreticulin as 
peripherally accessible potential protein biomarkers capable of reporting on disease 
progression in muscle as well as in skin samples. Finally I identified a role for 
ubiquitin-dependent pathways in regulating neuromuscular pathology in SMA. 
Levels of ubiquitin-like modifier activating enzyme 1 (UBA1) were reduced in 
spinal cord and skeletal muscle tissue of SMA mice. Dysregulation of UBA1 and 
subsequently the ubiquitination pathways led to the accumulation of β-catenin. I 
show here that pharmacological inhibition of β-catenin robustly ameliorates 
neuromuscular pathology in animal models of SMA. Interestingly, downstream 
disruption of β-catenin was restricted to the neuromuscular system in SMA mice. 
Pharmacological inhibition of β-catenin failed to prevent systemic pathology in 
organs. Thus disruption of ubiquitin homeostasis, with downstream consequences for 
β-catenin signalling, contributes to the pathogenesis of SMA, thereby highlighting 
novel therapeutic targets for this disease. 
  
	   VI	  
Table of contents 
 
 
Declaration          I 
Acknowledgements         II 
Abstract          IV 
Table of contents         VI 
List of abbreviations        XII 
 
Chapter 1 Introduction 
1.1 Autosomal recessive spinal muscular atrophy    1 
1.1.1 Clinical manifestations      1 
1.1.2 Genetics        2 
1.1.3 Role of SMN protein      4 
 1.2 Neuromuscular system       5 
                   1.2.1 The neuromuscular junction     5 
        1.2.2 Motor neuron pathfinding      6 
        1.2.3 Development of muscle      7 
                   1.2.4 Formation and maintenance of the neuromuscular junction  8 
 1.3 Neuromuscular pathology in SMA      10 
        1.3.1 Selective vulnerability of neuromuscular junctions    12 
 1.4 The contribution of muscle to SMA pathology    14 
 1.5 Are other tissues affected in SMA?     17 
        1.5.1 Heart defects       17 
                   1.5.2 Vascular defects       18 
        1.5.3 Metabolic abnormalities      18 
 1.6 Therapies for SMA       19 
        1.6.1 SMN2 gene activation treatment     19 
        1.6.2 Stabilization of SMNdelta7 transcript                21
        1.6.3 SMN2 alternative splicing modulation    21 
        1.6.4 Neuroprotective agents      22 
        1.6.5 Gene therapy       23 
        1.6.6 Stem cell therapy       24 
 1.7 Biomarkers for SMA       29 
 1.8 Pathways involved in SMA independent of SMN    30 
        1.8.1 Plastin-3        30 
	   VII	  
        1.8.2 Myostatin pathway      31 
        1.8.3 Ubiquitination pathway      31 
 1.9 Aims         32 
  
Chapter 2 Materials and methods  
 2.1 Animals and colony maintenance      33 
 2.2 Human tissue        34 
 2.3 Genotyping        35 
 2.4 Surgery         37 
 2.5 Muscle, spinal cord and organ preparation     37 
               2.5.1 Synaptosome preparation      38 
 2.6 Immunohistochemistry       39 
 2.7 Image analysis        39 
 2.8 Quantification of endplates      40 
 2.9 H2AX cell counts        41 
 2.10 Muscle fiber diameter measurements     41 
 2.11 Protein level quantification      41 
 2.12 Quantitative fluorescent (Li-COR) western blotting   42 
 2.13 Real-time PCR        43 
 2.14 In vitro experiments       44 
            2.14.1 Cells        44 
   2.14.1.1 UBEI-41 treatment     44 
   2.14.1.2 UCH-L1 inhibitor treatment    45 
 2.15 In vivo drug treatment       45 
2.16 Physical test and general health assessment    46 
2.17 Ex vivo vulnerability essay      46 
2.18 Proteomic techniques       47 
         2.18.1 iTRAQ        47 
         2.18.2 Label-free proteomics                  49
 2.19 In silico protein network analysis      50 





	   VIII	  
Chapter 3 Muscle pathology in mouse models of SMA 
3.1 Introduction        52 
3.2 Results         55 
3.2.1 Characterization of the caudal and rostral band of levator   55 
auris longus 
3.2.2 The rostral band of levator auris longus allows examination of        59 
intrinsic changes to skeletal muscle in SMA 
3.2.3 Label-free proteomics analysis of the rostral LAL reveals   64 
molecular alterations to skeletal muscle in pre-symptomatic severe  
SMA mice 
      3.2.4 Evidence for increased apoptotic cell death in SMA muscle  73 
3.2.5 Changes in the molecular composition of skeletal muscle in SMA  75 
mice are distinct from those elicited following acute or chronic  
denervation 
     3.2.6 Molecular pathology of muscle is recapitulated in SMA patients 78 
3.2.7 Molecular pathology of skeletal muscle is reversed by treatment 80  
with the FDA-approved histone deacetylase inhibitor, SAHA 
3.3 Discussion         84 
  3.3.1 Overview of results      84 
   3.3.2 Muscle is an important pathological target in SMA   84 
3.3.3 Proteins identified are known to be involved in other   86 
neuromuscular diseases 
3.3.4 Widespread protein changes in muscles of SMA mouse models  86 
and SMA patients  
3.3.5 Evidence of increased levels of cell death in muscle of SMA mice 88 
3.3.6 HDAC inhibitors revers altered molecular composition of skeletal 88  
muscle in SMA 
 
Chapter 4 Biomarker identification in mouse models of SMA 
4.1 Introduction        90 
4.2 Results          93 
4.2.1 Label-free proteomics analysis reveals a list of 23 putative   93 
biomarkers of disease status in skeletal muscle from severe SMA mice  
4.2.2 Validation of putative protein biomarkers in the rostral band of  99 
levator auris longus 
	   IX	  
4.2.3 Validation of proteins in the Taiwanese mouse model of SMA      100 
4.2.4 Preliminary investigation suggests that levels of GRP75 and         102     
calreticulin are increased in SMA patient muscle biopsies 
4.2.5 Altered levels of GRP75 and calreticulin can be detected in skin   104 
biopsies from SMA mice 
4.2.6 Levels of GRP75 and calreticulin in skin from Taiwanese SMA    107  
mice change over time 
4.2.7 GRP75 and calreticulin respond to treatment with the HDACi       108 
TSA  
4.3 Discussion                  111 
  4.3.1 Overview of results               111 
4.3.2 Proteomics technology could be a powerful tool for biomarker      112 
discovery 
4.3.3 Advantages of SMA mouse models in biomarker identification     113
 4.3.4 GRP75 and/or calreticulin as a potential biomarker for SMA         114 
  4.3.5 Preliminary observations in human biopsies            115 
  4.3.6 Future investigations               115
   
Chapter 5 Disruption of ubiquitin and β-catenin signalling in SMA 
5.1 Introduction                 117 
5.2 Results                   119 
5.2.1 SMN protein is localised to axonal and synaptic compartments     119 
of neurons in vivo 
5.2.2 Assessing the functional consequences of SMN expression in       125 
synaptic mitochondria 
5.2.3 SMN protein is required for normal accumulation of            127 
β-actin mRNA at the synapse 
5.2.4 iTRAQ proteomic screen reveals disruption in synaptic           128 
proteome of SMA mice 
5.2.5 UBA1 levels are also disrupted in the neuromuscular system        131 
5.2.6 Disruption of ubiquitin homeostasis directly correlates with         133 
SMN levels, and is reversible by treatment with Trichostatin A 
5.2.7 Deregulation of UBA1 protein levels leads to accumulation         137 
of β-catenin in vitro 
 
	   X	  
5.2.8 Deregulation of UBA1 protein levels leads to accumulation of     139  
β-catenin in zebrafish and can be rescued by inhibition of β-catenin 
5.2.9 Inhibition of β-catenin signalling ameliorates neuromuscular       141 
pathology, but not systemic pathology in Taiwanese SMA mice 
5.2.10 UCH-L1 enzyme regulates levels of β-catenin          146 
5.2.11 Β-catenin protein levels are increased in muscle biopsies          150 
from SMA patients 
5.3 Discussion                153 
  5.3.1 Overview of results             153
  5.3.2 SMN protein is localised at the synapse and synaptic          153 
mitochondria 
5.3.3 Β-actin accumulation in the synapse is disrupted in a mouse        155 
model of SMA in vivo 
5.3.4 A role for the ubiquitin/proteasome pathway in SMA                   156 
 
Chapter 6 A dopamine agonist does not ameliorate neuromuscular pathology 
in a mouse model of SMA 
6.1 Introduction               160
 6.2 Results                162
   6.2.1 Treatment with NPA does not increase weight of SMA mice       162 
6.2.2 No improvement of neuromuscular pathology in SMA mice        163 
treated with NPA 
6.3 Discussion                166
  6.3.1 Overview of results             166 
 6.3.2 Future work              166
   
Chapter 7 General discussion 
 7.1 Overview of results              168 
 7.2 The importance of a new role for SMN protein           170 
7.3 Proteomics techniques in neuroscience research           172 
7.4 Ubiquitin pathology in neurodegenerative disease                                    175 
 7.5 Conclusion                 176 
 
References                 177
  
	   XI	  
 
Appendices                 199 
 Appendix 1 Co-immunoprecipitation of Gemin5 and SMN           199 
Appendix 2 Deregulation of UBA1 protein levels leads to accumulation      200  
of β-catenin in zebrafish and can be rescued by inhibition of β-catenin 
Appendix 3 Motor axons/nerves are abnormal in zebrafish embryos           202 
that are treated with smn morpholinos 
 Appendix 4 List of publications              203 
   
  
	   XII	  
Abbreviations 
 
ACh    Acetylcholine 
AChR    Acetylcholine receptor 
aCSF   Artificial cerebrospinal fluid 
ALS    Amyotrophic lateral sclerosis 
ASO    Antisense oligonucleotide 
BCA    Bicinchoninic acid (assay) 
BTX    Bungarotoxin 
CNS    Central nervous system 
DeSyn   Delayed synapsing 
DMSO   Dimethyl sulfoxide 
FaSyn    Fast synapsing 
FDB    Flexor digitorum brevis 
FITC   Fluorescein isothiocyanate 
GRP75  Stress-protein 70 
HDACi   Histone deacytelase inhibitor  
IPI   International protein index 
IPA   Ingenuity pathway analysis 
iTRAQ  isobaric Tags for Relative and Absolute Quantitation 
KO   Smn-/-;SMN2 mouse  
LAL    Levator auris longus 
LC-MS  Liquid chromatography–mass spectrometry    
Mgf   Mascot generic file 
MND    Motor neuron disease 
	   XIII	  
MuSK   Muscle-specific receptor tyrosine kinase 
NMJ    Neuromuscular junction 
P    Postnatal (i.e. P5 = postnatal day 5) 
PAGE   Polyacrylamide gel electrophoresis 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PFA   Paraformaldehyde 
qRT-PCR   quantitative Reverse Transcription polymerase chain reaction 
RIPA   Radio-immunoprecipitation assay 
RRBP1  Ribosome-binding protein 1 
SAHA   Suberoylanilide hydroxamic acid 
SDS    Sodium dodecyl sulfate 
SMA    Spinal muscular atrophy 
Smn/SMN/SMN  Murine/human survival motor neuron gene/protein 
snoRNP  Nucleolar ribonucleoproteins 
snRNP   Small nuclear ribonucleoproteins 
TCPB   T-complex protein 1 subunit beta 
TRITC   Tetramethylrhodamineisothiocyanate 
TSA   Trichostatin A 
TVA    Transversus abdominis 
UBA1   Ubiquitin-like modifier activating enzyme 1 
UCL-l1  ubiquitin carboxyl-terminal esterase L1 
VDAC2  Voltage-dependent anion-selective channel protein 2 
WT   Wild-type 
	   1	  
 
Chapter 1  
Introduction 
 
1.1 Autosomal recessive spinal muscular atrophy 
 
Motor neuron disease (MND) is a group of progressive diseases that result from the 
degeneration and death of the large motor neurones in the brain and spinal cord. This 
leads to muscle weakness and ultimately paralysis, and in severe cases is fatal within 
a few years after diagnosis (Rezania and Roos 2013). Autosomal recessive proximal 
spinal muscular atrophy (SMA), first described by Werdnig and Hoffman in the late 
19th century, is a childhood form of motor neuron disease. It is the most common 
genetic cause of infant death in the western world, with an incidence of one in 6000-
10000 and with a carrier frequency of one in 50 (Pearn 1978; Feldkotter et al. 2002). 
 
1.1.1 Clinical manifestations 
There are three forms of childhood onset SMA based on the age of onset and the 
maximum motor milestone the patients achieve. Type I SMA (also known as 
Werdnig-Hoffmann disease) is the most severe and common type and is 
characterized by infantile hypotonia during the first 6-12 months of life (Pearn 1978; 
Markowitz et al. 2004). These patients never achieve the ability to sit unaided and 
most patients die within two years, because their intercostal muscles (found in the 
chest wall) are strongly affected, resulting in severe breathing problems and 
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increased risk of infection. With respiratory support patients can survive for more 
than two years (Lunn and Wang 2008).  
 
Type II SMA patients are able to sit unaided but fail to walk independently. The 
onset for this type is usually between 6-18 months. These patients often develop 
kyphoscoliosis, which is an abnormal curvature of the spine in both the coronal as 
well as the sagittal plane (Talbot 1999; Lunn and Wang 2008).  
 
Type III SMA (also known as Kugelberg-Welander disease) patients develop 
weakness after 18 months of age. Most patients achieve all major motor milestones, 
such as independent walking. However some might need a wheelchair in childhood, 
whereas others continue to walk until adulthood. Type III patients often develop 
scoliosis (Lunn and Wang 2008).  
 
In addition to these childhood onset forms of SMA there is also a type IV SMA. 
Patients with this form develop weakness in their twenties or thirties and their motor 
impairment is mild. They can live a relatively normal life (Zerres et al. 1995).  
 
1.1.2 Genetics 
Spinal muscular atrophy is caused by mutations in the survival motor neuron gene 
(SMN gene) resulting in loss of motor neurons from the ventral horn of the spinal 
cord. Linkage analysis studies have mapped the three childhood forms of SMA to 
chromosome 5q11.1-13.3 (Brzustowicz et al. 1990; Melki et al. 1990).  In 1995 the 
SMN gene was identified as the disease-causing gene by probing a human fetal brain 
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cDNA library with genomic DNA from the candidate region (Lefebvre et al. 1995). 
In addition, this group found that the SMN gene is duplicated within the 5q13 region 
(Lefebvre et al. 1995). In the human genome there is one telomeric copy (known as 
SMN1 gene) and several centromeric copies (known as SMN2 gene). The SMN2 gene 
differs from the SMN1 gene by five nucleotides (Lefebvre et al. 1995). In SMA 
patients both copies of the SMN1 gene are deleted or disrupted, however patients 
retain at least one of the SMN2 gene copies. In more than 95 % of cases, the patients 
have a homozygous deletion of the SMN1 gene. A small part manifests small 
intragenic mutations or undergoes gene conversions from SMN1 to SMN2. De novo 
mutations occur in 2 % of the patients, because 5q11.1-13.3 is an unstable region 
(Melki et al. 1994; Prior 2007).  
 
The number of SMN2 copies varies among individuals and in SMA patients there is a 
clear correlation between SMN2 copy number and disease severity. Studies have 
shown that between 80-95 % of type I SMA patients have one or two copies of the 
SMN2 gene. In type II SMA patients, 96 % have three copies of the SMN2 gene and 
in 96 % of type III SMA patients there are three or four copies (Feldkotter et al. 
2002; Mailman et al. 2002; Arkblad et al. 2009).  
 
One of the nucleotide differences between the SMN1 and the SMN2 gene is a C-to-T 
transition in an exonic splicing enhancer (ESE) located in exon7 of SMN2 (Lorson et 
al. 1999). This causes differential processing of the SMN1 and SMN2 pre-mRNAs, 
leading to exclusion of exon7 from the SMN2 messenger RNA (mRNA) transcripts 
and results in the production of a non-functional and rapidly degrading version of the 
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SMN protein that is normally produced by the SMN1 gene (Lorson and Androphy 
2000). However, in 10 % of the SMN2 mRNA transcripts exon7 is not spliced out 
and is subsequently translated into the normal full-length SMN protein (Lefebvre et 
al. 1995). This results in low levels of SMN protein in SMA patients.  
 
1.1.3 Role of SMN protein 
SMN protein is ubiquitously expressed, with particularly high levels in the central 
nervous system and in the liver. This reflects the fact that it plays a role in a 
fundamental activity required by all cells. In humans, SMN is a 294 amino acid long 
protein of about 38 kDA and is encoded by eight exons (Lefebvre et al. 1995). SMN 
is found in both the cytoplasm and in the nucleus of cells (Gubitz et al. 2004). In the 
nucleus, SMN protein is highly enriched within bodies called gems (Liu and 
Dreyfuss 1996). Gems are closely associated with Cajal bodies, which are known to 
contain high levels of factors that are involved in transcription and processing of 
many types of nuclear RNAs, for example small nuclear ribonucleoproteins 
(snRNPs), nucleolar ribonucleoproteins (snoRNPs) and RNA polymerases (Ogg and 
Lamond 2002; Gall 2003). However, they are distinct nuclear structures. In the gems 
SMN forms a complex with a group of proteins called gemins. These include gemins 
2 – 7 (for references see review (Gubitz et al. 2004)), which have also been found in 
the cytoplasm. The SMN complex interacts with several proteins that are involved in 
diverse aspects of RNA processing, including Sm proteins and Sm-like proteins of 
the snRNPs, which are essential components in the splicing machinery (Liu et al. 
1997). These observations led to the hypothesis that SMN plays an important role in 
many aspects of cellular RNA metabolism.     
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However, studies have suggested a different, specific role for SMN in the motor 
neurons, since these are the cells that are primarily affected in SMA. In a neuronal 
cell culture SMN protein was identified in growth cones and filopodia-like structures, 
suggesting a role for SMN in neurite outgrowth (Fan and Simard 2002). Growth 
cones are dynamic structures that respond to intra- and extra-cellular cues to guide 
neurites towards their appropriate targets during neuronal development (Berman et al. 
1993). SMN protein has also been linked in the transport of axonal messenger RNAs 
along axons (Rossoll et al. 2003), for example β-actin mRNA, which is involved in 
motor axon pathfinding and outgrowth during development (Rossoll et al. 2003). In 
addition, studies in a zebrafish model of SMA show aberrant motor axon outgrowth 
and pathfinding defects (McWhorter et al. 2003; Beattie et al. 2007). This additional 
function of SMN protein specific to motor neurons might explain the selective 
vulnerability of spinal cord motor neurons and in particular the distal axonal parts 
and the neuromuscular synapse.  
 
1.2 Neuromuscular system 
 
1.2.1 The neuromuscular junction 
Lower motor neurons are located in the ventral horn of the spinal cord. Their axons 
leave the spinal cord via ventral roots and travel long distances through peripheral 
nerves to their target muscles. At the point of contact with the muscle a specialized 
synapse is formed, called the neuromuscular junction (NMJ). Once an axon reaches a 
muscle it branches numerous times intramuscularly to innervate between tens and 
hundreds of muscle fibers (Sanes and Lichtman 1999). A motor neuron along with 
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the muscle fibers it innervates is called a motor unit. The cells that make up the 
neuromuscular junction are the skeletal muscle fiber, motor nerve terminal and 
terminal Schwann cells. More recently a fourth cell type known as a ‘capping’ cell, 
has been identified (Sanes and Lichtman 1999; Court et al. 2008). 
 
1.2.2 Motor neuron pathfinding 
The distal tip of a developing axon contains a growth cone, which is a dynamic 
structure that responds to multiple sources of spatial information to guide the axon to 
its target (Lowery and Van Vactor 2009). The growth cone travels by adhering to 
adhesive molecules that are presented on neighbouring cell surfaces (Maness and 
Schachner 2007) or assembled into a dense extracellular matrix (Evans et al. 2007). 
These molecules can also activate intracellular signalling pathways by binding to 
receptors on the growth cone. The morphology of growth cones is defined by the 
underlying structure of the cytoskeleton. While the axon is dominated by parallel-
aligned microtubules, the growth cone mainly consists of actin filaments (Schaar and 
McConnell 2005). When a growth cone makes first contact with its target (e.g. a 
muscle fiber), it appears as a bulbous enlargement (called bouton) with very few 
vesicles. Subsequently, the number of vesicles increases and the cytoskeletal 
elements that are characteristic of axons disappear. Active zones are formed where 
vesicles become clustered and where neurotransmitter release will take place (Sanes 
and Lichtman 1999). When a motor axon is stimulated, an action potential 
depolarizes the presynaptic membrane, which results in an influx of Ca2+ into the 
synaptic terminal, which causes the vesicles to fuse with the membrane and 
subsequently releases the neurotransmitter, acetylcholine (ACh). ACh acts on the 
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nicotinic cholinergic receptors that are clustered on the muscle fiber, the so-called 
postsynaptic endplate (Sanes and Lichtman 1999).  
 
1.2.3 Development of muscle 
Skeletal muscle represents nearly half of the total body mass and is therefore the 
most abundant tissue in the body. The skeletal muscles induce coordinated body 
movements through their attachment to the skeleton (Grefte et al. 2007).  
During embryonic development skeletal muscle precursor cells arise from 
mesodermal progenitor cells (Yusuf and Brand-Saberi 2012). However, not all 
muscle precursor cells have the same site of origin within the mesoderm. For 
example, a significant bulk of trunk muscles are derived from the paraxial mesoderm, 
flanking both sides of the neural tube and notochord (Christ and Ordahl 1995). The 
paraxial mesoderm splits into clusters of cells, called somites, starting at the rostral 
end and continuing caudally. Dorsal somites expressing the transcription factors 
Pax3 and Pax7 form the dermomyotome. Once the dermomyotome is formed, 
muscle progenitor cells delaminate from it and migrate to the limb buds (Gros et al. 
2004), through the action of the membrane receptor c-Met and Pax3 (Dietrich et al. 
1999). These delaminated cells then down-regulate Pax3 and become myoblasts. The 
myogenic regulatory factors, Myf5, Mrf4 and MyoD are important regulators for the 
differentiation of myoblasts into myocytes (Rudnicki et al. 1993; Kassar-Duchossoy 
et al. 2004). Myocytes fuse to form myotubes. This process is influenced by many 
signals from other tissues, for example sonic hedgehog (SHH) and Wnt proteins 
(Cossu et al. 1996; Borycki and Emerson 2000).  Once the myotubes are formed they 
begin to transcribe acetylcholine receptor (AChR) subunit genes (α, β, γ and δ; 
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(Sanes and Lichtman 2001)) to form an embryonic form of the receptor (α2βγδ). 
Initially the AChRs are present at a low level throughout the myotube surface. At the 
same time as the myotube forms, motor axons reach the myotube and once they 
contact the myotube, a synapse is formed and synaptic transmission commences. 
This leads to a highly concentrated area of AChRs at the point where the nerve 
contacts the muscle fiber, the postsynaptic endplate.  
 
Satellite cells are the muscle stem cells located between the sarcolemma and the 
basal lamina of muscle fibers and represent the major reproductive population in 
skeletal muscle. Postnatal muscle growth is driven by the proliferation and 
differentiation of these satellite cells (Hayhurst et al. 2012).  
 
1.2.4 Formation and maintenance of the neuromuscular junction 
The NMJ undergoes dramatic changes in structure and function in the first few 
postnatal weeks (Sanes and Lichtman 1999). At birth, muscle fibers are innervated 
by multiple motor axons in mice. All inputs compete for innervation with ‘losing’ 
axons withdrawing and the ‘winning’ axon reinnervating. This takes place in the first 
two weeks after birth through a process called synapse elimination (Lichtman and 
Colman 2000). During the process of synapse elimination the shape of the synapse 
changes. At first the postsynaptic endplate is a uniform plaque of AChRs, but after 
axonal inputs retract, spots of low AChR density appear as perforation within the 
plaque. Changes continue until the postsynaptic endplate acquires a pretzel-like form 
(Balice-Gordon and Lichtman 1993; Sanes and Lichtman 2001). Together with the 
changes in shape, the postsynaptic endplate also undergoes molecular alterations. 
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The AChRs change from an embryonic to an adult form. The embryonic receptor 
contains a gamma subunit that is replaced by an epsilon subunit (forming the adult 
receptor; α2βεδ) during the first postnatal week (Martinou and Merlie 1991; Sanes et 
al. 1991).  
 
Other genes that are important for the formation and maintenance of the NMJ are 
muscle-specific receptor tyrosine kinase (MuSK), motor neuron derived agrin, Dok-7, 
rapsyn and Lrp4 (DeChiara et al. 1996; Kim et al. 2008). MuSK is a protein that has 
been shown to colocalize with the AChR at the NMJ (Valenzuela et al. 1995). In 
MuSk null mice the muscle fibers were formed as normal and normal levels of 
AChR expression were observed, however the clustering of AChR was disrupted and 
no NMJs were formed (DeChiara et al. 1996). This suggests that MuSK is important 
for the initial formation of postsynaptic AChR clustering (Lin et al. 2001). Dok-7 
and rapsyn were both closely linked to MuSk and identified to be important for 
clustering of AChRs and maintaining structural integrity of the endplate (Gautam et 
al. 1995; Okada et al. 2006). Interestingly, formation of the postsynaptic endplate 
started prior to axon arrival. Agrin, which is a glycoprotein synthesized by the motor 
neuron and released at the NMJ, acts through MuSK to promote apposition of nerve 
terminals to these nerve independent AChR clusters and also to induce new 
postsynaptic sites (Lin et al. 2001). Agrin is also required for the growth and 
maintenance of the synapses. MuSK and agrin do not physically interact. Lrp4 was 
identified as a coreceptor of MuSK that can directly interact with agrin (Kim et al. 
2008). Taken together, the formation and the maintenance of the NMJ are dependent 
on the interaction of a wide variety of different genes. 
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1.3 Neuromuscular pathology in SMA 
 
Since the molecular genetics for SMA are known, it has been possible to generate 
transgenic animals that recapitulate the disease allowing us to study neuromuscular 
pathology. When the SMN gene is homozygously disrupted in all cell types this 
results in early embryonic lethality (Frugier et al. 2000). Therefore, the most 
commonly used models are mouse models in which the endogenous SMN gene is 
disrupted (note that only humans have the SMN2 gene (Lefebvre et al. 1995)), but 
human SMN2 transgenes are inserted to express low levels of SMN protein. One 
severe mouse model of SMA was made by Monani et al. in 2000 (Smn-/-;SMN2, 
hereafter referred to as severe SMA mice). These mice die by postnatal day 5/6 
(Monani et al. 2000). A less severe phenotype has been observed in mice when an 
additional copy of the SMN2 gene without exon7, called the delta7 transgene, is 
inserted ((Le et al. 2005); Smn-/-;SMN2;SMNdelta7, hereafter referred to as delta7 
SMA mice). These mice live for ~ 2 weeks. Another mouse model known as the 
Taiwanese SMA mice have two copies of the SMN2 gene on one allele and these 
mice survive for ~ 12 days (Smn-/-;SMN2tg/+; (Hsieh-Li et al. 2000; Riessland et al. 
2010). 
 
Several studies in these different mouse models of SMA have shown early 
morphological abnormalities at the NMJ, occurring before axonal degeneration and 
motor neuron death (Murray et al. 2008; Kong et al. 2009; Dachs et al. 2011). The 
number of lumbar motor neurons was not significantly reduced in newborn SMA 
mice and was only moderately reduced at late stages of disease, whereas NMJ 
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defects were observed during this time (Dachs et al. 2011). In SMA, NMJ 
abnormalities include both presynaptic and postsynaptic defects. A major hallmark is 
loss of presynaptic motor nerve terminals at the NMJ, leaving the muscle fibers 
denervated. Accumulation of neurofilament has been shown at the NMJ as well as 
poor terminal arborisation, immature plaque-like AChRs and embryonic γ-subunit 
containing forms of the receptor (Kariya et al. 2008; Wyatt and Keirstead 2010). In 
addition to the morphological changes, functional abnormalities were observed. A 
study showed a ~ 50 % reduction of overall synaptic vesicle density at the NMJ of 
severe SMA mice (Kong et al. 2009). In addition, a selection of molecular 
components of the presynaptic terminal was down-regulated in normally innervated 
muscles, including Rab3A and calcitonin gene related peptide (CGRP) (Dachs et al. 
2011). Rab3A is a GTP-binding protein involved in targeting synaptic vesicles to the 
active zones and plays a role in neurotransmitter release in the synaptic cleft. This 
observation is in agreement with another study that has found decreased 
neurotransmitter release before appearance of extensive denervation (Ruiz et al. 
2010). Based on the defects found at the NMJs of SMA mice two independent 
studies have investigated NMJ pathology in humans (Kariya et al. 2008; Martinez-
Hernandez et al. 2013). Kariya et al. confirmed consistent structural defects of the 
NMJ in humans. Pre-terminal axons and nerve terminals in the diaphragm (a sheet of 
skeletal muscle that extends across the bottom of the rib cage) of type I SMA 
patients (younger than six months of age) were characterized as having abnormal 
accumulation of neurofilament. In addition, they found that motor endplates were 
small and structurally poorly developed when compared to controls (Kariya et al. 
2008). Interestingly, defects were also observed in development of the diaphragm 
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and in limb muscles in SMA fetuses (Martinez-Hernandez et al. 2013). This study 
used confocal and electron microscopy to reveal changes in AChR clustering, 
abnormal pre-terminal accumulation of vesicles and aberrant ultrastructure of nerve 
terminals prenatally (Martinez-Hernandez et al. 2013). In addition, they confirmed 
results showed by Kariya et al. that there is a delay in maturation of postnatal muscle 
of type I SMA patients. Thus, the NMJ is considered as an early pathological target 
in SMA.  
 
1.3.1 Selective vulnerability of neuromuscular junctions 
Interestingly, NMJs in different muscles show differences in vulnerability due to low 
levels of SMN. In addition, the same muscles can be differently affected between 
mouse models of SMA. Systematic studies have been performed to investigate which 
factors, such as muscle location, motor neuron pools, muscle fiber type or synapsing 
phenotypes contributed to synapse vulnerability ((Murray et al. 2008; Ling et al. 
2012; Thomson et al. 2012). In general, axial muscles are more vulnerable, however 
both proximal and distal regions contain both resistant and vulnerable muscles in the 
delta7 SMA mouse (Ling et al. 2012). This study found that the vast majority of 
vulnerable muscles were innervated by motor neurons located in the cervical and 
thoracic spinal cord segments.  
 
Muscle fiber type (i.e. fast twitch versus slow-twitch muscle fibers) has been 
proposed to modulate synapse vulnerability in neurodegenerative diseases. In 
amyotrophic lateral sclerosis (ALS) for example, fast-twitch muscle fibers innervated 
by fast fatigable motor neurons are more vulnerable (Hegedus et al. 2007). However, 
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two different mouse models of SMA (severe SMA mice and delta7 SMA mice) have 
shown that there is no correlation between muscle fiber type and NMJ pathology 
(Murray et al. 2008; Ling et al. 2012). In addition, no correlation between factors 
such as motor unit size, total length of intramuscular axonal arbors, motor unit 
branching patterns, numbers of synaptic glia and intrinsic remodelling capabilities 
was found in SMA (Thomson et al. 2012). However, a possible explanation could be 
the synapsing phenotype, characterized as fast-synapsing (FaSyn) and delayed-
synapsing (DeSyn), according to intrinsically distinct features of focal AChR 
clustering and the rate at which they acquire the characteristic organization of a 
mature NMJ. In muscles with a FaSyn phenotype focally organized clusters of 
AChRs in the absence of nerve contact become aligned to presynaptic nerve and 
Schwann cells in one day of development, whereas in DeSyn muscles this process 
takes up to five days and exhibits dispersed microclusters of AChRs. During this 
developmental time, nerves and Schwann cells fail to align with AChR microclusters, 
and extensive sprouting is detected (Pun et al. 2002). FaSyn muscle may be more 
vulnerable to SMA-induced synapse loss (Murray et al. 2008). However, not all 
FaSyn muscles were vulnerable. In contrast, all DeSyn muscles were resistant to 
denervation in SMA mice (Ling et al. 2012).  NMJ vulnerability in SMA cannot be 
attributed to a single determinant, but it is likely to be a combination of various risk 
factors involving both muscle and nerve. More research is therefore needed to reveal 
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1.4 The contribution of muscle to SMA pathology 
 
The development of muscle and the survival of motor neurons are dependent on 
signals from and physical contact with one another (Greensmith and Vrbova 1997; 
Vrbova 2008). In SMA both muscle and nerve undergo clear pathological alterations. 
Whether changes in muscle are a secondary effect of lower motor neuron 
degeneration or whether muscle pathology contributes to SMA pathology directly 
has been a matter of debate. Henderson et al. demonstrated a potential role for 
muscle in 1987 for the first time (Henderson et al. 1987). This study showed that 
muscle extracts from SMA patients contained substances that inhibit normal neurite 
outgrowth of chick spinal motor neurons in vitro. In addition these inhibitory 
substances were unique to muscles from SMA patients, as these were not observed in 
control tissue from other diseases. Co-cultures between SMA patient satellite cells 
(muscle stem cells) and rat spinal cord have shown degeneration after three weeks in 
culture, characterized by sarcomeric disorganization and large electron-lucent 
vacuoles (Braun et al. 1995; Braun et al. 1997). In mixed co-cultures of 50 % cloned 
satellite cells from SMA patients and 50 % of cloned satellite cells from healthy 
donors, the degeneration was not observed after innervation (Guettier-Sigrist et al. 
1998). These studies suggest that survival of motor neurons depends on receiving 
signals from muscle.  
 
The discovery of SMN protein in muscle, in sarcomeres of Drosophilia (Walker et al. 
2008), supports these results suggestive of a role for muscle in SMA. Similarly, 
myoblast cultures from type I SMA patients show defects in the formation of 
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myotubes and aggregation of AChR (Arnold et al. 2004). This was confirmed by a 
recent study showing that satellite cells isolated from severe SMA mice differentiate 
more rapidly. More interestingly, these cells failed to form myotubes (Hayhurst et al. 
2012). To determine whether a defect of SMN in skeletal muscle might have a role in 
SMA pathogenesis in vivo, Cifuentes-Diaz et al. developed a mouse model in which 
deletion of SMN exon7 was restricted to skeletal muscle. The decrease of SMN led to 
a severe phenotype characterized by an onset of muscle paralysis after three weeks of 
age and leading to death at a mean age of 33 days. In addition, necrotic muscle fibers, 
regenerating myocytes and mononuclear cell infiltration were observed (Cifuentes-
Diaz et al. 2001). It must be noted that in this mouse model they completely knocked 
out SMN in skeletal muscle, which does not represent a model of SMA as there is 
still low levels of SMN protein in SMA. In comparison, disruption of SMN directed 
to motor neurons alone, showed abnormal motor behaviour, characterised by 
abnormal posture of their hind limbs and severe impairment in their ability to right 
themself when they were positioned on their back. These mice show skeletal muscle 
denervation and die at a mean age of 25 days (Frugier et al. 2000).  
 
The next question to ask is whether restoring SMN protein levels in skeletal muscle 
rescues the SMA phenotype. Gavrilina et al. made two mouse models, one of which 
restored SMN levels in skeletal muscle under the human skeletal actin (HSA) 
promoter and the other restored SMN levels in motor neurons only under the prion 
promoter (PrP). The severe SMA mice were used in this study. This study concluded 
that replacement of SMN in neurons rescues the SMA phenotype and increases the 
survival of the mice, whereas replacement of SMN levels in muscle fibers alone has 
	   16	  
no effect on the SMA phenotype or the survival of the mice (Gavrilina et al. 2008). 
However, this study cannot exclude that expression of SMN in both neurons and 
muscles is needed for the rescue, since the PrP promoter was not completely specific 
for motor neurons and showed low levels of expression in muscle as well. In contrast, 
a recent study used MyoD and Myf5 promoters to restore SMN levels in muscle 
precursor cells and myofibers. The restoration of SMN levels in both satellite cells 
and myofibers completely rescued myofiber growth accompanied by an increase in 
median survival and motor behaviour, however no improvement was observed in 
NMJ structure (i.e. neurofilament accumulation and denervation of endplate was 
observed) (Martinez et al. 2012). A study performed by Bosche-Marce et al. 
attempted to rescue the muscle phenotype by overexpressing muscle specific insulin-
like growth factor 1 (IGF-1) (Bosch-Marce et al. 2011). IGF-1 is a small 
polypeptidic hormone important during muscle development and muscle 
regeneration after injury and denervation. This study showed that muscle mass was 
increased and the survival of the mice was improved by 40 %, however this was not 
accompanied by a measurable improvement in motor function (Bosch-Marce et al. 
2011). Take together, these results show that the role of muscle is still not fully 
understood and needs further investigation. In addition, the experiments that have 
been performed to date cannot rule out that the changes observed in muscle are 
simply occurring as a secondary effect of denervation due to pathology in the 
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1.5 Are other tissues affected in SMA? 
 
The main pathological feature of SMA is a specific loss of lower motor neuron in the 
ventral horn of the spinal cord. From the studies described earlier there is some 
evidence that muscle tissue might be a pathological target in SMA. Recent work has 
identified a range of additional cell and tissue types that show selective vulnerability 
to low levels of SMN (Hamilton and Gillingwater 2013). Since defects in non-
neuronal tissue have been shown to develop in parallel with neuromuscular 
pathology this could suggest that SMA is a multi-system disorder rather than a 
purely motor neuron disease.  
 
1.5.1 Heart defects 
One of the most commonly observed abnormalities in SMA outside of the 
neuromuscular system are congenital heart defects. In a study with a type I SMA 
patient cohort, three out of four patients were observed with major cardiac septal 
defects (Rudnik-Schoneborn et al. 2008). Electrocardiography (ECG) studies in a 
mouse model of SMA (Smn-/-;SMN2;SMNdelta7; (Le et al. 2005)) revealed severe 
bradycardia characterized by progressive heart block and impaired ventricular 
conduction throughout development (Heier et al. 2010). Interestingly heart failure, 
like septum thinning, started at different time point between different mouse models. 
In the severe SMA mice (Smn-/-;SMN2; (Monani et al. 2000)) this was observed in 
embryonic stages and between postnatal day two and postnatal day five in the delta7 
SMA mice (Shababi et al. 2010). This indicates an important role for SMN in cardiac 
development and maintenance. 
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1.5.2 Vascular defects 
Vascular defects, such as digital necrosis and capillary bed defects, have been 
observed in both patients and animal models of SMA. These defects became 
apparent when survival was prolonged in patients with the aid of invasive ventilation 
or in mice after drug treatment (Foust et al. 2010; Rudnik-Schoneborn et al. 2010; 
Valori et al. 2010). Two studies showed that capillary defects did not proceed NMJ 
pathology, but rather developed in parallel. It is possible that there is an essential role 
of SMN deficiency in these tissues and that defects are not developing exclusively 
secondary to neuromuscular pathology (Somers et al. 2012; Schreml et al. 2013). 
 
1.5.3 Metabolic abnormalities 
Metabolic abnormalities have been found in SMA mouse models. Glucose 
metabolism defects have been observed as a result of loss of the insulin producing  
β-cells and a corresponding increase in the number of the glucagon producing α-cells 
in the pancreas (Bowerman et al. 2012). Muscle has a key role here as well, as it is a 
central player in glucose metabolism via its role in insulin-dependent glucose uptake. 
In addition, low levels of SMN have recently been shown to have an effect on the 
liver (Hua et al. 2011). SMA mice had decreased hepatic insulin-like growth factor 
binding protein, acid labile subunit (Igfals) expression, which led to a reduction in 
circulating insulin-like growth factor 1 (IGF1).  IGF1 is a neurotrophic factor and is 
important for normal postnatal growth (Wu et al. 2009). Interestingly, IGF1 levels 
were rescued by restoring SMN levels systemically (Hua et al. 2011).  
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1.6 Therapies for SMA 
 
At present there is no cure for SMA. Most therapeutic approaches are based on 
attempts to increase the amount of SMN protein produced by SMN2 genes with small 
molecule drugs or gene therapy approaches (Bebee et al. 2012). SMN protein levels 
can be increased by a variety of approaches, including increasing inclusion of exon7 
in the SMN2 transcript, increasing SMN2 transcription, or increasing the stability of 
SMN protein generated by SMN2 (Chang et al. 2001; Sumner et al. 2003; Avila et al. 
2007; Sumner et al. 2009; Tiziano et al. 2010; Farooq et al. 2011; Mentis et al. 2011). 
Additional therapies include reintroduction of SMN using viral gene therapy, genetic 
induction of SMN and reintroducing healthy cells to replace the loss of motor 
neurons. These approaches have been tested in vitro, in mouse models of SMA and 
some have already been tested in clinical trials (Brahe et al. 2005; Brichta et al. 
2006; Mercuri et al. 2007; Swoboda et al. 2010; Tiziano et al. 2010; Abbara et al. 
2011; Darbar et al. 2011; Kissel et al. 2011). However, there is no FDA-approved 
treatment for SMA at present. Table 1.1 shows a list of therapies that have been 
tested for SMA treatment in vitro, in animal models and in patients up to date. 
  
1.6.1 SMN2 gene activating treatment 
One of the first drugs tested as an SMA therapeutic was hydroxyurea (HU), which is 
a ribonucleotide reductase inhibitor. HU showed increased levels of full length SMN 
mRNA in lymphoblastoid cells from SMA patients by promoting inclusion of exon 7 
during SMN2 transcription (Grzeschik et al. 2005). In adult severe SMA carrier mice 
(Smn+/−;SMN2, (Monani et al. 2000)) HU increased the expression of human SMN2 
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protein in spinal cord after a single intra-peritoneal injection (Mattis et al. 2008). HU 
has also been taken to clinical trials, where it has been proven to be safe, and can be 
administered orally and has a high bioavailability in children, however it failed to 
improve outcome measures such as motor function, strength, lung function, or levels 
of full length SMN mRNA (Wang et al. 2001; Chen et al. 2010). 
 
Another class of drugs that have shown to be effective in SMA function are histone 
deacytelase inhibitors (HDACi) (Andreassi et al. 2004; Hahnen et al. 2006; 
Riessland et al. 2006; Avila et al. 2007; Narver et al. 2008; Tsai et al. 2008; Garbes 
et al. 2009; Riessland et al. 2010). Histones are basic proteins and their positive 
charge allows them to associate with DNA to form condense chromatin. Histones 
undergo post-translational modifications, including acetylation, phosphorylation, 
methylation, ubiquitination and ADP-ribosylation (Strahl and Allis 2000), which 
regulates the conformation of chromatin and partially controls the access of the 
transcriptional machinery to DNA. Acetylation of specific Lysine residues in the 
amino termini of the core histones, plays a fundamental role in transcriptional 
regulation (Grunstein 1997; Struhl 1998). Levels of acetylation of histones result 
from the balance of the enzymes histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) (Struhl 1998). Transcriptional activity is associated with 
increased levels of acetylation, whereas decreased levels of acetylation are associated 
with repression. There are four classes of histone deacetylases based on their 
homology to yeast deacetylase proteins: Class I-III and HDAC11 (de Ruijter et al. 
2003). HDAC inhibitors have been shown to increase SMN levels by driving 
endogenous SMN2 promoter activity. Most HDACi that are effective in increasing 
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SMN levels target both class I and II HDACs (Evans et al. 2011). One important side 
effect of HDACi is that these drugs are not gene-specific and therefore might have 
detrimental off-target effects.  
 
1.6.2 Stabilization of SMNdelta7 transcript  
Another approach to treat SMA is to stabilize the SMN transcript without exon 7 
(SMNdelta7). SMNdelta7 has a shorter half-life compared to full length SMN. 
However, it has been shown to be more stable when it forms heterotypic complexes 
with full length SMN (Burnett et al. 2009). A class of antibiotics, known as 
aminoglycosides, has been shown to increase SMNdelta7 stability. Aminoglycosides 
have the ability to suppress efficient recognition of stop codons. When the first stop 
codon of SMNdelta7 exon eight is not recognized this will allow the translational 
machinery to elongate the protein with five amino acids. Studies have shown that this 
protein is more stable, can promote neurite outgrowth and can increase the assembly 
of the spliceosome (a macromolecule complex containing snRNPs) in vitro (Mattis et 
al. 2008). An increased level of SMN protein in fibroblasts from SMA patients, a 
significant elongation of lifespan and an increased number of cells in the ventral horn 
of the spinal cord in delta7 SMA mice have been observed (Heier and DiDonato 
2009; Mattis et al. 2009).  
 
1.6.3 SMN2 alternative splicing modulation 
Another potential treatment is to enhance alternative splicing to restore the 
expression of the full length SMN protein. Several drugs have been shown to be 
effective, including tetracycline and quinazoline (Thurmond et al. 2008; Hastings et 
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al. 2009; Butchbach et al. 2010). Alternative splicing has also been increased by 
using antisense oligonucleotides (ASOs). These are single stranded RNA molecules 
that are complementary to a certain mRNA sequence to block access to a specific site. 
An antisense oligonucleotide directed toward the intron seven/exon eight junction in 
the SMN2 pre-mRNA reduces the recognition of the exon eight 3′ splice site. As a 
consequence, the splice site pairing competition between exons seven and eight was 
altered to favour exon7 inclusions and led to a 2-fold increase of SMN2 exon7 
inclusion in vitro (Lim and Hertel 2001). Several studies have shown that injections 
of ASOs intra-cerebralventricularly (ICV) to deliver the ASO into the cerebrospinal 
fluid (CSF) increased exon7 inclusion and subsequently increased SMN levels in 
brain and spinal cord (Williams et al. 2009; Hua et al. 2010; Hua et al. 2011; Passini 
et al. 2011), resulting in improved motor function and modest extended survival. 
Interestingly, when the ASOs were delivered systemically via a subcutaneous 
injection, exon7 inclusion and SMN levels were also increased in heart and liver, 
leading to a more robust rescue in Taiwanese SMA mice (Hua et al. 2011). This 
again suggests that SMN has an important function, not only in motor neurons but 
also in peripheral tissues.   
 
1.6.4 Neuroprotective agents 
Neuroprotective agents could be an effective intervention to delay or limit motor 
neuron loss and disease progression in SMA (Rose et al. 2009). This treatment might 
be beneficial especially for patients with a milder form of SMA (Swoboda et al. 
2007). An example of such an agent is riluzole, which acts on voltage-dependent 
sodium channels to limit the release of the neurotransmitter glutamate. In this way it 
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reduces exitotoxicity (Haddad et al. 2003). In addition, it has been shown to exhibit 
neurotrophic activity and it enhances expression of brain-derived neurotrophic factor 
(BDNF) (Katoh-Semba et al. 2002). Riluzole dependent blockage of sodium 
channels result in a reduction of ATP release followed by depletion of ecto-
adenosine, which is thought to increase BDNF synthesis. Increased levels of BDNF 
have been shown to promote neuronal survival, guide axonal pathfinding, and 
participate in activity dependent synaptic plasticity (Katoh-Semba et al. 2002). A 
study in a mouse model of mild SMA showed that with riluzole treatment from 
postnatal day 21 the neuromuscular junction organization was improved (i.e. there 
was less neurofilament accumulation) and the median survival was increased 
(Haddad et al. 2003).  
 
1.6.5 Gene therapy 
The first gene therapy attempt to enhance SMN protein levels in motor neurons was 
done by an intra-muscular injection with a lentiviral vector encoding the full length 
SMN protein (Azzouz et al. 2004). The theory behind this study was that intra-
muscular injection would result in infection of the presynaptic termini of motor 
neurons and subsequent retrograde axonal transport of the viral vector to the motor 
neuron cell soma. The treated mice showed a reduction in motor neuron death, 
however the effect on survival was modest (Azzouz et al. 2004). Subsequent 
approaches used systemic delivery via the temporal facial vein using a self-
complementary adeno-associated vector serotype 9 (scAAV9). Three individual 
studies showed that this approach rescued characteristic SMA phenotypes such as 
muscle atrophy, immobility and weight loss. In addition the therapy substantially 
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improved survival of the SMA mice (Foust et al. 2010; Valori et al. 2010; 
Dominguez et al. 2011). Foust et al. also showed that the scAAV9 vector traverses 
the blood-brain barrier in a nonhuman primate, which supports the possibility of 
translating this treatment to humans (Foust et al. 2010). An alternative to system 
delivery is to deliver the vector directly into the CNS (Passini et al. 2010). This 
showed improvement of motor behaviour, body weight and overall survival, 
although the mice still died prematurely. This suggests that rescue of tissue, other 
than the motor neurons, is needed for complete rescue of the mice. 
 
1.6.6 Stem cell therapy 
Neural stem cell therapy was first shown to be effective in a mouse model of ALS. 
These mice showed a modified disease progression via neurogenesis and also via 
growth factor release (Corti et al. 2007). The beneficial effect was not only mediated 
by cell replacement but also by the neuroprotective effect of factors released by the 
donor cells. The first attempt of stem cell therapy in a mouse model of SMA used 
primary murine neural stem cells (Corti et al. 2008). The same group also showed 
that embryonic stem cell-derived neural stem cells can differentiate into motor 
neurons in vitro, and when transplanted into the cerebrospinal fluid can migrate 
along the spinal cord (Corti et al. 2010). Approximately 15% of these cells engrafted 
in the spinal cord where most exhibited astrocyte like characteristics and to a lesser 
extent motor neuron characteristics. Surprisingly, this still revealed an increase in 






Table 1.1 SMA treatments tested in vitro, in animal models and in patients 
 
Treatment Target Effects   Reference 
	   	     In vitro   In vivo  In patients (clinical trial) 	  
SMN2 gene activation     
HDAC inhibitors  	   	   	    





Increased expression of exon7-
containing SMN protein from 
the SMN2 gene in Epstein–Barr 
virus-transformed lymphoid cell lines 
from type I - III SMA patients 
Increased amount of full-length mRNA of the 
SMN2 gene. Pregnant type II and III SMA 
mice received water with sodium butyrate ad 
libitum. This resulted in reduced number of 
pups born with severe SMA and increased 
the survival by 39 % 








Increased SMN2 gene expression in 
SMA patients fibroblast cultures 
not tested Increased SMN expression in 
peripheral blood leukocytes. 
Increased muscle strength was 
observed (Brahe et al.). Mercuri 
et al. showed no improvement in 
motor and lung function 
Andreassi et al. 
2004; Brahe et al. 
2005; Mercuri et 
al. 2007 
Trichostatin A (TSA) Histone 
deacetylase 
inhibition 
Increased expression of exon7- 
containing SMN2 transcripts in a 
fibroblast cell line of a type III SMA 
patient 
Treatment from P5 in delta7 SMA mice 
improved survival (19 %), motor function, 
muscle fiber size, and spinal motor neuron 
size. Additional nutritional supplementation 
improved survival by 170 % even with 
treatment cessation at 20 days. Sensory 
neuronal circuitry defects were corrected 
not tested Avila et al. 2007; 
Narver et al. 
2008; Mentis et 
al. 2011 






containing SMN transcript levels, 
SMN protein levels, and gem 
number in type I SMA patient–
derived fibroblast cell lines in a dose-
dependent fashion 
In a mouse model of SMA type III, motor 
neuron loss was prevented, improvement of 
motor function and muscle pathology and 
reduced NMJ defects were observed. 
Increased SMN protein levels in the spinal 
cord 
SMN2 mRNA levels were 
increased in 50 % of the patients 
(Brichta et al.). In type II patients 
an improvement in motor 
function test was observed. This 
was not seen in type III patients 
(Darbar et al.). No improvement 
in strength or function in 
ambulant and non- ambulant 
children was observed (Kissel et 
al. and Swoboda et al. 2010) 
Sumner et al. 
2003; Brichta et 
al. 2006; Tsai et 
al. 2008; 
Swoboda et al. 
2010; Darbar et 











Increased SMN levels in a fibroblast 
cell line derived from SMA patients 
Treatment of pregnant mother mice rescued 
embryonic lethality of severe SMA pups. In 
Taiwanese SMA pups SAHA increased the 
mean survival by 30%. Body weight and 
motor abilities were increased. SMN2 
transcripts, Full-length SMN2 and delta7-
SMN2 levels were increased in brain, liver, 
spinal cord and muscle 
not tested Hahnen et al. 
2006; Riessland 





Increased SMN levels in a fibroblast 
cell lines derived from SMA patients, 
in human neural stem cells and in 
murine fibroblasts derived 
from SMN2-transgenic mice. SMN is 
post-translationally stabilized via 
reduced ubiquitination as well as 
enhanced incorporation into the SMN 
complex 
Treatment of 3-month old SMA carrier mice 
showed increased SMN protein levels 





Increased SMN2 protein expression in 
a fibroblast cell line derived from SMA 
patients up to 7-fold. Increased total 
number of gems/nucleus as well as 
the number of nuclei that contain 
gems 





Increased levels of full length SMN 
mRNA 
Increased expression of SMN2 protein in 
spinal cord 
No improvement in motor 
function, strength or lung 
function. No increased levels of 
serum full length SMN mRNA in 
SMA patients with type II and III. 
Neutropenia was observed as a 
side-effect 
Grzeschik et al. 
2005; Mattis et al. 
2008; Chen et al. 
2010 
Prolactin Stat5 pathway Increased level of SMN mRNA and 
protein levels in a human neuronal 
cell line and in murine motor neuron 
MN-1 cells 
Significant up-regulation of SMN levels in 
motor neurons and improvement of motor 
function in the delta7 SMA mice. They 
showed a 70% increase in lifespan. All SMA 
pups responded to the treatment 






Salbutamol Exon 7 inclusion Increased levels of SMN2 full length 
transcripts in SMA fibroblasts 
not tested Increased SMN2 full length 
transcript levels 
Angelozzi et al. 
2008; Tiziano et 
al. 2010 
SMNdelta7 transcript stabilization     
Aminoglycosides      
Geneticin (G418) Modulate SMN 
translation. 
Bypasses stop 
codons in the 
SMN delta7 
transcript 
Full length SMN protein levels were 
increased in human and mouse cell 
lines as well as in patient fibroblasts 
Delta7 SMA mice showed increased levels of 
full length SMN protein in brain and spinal 
cord and a significant increase in motor 
function. Drug was found to be toxic after 
treatment for 9 days 
not tested Heier and 
Didonato et al. 
2009 
TC007 Modulate SMN 
translation. 
Bypasses stop 
codons in the 
SMN delta7 
transcript 
Increased SMN levels in induced 
pluripotent stem cell-derived human 
SMA motor neuron cultures 
In delta7 SMA mice the number of motor 
neurons was increased in spinal cord, motor 
function was improved and mean survival 
was increased by 30% 
not tested Mattis et al. 2009 
Neuroprotection 	       
Follistatin Inhibition of the 
myostatin 
pathway 
not tested Increased muscle mass, motor function and 
number of motor neurons in the spinal cord 
and increased mean survival by 30%. 
Transgenic expression of follistatin in muscle 
failed to improve SMA phenotype and 
survival of delta7 SMA mice 
not tested Rose et al. 2009; 









not tested Median survival was increased by 15% and 
exerted a protective effect against aberrant 
cytoskeletal organization of motor synaptic 
terminals but not against loss of proximal 
axons 
Phase I clinical trial to optimize 
the pharmacokinetics of riluzole 
Haddad et al. 










Stimulates exon 7 splicing and 
increases SMN protein levels in SMA 
patient and carrier fibroblasts 
Stimulates exon 7 splicing and increases 
SMN protein levels in liver of SMA mice. The 
compound can not cross the blood-brain 
barrier 
not tested Hastings et al. 
2009 
quinazoline SMN2 splicing 
modulation 
Activating SMN2 promoter activity and 
increased levels of SMN protein in 
SMA patient fibroblasts 
Increased SMN levels in the spinal cord, 
amelioration of the SMA motor phenotype 
and an increase of the mean survival by 20-
30% in delta7 SMA mice 
not tested Thurmond et al. 
2008; Butchbach 






A 2-fold increase of SMN2 exon 7 
inclusion  
Administered directly into CNS corrects exon 
7 splicing. Prevents tail and ear necrosis in 
SMA type III mice. Increased number of 
motor neurons in the spinal cord, 
improvement of motor function and increase 
in weight. Mean survival increased with 18-
26%. Administration sub-cutaneously 
improved survival up to 248 days 
not tested Lim and Hertel et 
al. 2001; Williams 
et al. 2009; Hua 
et al. 2010; 
Passini et al. 
2011; Hua et al. 
2011 





SMN1 delivery Restoration of SMN protein 
concentration and number of gems in 
an SMA type I fibroblast cell line 
Lentiviral administration by intramuscular 
injection improved weight gain and motor 
neuron numbers. Survival was extended by 
20-40%. An scAAV8 CNS injection increased 
survival up to 157 days and improved motor 
function and NMJ pathology. Systemic 
delivery with scAAV9 increased survival up 
to more than 250 days in the delta7 SMA 
mice. Improved weight, neuromuscular 
physiology and motor function 
not tested Azzouz et al. 
2004; Foust et al. 
2010; Valori et al. 
2010; Passini 
2010; Dominguez 
et al. 2011  
Stem cell therapy      
Stem cells Neurotrophic 
support 
 Primary motor neuron stem cells injected into 
the spinal canal engrafted to the spinal cord, 
improved motor function and extended 
survival by 39%. Embryonic stem cell-
derived neural stem cells injection in the 
cerebrospinal fluid showed a 24% increase 
of mean survival compared to injections of 
motor neuron stem cells 
not tested Corti et al. 2008; 
Corti et al. 2010 
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1.7 Biomarkers for SMA 
 
Now that there are potential approaches to treat SMA, reliable clinical outcome 
measures and biomarkers are essential to effectively evaluate these approaches. It is 
essential for a reliable biomarker to 1) overcome the risk of placebo effect, 2) allow 
comparison of clinically heterogeneous individuals, 3) help to distinguish between 
responder and non-responder individuals to a given treatment and 4) facilitate the 
accuracy and speed of a clinical trial (Tiziano et al. 2013). Different motor function 
(Hammersmith Motor Function Scale or HMFS specifically designed for SMA 
(Main et al. 2003)), quality of life and respiratory measures as well as strength tests 
have been piloted as outcome measures in these studies (Cook et al. 1990; Samaha et 
al. 1994; Main et al. 2003; Lewelt et al. 2010; Kaufmann et al. 2011).  However, 
these measures have raised a number of concerning issues. These tests depend on the 
motivation and state the patients are in. For example, some tasks might be 
unbearable for patients. Moreover, some complications related to the disease such as 
scoliosis, retractions and weight gain could further impair motor functions. Therefore 
recent studies have been investigating molecular biomarkers, including SMN 
transcript and protein levels from accessible peripheral tissues such as blood and 
urine (Crawford et al. 2012; Finkel et al. 2012). Sensitive techniques are needed to 
reliably quantify the level of a biomarker. An immunoassay has been developed 
suitable for SMN protein quantification in peripheral blood mononuclear cells 
(PBMC) (Kolb et al. 2006). However, a reduction in SMN levels was only found in 
PBMC from type I SMA patients and did not correlate with phenotypic severity. 
These findings raise the question of whether the technique is sensitive enough or 
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whether SMN protein levels in PBMC are a good readout of disease severity. In 
addition, association between clinical phenotype and molecular characteristics in 
type III SMA patients has been investigated (Tiziano et al. 2013). This study did not 
find a correlation between motor performance and SMN2 copy number. These 
findings suggest that there is an urgent and essential need for a reliable biomarker for 
SMA. 
 
1.8 Pathways involved in SMA independent of SMN 
 
The pathogenesis of SMA has been extensively studied, however detailed disease 
mechanisms remain to be fully understood. In addition, it has only recently been 
appreciated that non-neuronal tissues, such as muscle and other organs, are affected 
in SMA. Treatments to date have not been successful in rescuing the disease, 
therefore there might be other pathways and regulatory proteins involved in the 
pathogenesis of SMA.  
 
1.8.1 Plastin-3 
The first potential SMN-independent disease modifier identified was plastin-3. 
Increased levels of plastin-3 protein were discovered in individuals with a 
homozygous deletion of SMN1, who were fully asymptomatic despite carrying the 
same number of SMN2 copies as their affected siblings (Oprea et al. 2008). Plastin-3 
is an actin binding protein and regulates actin filament organization. It colocalizes 
with SMN in granules throughout motor neuron axons and it shows reduces levels in 
brain and spinal cords of SMA mice (Bowerman et al. 2009).  A recent study in the 
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Taiwanese SMA mice overexpressing plastin-3 showed neuromuscular improvement 
(Ackermann et al. 2013), confirming its protective role in SMA. However, the 
mechanism behind the protective effect of plastin-3 has yet to be fully investigated. 
 
1.8.2 Myostatin pathway 
The myostatin pathway has been proposed to be involved in SMA. Myostatin 
(MSTN) is a member of the transforming growth factor-beta (TGF-beta) family and 
it is proposed to be a negative regulator of muscle growth. Several proteins reduce 
the activity of MSTN, including follistatin. Administration of follistatin to delta7 
SMA mice showed an improved lifespan and gross motor functions associated with 
an increase in muscle mass and the preservation of motor neurons (Rose et al. 2009). 
Interestingly SMN levels were not changed after follistatin treatment. This suggests 
that follistatin induced rescue by acting on the MSTN pathway and rescued the SMA 
phenotype in an SMN independent manner. However, this study is contradicted by a 
study that took a genetic approach and knocked out the MSTN gene in delta7 SMA 
mice (Rindt et al. 2012). In this study no improvement of survival or motor function 
was observed. This might suggest that the inhibition of MSTN may have been 
suboptimal and furthermore follistatin might have additional targets influencing 
muscle growth.  
 
1.8.3 Ubiqitination pathway 
X-linked infantile spinal muscular atrophy (XL-SMA) is a disease closely linked to 
SMA. XL-SMA patients present similar clinical characteristics, including hypotonia, 
areflexia, and multiple congenital contractures associated with loss of cells in the 
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ventral horn of the spinal cord (Ramser et al. 2008). Using mutation screening in six 
XL-SMA families, mutations were located in the ubiquitin-like modifier-activating 
enzyme 1 gene (UBA1). UBA1 catalyses the first step in the ubiquitination pathway 
for proteasome degradation (Rubinsztein 2006).  In addition, ubiquitin carboxy-
terminal hydrolase L1 (UCHL1), which is also an enzyme in the ubiquitination 
pathway, is increased in fibroblasts from type I SMA patients (Hsu et al. 2010). 




Based on the current literature the following questions were raised and will be 
addressed in this thesis  
Chapter 3: Is there a direct role for skeletal muscle in the pathogenesis of SMA? 
Chapter 4: Can biomarkers be identified in skeletal muscle? Are these potential 
biomarkers also measurable in more accessible peripheral tissues, such as blood 
and skin?  
Chapter 5: Can new pathways involved in SMA pathogenesis be identified? Does 
targeting this pathway with a pharmacological compound ameliorate the SMA 
phenotype in a mouse model of SMA?  
Chapter 6: Does a dopamine agonist ameliorate the SMA phenotype in a mouse 
model of SMA? 
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Chapter 2  
Materials and methods 
 
2.1 Animals and colony maintenance 
  
Smn+/-;SMN2 mice (Jackson labs strain no. 005024) were maintained as 
heterozygous breeding pairs under standard SPF conditions in animal care facilities 
in Edinburgh. This breeding scheme gave rise to severe SMA mice (Smn-/-;SMN2) 
and two different control littermates; heterozygous (Smn+/-;SMN2) and wild-type 
(Smn+/+;SMN2). Taiwanese SMA mice were maintained as two separate stocks; 
Smn+/- (crossed with wild-type FVB mice to maintain the stock) and Smn-/-;SMN2tg/tg. 
Smn+/- and Smn-/-;SMN2tg/tg were crossed to obtain SMA mice (Smn-/-;SMN2tg/wt) or 
control littermates (Smn+/-;SMN2tg/wt). The SMN2 transgene carries two SMN2 copies. 
Taiwanese SMA mice treated with SAHA (tissue used in chapter 3) were bred and 
maintained in micro-isolation chambers in Cologne as previously reported (Riessland 
et al. 2010). C57Bl/6 mice were maintained as breeding colonies in the animal care 
facilities in Edinburgh under standard SPF conditions.  
 
Mice were housed in individual ventilated cages (IVC) and were fed a standard chow 
diet. Mice older than postnatal day five (P5) were sacrificed by intra-peritoneal 
injection of sodium pentobarbital or an overdose of isofluorane. Mice younger than 
P5 were chilled on ice and decapitated. All animal procedures and breeding were 
performed in accordance with Home Office guidelines in the UK and according to 
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guidelines established by the Landesamt fur Natur, Umwelt und Verbraucherschutz 
NRW in Germany. 
 
2.2 Human tissue 
 
Quadriceps femoris biopsy samples from SMA and control patients were obtained 
from Fondazione IRCCS Istituto Neurologico “C. Besta” in Milan, Italy and 
Fondazione Ospedale Maggiore Polclinico Mangiagalli en Regina Elena, IRCCS in 
Milan, Italy through EuroBioBank (http://www.eurobiobank.org/). 
 
Table 2.1 Biopsy obtained from Fondazione IRCCS Istituto Neurologico "C. Besta" 
in Milan, Italy.  
 
Code Sex Age Type 
6306 Female 3 years SMA II 
 
Table 2.2 Biopsies obtained from Fondazione Ospedale Maggiore Policlinico 
Mangiagalli en Regina Elena, IRCCS in Milan, Italy. 
 
Code Sex Age Type 
8916 Female 25 years SMA III 
9150 Female 4 years SMA II 
9012 Male 22 years Control 
9110 Male 27 years Control 
9426 Male 17 years Control 
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2.3 Genotyping 
 
DNA was extracted from ear clips (for genotyping stock mice) or from a tail tip (for 
genotyping experimental mice) and a PCR was performed to genotype the mice. The 
following primers were used for genotyping mice from the severe SMA colony: 
 
SMN knock out primers (NEO insert)  
Forward: CTTGGGTGGAGAGGCTATTC 
Reverse: AGGTGAGATGACAGGAGATC 
PCR product is 280 base pairs (bp). 
 
SMN wild-type primers  
Forward: TTTTCTCCCTCTTCAGAGTGAT 
Reverse: CTGTTTCAAGGGAGTTGTGGC 
PCR product is 420 bp. 
 
PCR program  
Step 1 Separation   94°C 120 sec 
Step 2 Denaturation   94°C 30 sec 
Step 3 Annealing  61°C  30 sec 
Step 4 Polymerization  72°C 45 sec 
Step 5 Final   72°C 120 sec 
Step 2-4 are repeated 27 times. 
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For genotyping the Taiwanese SMA mice the following primers were used: 
Forward: ATAACACCACCACTCTTACTC 
Reverse 1: GTAGCCGTGATGCCATTGTCA 
Reverse 2: AGCCTGAAGAACGAGATCAGC 
SMN1 gene products: A band of 1050 bp and a band of 950 bp for heterozygous mice 
(Smn+/-;SMN2tg/wt) and only one band of 950 bp for SMA mice (Smn-/-;SMN2tg/wt). 
 
PCR program 
Step 1 Separation  95°C  180 sec 
Step 2  Denaturation  94°C  30 sec 
Step 3  Annealing  59°C  30 sec 
Step 4  Polymerization 68°C  60 sec  
Step 5  Final   68°C  5 min 
Step 2-4 are repeated 35 times. 
 
Products were separated by gel electrophoresis and genotype assigned by presence or 
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2.4 Surgery 
 
Surgery was performed by Laura Comley 
Mice were anaesthetised by inhalation of halothane (2% in 1:1 N2O/O2) before 
exposing the sciatic nerve in the thigh. A ~1 mm section of the sciatic nerve was 
removed to ensure complete transection before suturing the skin and allowing the 
mouse to recover. 
 
2.5 Muscle, spinal cord and organ preparation  
 
Levator auris longus (LAL, from the dorsal surface of the neck), flexor digitorum 
brevis (FDB; from the plantar surface of the hind-paw) and/or transversus abdominis 
(TVA; from the antero-lateral abdominal wall) were dissected in oxygenated 
mammalian physiological saline (120 mM NaCl , 5 mM KCl,  2 mM CaCl2, 1 mM 
MgCl2, 0.4 mM NaH2PO4, 23.8 mM NaHCO3, 5.6 mM D-glucose) in a Sylgard-lined 
dish. Gross dissection was done before fixing the tissue in 0.1 M phosphate buffered 
saline (PBS) containing 4% paraformaldehyde (Electron Microscopy Services) for 
10 min. The tissue was cleaned and further dissected after fixation. For proteomics 
and/or quantitative fluorescent western blotting experiments, spinal cord, heart, liver, 
LAL (separated in rostral and caudal band), FDB and/or gastrocnemius (from the 
hind limb) muscles were quickly frozen on dry ice. The muscles were stored in  
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2.5.1 Synaptosome preparation 
Synaptosomes were made from either whole brain or hippocampus only. High Mg2+ 
artificial cerebrospinal fluid (aCSF, 125 mM NaCl, 26 mM NaHCO3, 25 mM 
glucose, 2.5 mM KCl, 1.25 mM NaH2PO4(2H2O), 1mM CaCl2, 4 mM MgCl2) was 
prepared and cooled in the freezer to the point of becoming slush. The brain was 
removed and dropped immediately into ice-cold sucrose solution (0.2 M sucrose, 1 
mM EDTA and 5 mM Tris-HCL, pH 7.4) or when hippocampal synaptosomes were 
made dropped into high Mg2+ aCSF first, to increase firmness for cutting. Once the 
tissue was firm enough the brain was cut in the sagittal plane just off the midline. 
The hippocampus was then scooped out of both hemispheres before being dropping 
into ice-cold sucrose solution. The tissue was homogenized in 1 ml or 100 µl ice-cold 
sucrose solution, for whole brain and hippocampus respectively, and then centrifuged 
in a fixed-angel rotor at 900 g for 10 min. The supernatant (S1, containing the 
synaptosomes) was collected in a new tube. The pellet (P1) was resuspended in fresh 
sucrose solution and centrifuged again at 900 g for 10 min. The supernatant (S2) was 
collected in the same tube as S1 and this was centrifuged again at 20 000 g for 20 
min. The supernatant was removed and the pellet, containing the synaptosomes, was 
stored in the -80 °C freezer until used for further analyses. For isolation of the 
mitochondria the pellet with the synaptosomes was resuspended in RIPA buffer with 
10 % protease inhibitor cocktail and centrifuged at 6000 g for 15 min (Cox and Emili 
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2.6 Immunohistochemistry 
 
The fixed muscles were washed in a solution of PBS and 4% Triton for 30 min 
before it was blocked in blocking solution (4% bovine serum albumin and 2% 
Triton-X in PBS) for 30 min. The muscle dissections were then incubated in primary 
antibodies anti-2H3 and anti-SV2 to label axonal neurofilament (both 1:100, 
Developmental studies hybridoma bank), parvalbumin (1:200, Abcam) or phospho-
H2AX (1:200, Upstate) on a rocking plate in the cold room overnight. The next day 
the muscle dissections were washed in PBS for two hours on the rocker at room 
temperature before being incubated in α-Bungarotoxin (BTX) conjugated to 
tetramethyl-rhodamin isothiocyanate (TRITC-α-BTX; 5 mg/ml, Molecular Probes) 
to label post-synaptic acetylcholine receptors or TOPRO-3 (Alexa Fluor 647®; 0.7 
mg/ml, Life Technologies) to label nuclei for 10 min. Hereafter the muscle 
dissections were incubated in goat-anti mouse Dylight-488 (1:200, Thermo 
Scientific) or donkey-anti goat Cy-3 (1:200, Jackson laboratory) for two hours at 
room temperature. After washing in PBS for 45 min the muscle preparations were 
mounted on glass slides in Mowiol® and covered with a cover slip for subsequent 
imaging.  
 
2.7 Image analysis 
 
Muscle dissections were viewed using a phase contrast microscope (for muscle fiber 
measurements), a standard epi-fluorescence microscope equipped with a chilled 
CCD camera (x10 0.3NA, x40 0.6NA lens; Nikon IX71 microscope; Hammamatsu 
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C4742-95), and/or a laser scanning confocal microscope (Zeiss Axiovert LSM 150, 
x40 1.3NA, x63 1.4NA oil immersion lenses). TRITC-α-BTX-labelled muscle 
dissections were imaged using 543 nm excitation and 590 nm emission optics and 
FITC-labelled muscle dissections were imaged using 488 nm excitation and 520 nm 
emission optics. For confocal microscopy, 488 nm (green), 543 nm (red) and 633 nm 
(far-red) laser lines were used for excitation and confocal Z-series were merged 
using Lasersharp (Biorad). All images were then assembled using Adobe Photoshop. 
The montage of immunohistochemically labelled LAL muscle was produced in 
Adobe Photoshop software by layering and combining multiple micrographs 
covering the entire muscle. 
 
2.8 Quantification of endplates 
 
A minimum of 30 endplates from a minimum of three fields of view per 
muscle/muscle band was examined. Muscles with poor staining or that were 
damaged were excluded from quantification. The quantification was done blind. 
Endplates were examined for basic occupancy counts and for the total number of 
axonal inputs per endplate. For basic occupancy counts the endplates were 
categorized as either fully occupied (neurofilament staining overlies the endplate 
entirely), partially occupied (neurofilament staining overlies the endplate partially) or 





	   41	  
2.9 H2AX cell count 
 
LALs were examined using the confocal microscope, 63 x magnification. Nuclei 
were examined in 20 fields of view per muscle. Nuclei were either scored as having 
no H2AX labelling, moderate accumulation or intense H2AX labelling.  
  
2.10 Muscle fiber diameter measurements 
 
Muscle fiber diameter measurements were taken from phase contrast micrographs of 
teased muscle fiber preparations. Fifty pictures were taken per muscle. Per muscle 
fiber three diameter measurements were taken in Image J and these were averaged in 
excel before statistics were performed. Only isolated fibers with no overlapping 
fibers obscuring their profile were included in these analyses.  
 
2.11 Protein level quantification 
 
Tissue from mouse (either muscle, spinal cord, skin, blood, heart or liver) and human 
(muscle biopsy) was homogenized in RIPA buffer (Thermo scientific) and 10% 
protease inhibitor cocktail (Thermo scientific) using a pestle. The homogenate was 
left on ice for a few minutes and then vortexed before centrifugation at 14 000 rpm 
for 30 min. The supernatant was collected. Protein quantification was performed 
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2.12 Quantitative fluorescent (Li-COR) western blotting 
 
Samples were mixed with 4 x LDS sample buffer (Novex) before being boiled for 2 
min at 98 °C. After a brief spin 10 µl of the samples was loaded onto a NuPage 4-
12% Bis Tris gradient gel (Invitrogen) in NuPage MES SDS running buffer 
(Invitrogen). After electrophoresis (180 V for 45 min) the samples were transferred 
onto a PVDF membrane using an iBlot (Invitrogen, transfer time 8.5 min). The 
membranes were blocked using Odyssey blocking buffer (Li-COR) for 30 min at 
room temperature. Hereafter membranes were incubated overnight at 4°C with either, 
anti-calreticulin (1:1000, Lifespan) anti-β-catenin (1:1000, BD Transduction 
laboratories), anti-COX IV (1:1000, Mitosciences), anti-cytochrome-C (1:1000, 
Abcam), anti-E1-ubiquitin activating enzyme (1:1000, Abcam), anti-phospho-H2AX 
(1:1000, Upstate), anti-histone H2B (1:1000, Active Motif), anti-GEM5C (1:100, 
obtained from Glenn Morris’ laboratory), anti-GRP75 (1:2000, Lifespan), anti-
ManSMN12 (1:100, obtained from Glenn Morris’ laboratory) anti-parvalbumin 
(1:500, Abcam), anti-RRBP1 (1:500, Abcam), anti-SMN (1:500, BD transduction 
laboratories), anti-synaptophysin (1:1000, DAKO), anti-TCPB-beta (1:1000, Abcam), 
anti-β-III-tubulin (1: 5000, Abcam), anti-β-V-tubulin (1:500, Abcam), anti-ubiquitin 
(1:500, Millipore), anti-UCH-l1 (1:2000, Novus Biologicals), anti-VDAC2 (1:1000, 
Abcam) in 5 ml Odyssey blocking buffer (Li-cor) with 1 % TWEEN 20 (Promega). 
After washing in 1 x PBS for 30 min, the membranes were incubated for two hours 
at room temperature with either goat anti-rabbit, goat anti-mouse or donkey anti-goat 
(all Odyssey IRDye 680 or 800 dependent on required combinations, 1:1600) in 5 ml 
Odyssey blocking buffer with 1 % TWEEN 20. After washing for 30 min with 1 x 
	  
	   43	  
PBS the membranes were imaged using an Odyssey Infrared Imaging System (Li-
COR Biosciences). Scan resolution of the instrument ranges from 21-339 µm and the 
membranes were imaged at 169 µm. Laser intensity levels were changed according 
to the brightness of the band of interest. Fluorescent intensity of each individual band 
was measured using the software provided with the Li-COR or with ImageStudioLite 
(free Li-Cor software). Where possible, western blot membranes were scanned twice 
and two independent sets of measurements were taken from it to minimise user 
variability and to provide a more accurate result.   
 
2.13 Real-time PCR 
 
To extract total RNA, the pellet with the synaptosomes was resuspended in tri-
reagent before chloroform was added to separate the different layers. The top 
aqueous layer was collected and isopropanol was added to extract RNA. After 
centrifugation for 15 min at 14000 rpm at 4 °C supernatant was removed and RNA 
was resuspended in 0.1 % DEPC water. Samples were checked for DNA 
contamination and concentration was determined using a nanodrop 
spectrophotometer (Thermo Scientific). qRT–PCR was carried out using a Sybr-
Green ‘1 step qRT – PCR kit’ (Invitrogen) on a Model 7700 instrument (Applied 
Biosystems). The following primer sets were used: 
Beta actin primer set 1 forward – CATTGCTGACAGGATGCAGAAGG 
    reverse –  TGCTGGAAGGTGGACAGTGAGG 
Primers designed to a sequence on exon five.  
Amplifies a product of 138 bp. 
	  
	   44	  
Beta actin primer set 2 forward – ATGTTGAAGGTCTCAAACATGAT 
    reverse - ACCACACCTTCTACAATGAGCTG 
Primers designed to a sequence on the end of exon three and the start of exon four. 
Amplifies a product of 127 bp. 
 
2.14 In vitro experiments 
 
2.14.1 Cells 
NSC-34 cells and hippocampal neurons from embryonic day 17 old rat were kindly 
provided and plated out by Paul Skehel. The NSC-34 cells were cultured in DMEM 
media complemented with 10% fetal calf serum and the primary hippocampal 
neurons were cultured in BME serum free medium complemented with 1.6% of a 
32.5% glucose solution, 1% Sodium Pyruvate 100 nM solution, 1% N2 supplement 
and 5% B27 supplement respectively.  
 
2.14.1.1 UBEI-41 treatment 
UBEI-41 (Biogenova) is a cell-permeable ubiquitin E1 inhibitor and was kept at  
-20 °C. The cells were harvested and plated in a 12-wells plate (approximately  
1.6 x 10⌃5 cells per well) and kept in 500 µl of their normal culture media. The cells 
were treated with either 10 µM or 50 µM of UBEI-41. Control cells were treated 
with dimethyl sulfoxide (DMSO; Sigma) alone. The cells were left for 1, 2, or 16 
hours before the cells were harvested, by lysing the cells in RIPA buffer with 10 % 
protease inhibitor cocktail.  
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2.14.1.2 UCH-L1 inhibitor treatment 
UCH-L1 inhibitor (Millipore) was kept as a stock concentration of 25 mM at -20°C. 
Cells were plated in a 12-wells plate (approximately 1.6x10⌃5 cells per well) and 
kept in their normal culture media. Cells were treated with either 1 µM, 5 µM, 10 µM 
or 25 µM of the drug and left for 0.5, 1, 2, 3, or 6 hours in a total volume of 500 µl. 
Control cells were treated with the equivalent volume of DMSO only.  
 
2.15 In vivo drug treatment 
 
Mice were given a subcutaneous (only severe SMA mice) or intra-peritoneal 
injection daily from the day of birth (P1) until P4 for the severe mice and P9/P10 for 
the Taiwanese SMA mice. For the survival study mice were injected until they died, 
or looked too unhealthy and were subsequently killed. The mice were either injected 
with 10 mg/kg Trichostatin A (TSA; InvivoGen), 100 mg/kg, 50 mg/kg or 10 mg/kg 
Quercetin (Sigma) or 10 mg/kg NPA (Sigma) or an equivalent volume of DMSO 
alone.  
 
For SAHA experiments, litters of Taiwanese SMA mice were dosed twice daily from 
birth with either 25 mg/kg SAHA dissolved in DMSO, or an equivalent volume of 
DMSO alone, via oral application with a feeding needle. These injections were 
carried out in Cologne in Brunhilde Wirth’s laboratory and afterwards tissue was 
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2.16 Physical test and general health assessment 
 
All mice (SMA and control) were weighted and checked for general health every day 
during the time of drug treatment. Mice that looked very unhealthy (i.e. were not 
moving or felt cold) or had lost 10 % of their body weight per day over two 
consecutive days were killed. Every three days the righting reflex test was performed 
in order to assess neuromuscular function. In this test the pups were placed on their 
back on a flat surface and were timed for the amount of time it took them to 
reposition themselves dorsal side up. If the pups did not achieve this within 1 min it 
was noted as a failed attempt.  
 
2.17 Ex vivo vulnerability essay 
 
Whole brain synaptosomes from SMA and control mice were resuspended in 1 ml 
Krebs buffer (118.5 mM NaCl, 4.7 mM KCl, 1.18 mM MgSO4, 10 mM glucose, 1 
mM Na2HPO4, 20 mM hepes, pH 7.4).  CaCl2 was added to make a 1.3 mM solution. 
The samples were put on a rocking plate in an incubator at 37 °C. At different time 
points a 200 µl aliquot was taken from the samples for analysis. The aliquot taken at 
time point zero (TO) was used as a control. Hereafter aliquots were collected at 30 
min (T0.5), 1h (T1), 2h (T2), 3h (T3), 4h (T4), 5h (T5) and 6h (T6). The aliquots 
were centrifuged at 20 000 g for eight min. The supernatant was collected (Krebs 
buffer) and the pellet was resuspended in 50 µl RIPA buffer with protease inhibitors. 
The sample was vortexed for 15 sec before centrifuged again at 20 000 g for eight 
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min. The supernatant (synaptosol) was taken of the pellet (membranes and organel-
bound proteins) and stored separately until all samples were collected. 
 
2.18 Proteomic techniques  
 
2.18.1 iTRAQ proteomics 
Protein extracts were sent to Douglas Lamont at the ‘Fingerprint’ Proteomics 
facility in the university of Dundee, where the mass spectrometry with the necessary 
preparations was performed. 
Protein was extracted in an MEBC buffer (50 mM Tris, 100 mM NaCl, 5 mM 
NaEDTA, 5 mM NaEGTA, 40 mM β-glycerophosphate, 100 mM sodium fluoride 
(NaF), 100 mM sodium orthovanadate, 0.25 % NP-40, 1 Roche ‘complete’ protease 
inhibitor tablet, pH 7.4) before acetone precipitation and labelling for iTRAQ 
analysis. Synaptic hippocampal samples (N=9 mice per genotype) were precipitated 
with -20 °C chilled acetone (1:4, v/v) and stored at -20 °C overnight. The precipitates 
were spun at 4 °C for 10 min then washed with an acetone:water mixture (4:1,v/v) 
twice prior to air-drying. The pellets were then resuspended in an iTRAQ sample 
buffer (25 µl of 500 mM TEAB, 1 µl of denaturant (2% SDS) and 2 µl of reducing 
agent (TCEP)). The samples were allowed to incubate for 1 hour at 60 °C prior to 
protein estimation in triplicate (3 × 1 µl) by Micro BCA assay. Aliquots of each 
sample equivalent to 100 µg were made up to 28 µl using the iTRAQ sample buffer 
minus denaturant. To each sample, 1 µl of 84 mM indole-3-acetic acid (IAA) was 
added, and the samples were mixed and spun prior to incubation at room temperature 
in the dark for 30 min. To each sample, 10 µl of a 1 µg/µl solution of trypsin 
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(sequencing grade, Roche) in water was added and the samples incubated overnight 
on a shaking platform at 30 °C. To each vial of iTRAQ reagent, 70 µl of ethanol was 
added, mixed and spun prior to transfer to each sample vial. The pH value was 
checked for each sample to ensure pH was 8.0 prior to incubation for 1 hour at room 
temperature. One hundred microliters of water were added to each sample to quench 
the reaction prior to pooling of the four iTRAQ-labelled samples and subsequent 
drying by vacuum centrifugation. Samples were run in duplicate using the 4-plex 
system (114 &116 were extracts from Smn-/-;SMN2 and 115 & 117 were extracts 
from Smn+/+;SMN2). The pooled iTRAQ sample was re-suspended in 25 % 
acetonitrile/ 0.1 % formic acid (50 ml) prior to loading through a home-made SCX 
ziptip using a 10 % slurry of Poros HS (10 ml) in a methanol:water mixture (50:50). 
The SCX ziptip was equilibrated with 25 % acetonitrile/ 0.1 % formic acid (3 × 25 
ml) prior to loading of the pooled iTRAQ sample. After sample loading, the SCX 
ziptip was washed with 25 % acetonitrile in 0.1 % formic acid (3 × 25 ml). The 
bound iTRAQ peptides were eluted from the SCX ziptip using increasing millimolar 
concentrations of sodium chloride (5, 10, 20, 50, 100,150, 200, 150, 300, 400, 800) 
in 25 % acetonitrile/ 0.1 % formic acid (2 × 25 ml). A final elution of the SCX ziptip 
with 200 mM NH4OH in 50 % propanol was used to remove most of the 
hydrophobic peptides. Each fraction from the SCX ziptip was then dried by vacuum 
centrifugation and stored until analysed by nano liquid chromatography-mass 
spectrometry/mass spectrometry (nLC-MS/MS). Prior to the analysis, each dried 
SCX fraction was re-suspended in 35 µl of 1 % formic acid and 10 µl aliquots were 
injected onto an Agilent 6520 Q-TOF using an Agilent 1200 series nanoLC system 
with microfluidic interface. Raw data files were converted to mascot generic file 
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(mgf) by MassHunter workstation software prior to merging of the files with Mascot 
Daemon and subsequent database (international protein index; IPI Mouse) searching 
with the Mascot search engine (Matrix Science, Version 2.2). 
 
2.18.2 Label-free proteomics 
Protein was extracted in MEBC Buffer (50 mM TRIS, 100 mM NaCl, 5 mM 
NaEDTA, 5 mM NaEGTA, 40 mM β-glycerophosphate, 100 mM sodium fluoride 
(NaF), 100 mM sodium orthovanadate, 0.25 % NP-40, 1 Roche ‘complete’ protease 
inhibitor tablet, pH 7.4). Protein concentration was determined by BCA assay 
according to manufacturers instructions on solubilized muscle (WT-Rostral P1 was 
compared to KO-Rostral P1 and WT-Rostral P5 was compared KO-Rostral P5).  
 
Protein extracts were sent to Douglas Lamont at the ‘Fingerprint’ Proteomics 
facility in the university of Dundee, where the mass spectrometry with the necessary 
preparations was performed. 
Ten µg aliquots of each muscle type were reduced with 10 mM DTT and alkylated 
with 50 mM iodoacetamide prior to digestion with trypsin (Roche, sequencing grade) 
overnight at 30 °C. Technical replicates (3 x 2.5 µg) of each digested muscle type 
were injected onto a nLC-MS/MS system (Ultimate 3000 (Dionex) coupled to a LTQ 
Orbitrap XL (Thermo Scientific). The peptides from each digest were separated over 
a 65 min linear gradient from 5-35 % acetonitrile in 0.1 % formic acid. The LTQ 
Orbitrap XL was configured with a TOP 5 methodology comprising a 60 K 
resolution FT-MS full scan followed by IT-MS/MS scans for the 5 most intense 
peptide ions.  
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The raw data files were sent back to me for analysis. Progenesis LC-MS (version 
4.0) software was used for label free differential analysis and subsequent 
identification and quantitation of relative ion abundance ratios, both up-regulated and 
down-regulated. Individual peptide sequences generated by the proteomics analysis 
were submitted to the IPI database (chapter 3) or Swiss-Prot (chapter 4) for protein 
identification. As an indication of identification certainty, the false discovery rate for 
peptide matches above identity threshold was 9.39 % for P1 data and 3.34 % for P5 
data.  
 
2.19 In silico protein network analyses 
 
Ingenuity Pathways Analysis (IPA) application (Ingenuity Systems, version 1.0) was 
used. IPA dynamically generates networks of gene, protein, small molecule, drug, 
and disease associations on the basis of “hand-curated” data held in a proprietary 
database. More than 90 % of the information in this database is “expert-curated” and 
is drawn from the full text of peer-reviewed journals. Less than 10 % of interactions 
have been identified by techniques such as natural language processing. Networks 
generated by IPA were limited in this study to a maximum of 35 members and are 
enriched for the input proteins. To enhance the explorative interpretation of data, 
networks are ranked according to a score calculated via a right tailed Fisher’s exact 
test. This test outputs a value that takes into account the original input proteins of 
interest and the size of the network generated. The value enables the application to 
approximate how relevant the network is to the analysis. It should be noted that this 
score does not indicate the biological relevance or quality of the network but simply 
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provides a useful indicator with which to start an explorative analysis. Further 
information on the computational methods implemented in IPA can be obtained from 




When two groups were compared either the parametric unpaired two-tailed t-test or 
the non-parametric Mann Whitney test was used (P<0.05). For comparisons between 
more than two groups a one-way ANOVA with Tukey’s multiple comparison test or 
the non-parametric Kruskal-Wallis test with Dunn’s post test was used. All tests 
were performed in Prism software.  
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Chapter 3  





Whilst most research to date has focused on examining how low levels of SMN lead 
to pathological changes in motor neurons, the contribution of muscle to the 
pathogenesis of SMA remains unclear. Although pathological changes in muscle, 
including evidence of increased levels of apoptosis, are a well-established hallmark 
of SMA (Fidzianska et al. 1990; Tews and Goebel 1997; Guettier-Sigrist et al. 2002; 
Stathas et al. 2008; Dachs et al. 2011), it has generally been assumed that changes in 
muscle occur simply as a secondary consequence of the degeneration of innervating 
lower motor neurons, rendering muscle fibers denervated. Studies have shown that 
restoring SMN protein levels in neurons can significantly ameliorate disease 
progression in SMA animal models (Chan et al. 2003; Gavrilina et al. 2008). 
However, these studies cannot rule out an additional contribution resulting from 
restoration of SMN levels in muscle, raising the possibility that intrinsic responses to 
low levels of SMN in skeletal muscle may also contribute directly to SMA 
pathogenesis (Braun et al. 1995; Greensmith and Vrbova 1997; Cifuentes-Diaz et al. 
2001; Chan et al. 2003; Arnold et al. 2004; Shafey et al. 2005; Rajendra et al. 2007; 
Vrbova 2008; Martinez-Hernandez et al. 2009). Moreover, SMN protein is present in 
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muscle sarcomeres in both mice and Drosophila, alongside other associated SMN 
complex proteins such as gemins (Rajendra et al. 2007; Walker et al. 2008).  
Establishing whether skeletal muscle directly contributes to SMA pathogenesis 
therefore remains a critical question for understanding SMA pathogenesis as well as 
for the successful targeting of future therapeutic strategies.  
 
Previous attempts to address this question have been hampered, at least in part, by 
the fact that it has proven difficult to distinguish secondary pathological changes, 
induced as a consequence of denervation due to functional and structural deficits in 
lower motor neurons, from changes intrinsic to muscle. Moreover, in vitro studies of 
isolated muscle fibers from SMA patients (Anderson et al. 2003; Arnold et al. 2004; 
Martinez-Hernandez et al. 2009) are similarly defined by the fact that they are, as a 
direct result of the experimental protocol, devoid of lower motor neuron innervation 
and therefore denervated.  
 
In this chapter, I have utilised a skeletal muscle preparation from an established 
mouse model of SMA (Smn-/-;SMN2; hereafter referred to as the severe SMA mouse 
model (Monani et al. 2000)) where it is possible to examine molecular changes 
occurring in skeletal muscle in vivo, in the absence of any detectable denervation-
inducing changes in corresponding lower motor neurons. I used this preparation to 
reveal modifications in the molecular composition of skeletal muscle in SMA mice at 
a pre-symptomatic age, with a molecular profile distinct from that of denervated 
muscle. The findings were confirmed in a milder mouse model of SMA and also in 
muscle biopsies from SMA patients. Finally, I demonstrate that molecular pathology 
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of skeletal muscle in SMA mice can be ameliorated by treatment with the FDA-
approved histone deacetylase inhibitor, SAHA. 
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3.2 Results 
 
3.2.1 Characterisation of the caudal and rostral band of levator auris longus 
muscle 
Recent papers have shown that the rate of neuromuscular junction (NMJ) 
degeneration differs considerably between muscles in SMA (Ling et al. 2012; 
Thomson et al. 2012). Muscles (or distinct bands of muscles) such as levator auris 
longus caudal (caudal band of LAL), abductor auris longus (AAL) and transversus 
abdominus (TA) show approximately 60% denervation at late symptomatic time-
points (postnatal day 5; P5) in the severe SMA mouse model compared to littermate 
controls (Thomson et al. 2012). In contrast, other muscles such as levator auris 
longus rostral (rostral band of LAL) and extensor digitorum longus (EDL) show 
100% innervated endplates at the same time point (Thomson et al. 2012). 
 
To identify molecular changes occurring in muscle specifically as a result of low 
levels of SMN and with the absence of denervation due to degeneration of 
innervating lower motor neurons, the rostral band of LAL was used in this study. 
This muscle is located at the back of the neck of the mouse between the ears and is 
easily accessible by micro dissection (Murray et al. 2010). The rostral band of LAL 
is one of the two bands of the homogeneous fast-twitch levator auris longus (LAL) 
muscle. The two distinct bands (rostral and caudal) have separate pools of motor 
neurons innervating them. The motor neurons innervating the caudal band of LAL 
are susceptible to SMA pathology in the severe SMA mouse model, whereas those 
innervating the rostral band of LAL are resistant (Murray et al. 2008). Importantly, 
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previous studies have demonstrated that motor neurons innervating the rostral band 
of LAL develop normally in the pre-symptomatic period (P1-P2; (Murray et al. 
2010)), with both genetic and electrophysiological studies indicating an absence of 
lower motor neuron pathology or neuromuscular junction dysfunction in the rostral 
band of LAL from early-symptomatic SMA mice (Baumer et al. 2009; Ruiz et al. 
2010). The caudal and rostral band of LAL show intrinsically distinct features of 
focal Acetylcholine receptor (AChR) assembly in adult mice after paralysis (Pun et 
al. 2002; Murray et al. 2008). Murray et al. showed that after paralysing the LAL in 
a wild-type mouse for 1 month with repeated subcutaneous injections of Botulinum 
toxin (BotA), there were very few motor nerve terminals showing signs of collateral 
sprouting in the caudal band of the muscle. In contrast, more than 20% of endplates 
in the rostral band of LAL showed clear evidence of terminal collateral sprouting and 
the formation of ectopic AChR microclusters. These results reveal that the caudal 
band of LAL shows a fast synapsing (Fasyn) phenotype, whereas the rostral band 
shows a delayed synapsing (DeSyn) phenotype.  
 
To confirm the Fasyn and Desyn phenotype of the caudal and rostal band of LAL 
respectively, the AChR clustering in these bands were examined during development. 
At embryonic day 16.5 (E16.5) FaSyn muscles show focally organized clusters of 
AChRs assembling in the absence of nerve and the clusters rapidly become aligned 
to presynaptic nerve and Schwann cells. In contrast, DeSyn muscles exhibit 
dispersed microclusters of AChRs. During this developmental time, nerves and 
Schwann cells fail to align with AChR microclusters, and extensive sprouting is 
detected (Pun et al. 2002). Therefore, wild-type mice were taken at E16.5. The LAL 
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was dissected and acetylcholine receptors were labelled using TRITC-conjugated α-
Bungarotoxin (α-BTX). The AChR clusters were analysed in both the caudal and the 
rostral band of LAL, identifying each AChR cluster as one of five distinct degrees of 
compactness (as described in (Pun et al. 2002)) in order to assess their 
developmental status. Figure 3.1 shows example confocal pictures of the five distinct 
types of endplates. The descriptions for each group are shown in table 3.1. A 
compact, mature endplate is given a value 5, whereas a value 1 is given to an 
endplate that shows dispersed microclusters of AChRs and is the least mature form. 
 
Table 3.1 Compactness values of Acetylcholine receptor clusters 
Value Description 
1  prominent labelling along the central half of muscle fiber, multiple central clusters (immature endplate) 
2 prominent extra-cluster labelling, central cluster fragmented (immature endplate) 
3 detectable extra-cluster labelling, one uninterrupted central cluster (immature endplate) 
4 no detectable extra-cluster label, variations in labelling intensity within central synaptic cluster (immature endplate) 
5 no detectable extra-cluster label and uniform labelling of central synaptic cluster (mature endplate) 
 
Endplates from 12 LALs (N=6 fetuses) were scored for their developmental status, 
as shown in figure 3.1. In the caudal band of LAL most endplates appeared as a 
compact uniform labelled cluster of AChRs (value 4 and 5). By contrast, in the 
rostral band of LAL a variety of endplate morphologies were observed, with most 
having extra-cluster labelling, a sign of a not yet mature and compact endplate (value 
3). These observations confirm that the caudal band of LAL shows a FaSyn 
phenotype, whereas the rostral band of LAL shows a DeSyn phenotype. 
	  




Figure 3.1 Rostral band of LAL shows a Desyn phenotype whereas the caudal 
band shows a FaSyn phenotype in wild-type mice at E16.5. (A) Confocal 
micrographs representing compactness of acetylcholine receptor (AChR) clustering 
(AChR labelled with TRITC-conjugated α-Bungarotoxin). Value 1 endplates have 
dispersed microclusters of AChRs. Value 2 endplates have fragmented central 
clusters (indicated by arrow) and show extra-cluster labelling (indicated by asterisk). 
Value 3 endplates have one uninterrupted central cluster, but have extra-cluster 
labelling (indicated by asterisk). Value 4 endplates show variations in central cluster 
labelling, but no detectable extra-cluster labelling. Value 5 endplates represent a 
mature endplate, showing uniform labelling of one central cluster. (B) Graph 
showing percentage of endplates in each of the categories (value 1-5) for the rostral 
and caudal bands of 12 LALs from 6 wild-type mice at E16.5. The endplates were 
analysed and each endplate was identified as one of five distinct degrees of 
compactness. The majority of endplates in the rostral band of LAL were one central 
cluster but show prominent extra-cluster labelling (value 3). The caudal band of LAL 
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3.2.2 The rostral band of levator auris longus allows examination of intrinsic 
changes to skeletal muscle in SMA 
To validate the absence of any degenerative pathology in the lower motor neurons 
innervating the rostral band of LAL, the whole LAL was dissected from P5 severe 
SMA mice and was immunohistochemically labelled with antibodies against 
neurofilament protein (green), and AChR were labelled using TRITC-α-BTX (red) 
(figure 3.2). A higher level of nerve terminal loss (vacant endplates) was observed in 
the caudal band. Almost 30% of the endplates in the caudal band of LAL were 
denervated at this late symptomatic time point, whereas in the rostral band of LAL 
there is almost no denervation (Murray et al. 2008). The absence of any degenerative 
pathology in lower motor neurons innervating the rostral band of LAL in severe 
SMA mice at a pre-symptomatic age (P1) was validated: >95% of neuromuscular 
junctions were fully innervated by intact motor axon collaterals in both severe SMA 
mice and littermate controls and there was no evidence of abnormal neurofilament 
accumulations in motor nerve terminals in any of the muscles examined (figure 3.3; 
N=3 mice per genotype; P>0.05, Mann Whitney test).  
 
Similarly, there was no evidence for denervation-induced muscle fiber shrinkage in 
the rostral band of LAL from severe SMA mice at P1 (figure 3.4A/B; N=3 mice per 
genotype; P.0.05, unpaired, two-tailed t-test). In addition the muscle fibers showed a 
normal pattern of striations (figure 3.4C). In both genotypes the average muscle fiber 
diameter was 10 µm. Taken together with the previously published studies, this leads 
to the conclusion that the rostral band of LAL at P1 represents a muscle preparation 
from a SMA mouse where no detectable neuronal degeneration or muscle 
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denervation is present, making it ideal for intrinsic molecular studies of muscle in 
SMA. As expected, however, there was still a 70-80% reduction in expression levels 
of SMN protein in the rostral band of LAL from severe SMA mice at P1 compared 
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Figure 3.2 Selective vulnerability in synapses in the caudal band of LAL in 
SMA mice at P5. The middle panel shows a low-magnification overview of the 
entire muscle innervation pattern of the LAL from an SMA mouse (Smn-/-;SMN2). 
The red line indicates the demarcation point between the rostral band of the muscle 
(to the right) and the caudal band of the muscle (to the left). The left panel shows an 
example of a high-power confocal micrograph of the neuromuscular junctions in the 
caudal band of the muscle at postnatal day 5 (P5) (green; immunohistochemically 
labelled neurofilament and SV2 synaptic vesicle protein to highlight motor neurons/ 
red; AChR on skeletal muscle fibers labelled with TRITC-conjugated α-BTX). Note 
the presence of widespread neuronal pathology evidenced by the loss of neuronal 
inputs to the endplates. The right panel shows an example of a high-power confocal 
micrograph of neuromuscular junctions in the rostral band of the muscle at P5. Note 
the preservation of motor neuron inputs. Scale bar = 20 µm. 
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Figure 3.3 The rostral band of LAL at pre-symptomatic time point (P1) in SMA 
mice provides an experimental model to study SMN-induced changes in the 
molecular composition of muscle in the absence of neuronal pathology at P1. 
(A) Representative confocal micrographs showing immunohistochemically labelled 
neuromuscular junctions from the rostral band of LAL in SMA (right panel) and 
control mice (left panel) at postnatal day 1 (P1). Note the complete absence of any 
overt neuronal pathology (e.g. vacant endplates or neurofilament accumulations). 
(B) Bar chart (mean ± SEM) showing that there is no difference in the number of 
innervated endplates (N=3 mice per genotype; P>0.05, Mann Whitney test). Scale 
bar = 20 µm. 
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Figure 3.4 There is no muscle fiber shrinkage in the rostral band of LAL from 
SMA mice at pre-symptomatic time point (P1). (A) Representative western blots 
showing levels of SMN and beta-V-tubulin (loading control). (B) Bar chart (mean ± 
SEM) showing muscle fiber diameter in the rostral band of LAL from both SMA and 
control mice at P1. There is no denervation-induced muscle fiber atrophy in the 
SMA mice (N=3 mice per genotype; P>0.05; unpaired, two-tailed t-test). (C) Light 
microscopy micrographs show no shrinkage in muscle fiber size in SMA mice 
compared to littermate controls. In addition, muscle fibers from SMA mice show a 
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3.2.3 Label-free proteomics analysis of the rostral band of levator auris 
longus reveals molecular alterations to skeletal muscle in pre-symptomatic 
severe SMA mice 
A highly sensitive label-free proteomic analysis was used to quantify and compare 
the molecular composition of the rostral band of LAL in P1 severe SMA mice and 
littermate controls (WT littermate controls; Smn+/+;SMN2; N=9 mice per genotype; 
for a detailed description of the mass spectrometry see chapter 2). The raw mass-
spectrometry data from SMA and control mice was uploaded to Progenesis label-free 
software for analysis. From each sample three replicate runs were performed. One 
control replicate was chosen as a reference dataset, based on a clear and 
representative feature pattern with minimum distortion. All other runs were then 
aligned to this reference dataset using the Progenesis software. Alignment was 
performed to correct for the variable elution of peptides during chromatographic 
separation. Although Progenesis software automatically aligns data from each 
experimental run, vectors were also added manually to align peptide ions where 
needed. After aligning data from each of the runs, data filtering was performed. All 
ions that were identified with an early (less than 6 minutes) or late retention time 
(more than 72 minutes) were excluded. The runs were then grouped according to the 
genotype of the mouse (e.g. into pooled control and SMA datasets) and an ANOVA 
statistical test was performed to determine whether the means of the two groups were 
equal.  
 
At this stage further stringent filtering was performed by excluding all 1+ charged 
ions on the basis that they were unlikely to represent peptides. Once the list of 
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candidate peptide ions to identify was created, their MS/MS data was exported to the 
IPI mouse protein database to allow comparison to known peptides, and 
subsequently proteins. The output of this search was then re-imported to Progenesis 
software in order to allow further filtering by excluding peptides that were associated 
with more than one protein (conflict resolving). Also, peptides that were improperly 
cleaved by trypsin were excluded (e.g. any peptide that had a Lysine or Arginine mid 
sequence, or any peptides not ending with a Lysine or Arginine). A filtering protocol 
was then applied for subsequent stringent positive identification of proteins, with 
only those proteins identified by two or more unique peptides taken forward for 
further analysis. 
 
This stringent filtering resulted in a list of 65 out of the 345 identified individual 
proteins (19%) that were up-regulated >20% in severe SMA mice (table 3.2). Of 
these, 20 proteins showed a greater than 2-fold increase in expression levels. In 
addition, 32 out of the 345 identified proteins (9%) were down-regulated >20% in 
severe SMA mice (table 3.3). The increased expression profiles of many proteins in 
severe SMA tissue confirmed that the changes observed were active responses to low 
levels of SMN in muscle, and were not simply occurring as a result of a global 
decrease in protein synthesis. Initially the proteomics data was validated by 
quantifying expression levels of one significantly down-regulated protein 
parvalbumin, (PVALB, hereafter referred to as parvalbumin) in 
immunohistochemically labelled rostral band of LAL preparations (figure 3.5). The 
images (figure 3.5A/B) were taken with exactly the same settings on the microscope 
to ensure comparability (for example exposure time and digital gain). Fluorescence 
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intensity of parvalbumin staining was measured across four randomly selected areas 
of each muscle, revealing a ~25% decrease in levels in the SMA mouse compared to 
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Table 3.2 Proteins up-regulated > 20% with peptide count > 1 in the rostral 
band of LAL from SMA mice compared with littermate controls at P1 
  
Vdac2 Voltage-dependent anion-selective channel 
protein 2
IPI00122547.1 5.12 2 113.2 4.05E-04
Rpl32 60S ribosomal protein L32 IPI00230623.8 3.33 2 77.7 5.92E-03
Actc1 Putative uncharacterized protein IPI00654242.1 3.07 6 420.1 1.52E-06
Acta1 Actin IPI00110827.1 3.01 6 447.1 1.61E-06
Atp5c1 ATP synthase subunit gamma, IPI00313475.1 2.95 2 116.8 1.59E-04
- 11 kDa protein IPI00329998.3 2.58 2 117.1 4.67E-06
Alb Serum albumin IPI00131695.3 2.51 13 615.8 1.07E-05
Mylpf Myosin regulatory light chain 2 IPI00224549.3 2.5 6 372.8 5.08E-04
Rpl8 60S ribosomal protein L8 IPI00137787.3 2.48 2 92.1 9.31E-05
Pgk1 Phosphoglycerate kinase 1 IPI00555069.3 2.36 5 326.2 9.71E-08
Atp5b ATP synthase subunit beta IPI00468481.2 2.35 3 271.2 3.17E-05
Dcn Decorin IPI00123196.1 2.33 2 51.0 1.41E-04
Apoa1 Apolipoprotein A-I IPI00121209.1 2.24 2 93.5 2.01E-04
Lgals1 Galectin-1 IPI00229517.5 2.23 3 174.3 5.17E-04
Mdh2 Malate dehydrogenase, mitochondrial IPI00323592.2 2.21 3 143.5 6.59E-06
Cs Citrate synthase, mitochondrial IPI00113141.1 2.17 2 85.1 3.66E-05
Atp5o;  ATP synthase subunit O, mitochondrial IPI00118986.1 2.08 2 85.4 5.84E-04
Aco2 Aconitate hydratase, mitochondrial IPI00116074.1 2.05 5 219.6 9.84E-06
Trf Serotransferrin IPI00139788.2 2.02 11 645.3 9.07E-05
Afp Alpha-fetoprotein IPI00113163.1 2 5 288.8 1.20E-04
Eif4a1 Eukaryotic initiation factor 4A-I IPI00118676.3 1.98 2 115.4 9.41E-04
Tpt1;Gm14456 Translationally-controlled tumor protein IPI00129685.2 1.94 2 122.6 2.77E-06
Gm10916 Putative uncharacterized protein IPI00875087.1 1.93 2 100.5 2.08E-05
Srl Isoform 1 of Sarcalumenin IPI00224456.2 1.92 4 201.9 4.45E-04
Cct8 T-complex protein 1 subunit theta IPI00469268.5 1.91 2 82.3 1.56E-03
Spnb2 Isoform 2 of Spectrin beta chain, brain 1 IPI00121892.9 1.87 3 86.5 6.98E-03
Hnrnpk Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein K
IPI00223253.1 1.86 2 77.0 0.09
Myl1 Isoform MLC1 of Myosin light chain 1/3, IPI00312700.4 1.81 3 143.9 1.34E-04
Hist1h2bf;Hist1h2bj;
Hist1h2bl;Hist1h2bn
 Histone H2B type 1-F/J/L IPI00114642.4 1.8 2 134.6 2.52E-04
Rpl6 60S ribosomal protein L6 IPI00313222.5 1.8 2 62.4 6.34E-04
Spna2 Isoform 2 of Spectrin alpha chain, brain IPI00753793.2 1.79 3 120.5 7.42E-04
Anxa6 annexin A6 isoform b IPI00310240.4 1.78 4 289.0 1.20E-04
Nono Isoform 1 Non-POU domain-containing octamer-binding 
protein
IPI00320016.7 1.71 2 67.2 0.02
Des Desmin IPI00130102.4 1.7 2 112.4 7.06E-04
Hspb1 Isoform A of Heat shock protein beta-1 IPI00128522.1 1.69 3 81.8 1.62E-04
Tnnc2 Troponin C, skeletal muscle IPI00284119.7 1.69 2 125.2 2.80E-03
Myom2 myomesin 2 IPI00115823.2 1.68 3 102.2 5.32E-04
Tpm1 Isoform 1 of Tropomyosin alpha-1 chain IPI00123316.1 1.65 4 168.4 4.07E-03
Ywhag 14-3-3 protein gamma IPI00230707.6 1.62 2 100.7 0.02
Csrp3 Cysteine and glycine-rich protein 3 IPI00118153.1 1.62 2 96.4 4.59E-04
Idh2 Isocitrate dehydrogenase [NADP] IPI00318614.9 1.61 3 211.1 6.00E-05
Pfkm 6-phosphofructokinase, muscle type IPI00331541.5 1.59 4 148.6 1.92E-04
Nme2 Nucleoside diphosphate kinase B IPI00127417.1 1.57 5 183.0 3.35E-03
Pygm Glycogen phosphorylase, muscle form IPI00225275.5 1.56 3 144.8 9.94E-04
Hnrnpa1 Putative uncharacterized protein IPI00553777.2 1.55 2 118.3 6.14E-05
Ckm Creatine kinase M-type IPI00127596.1 1.53 13 886.2 3.24E-04
Eef1g Elongation factor 1-gamma IPI00318841.4 1.53 2 122.1 6.36E-03
Actb  Actin, cytoplasmic 1 IPI00110850.1 1.51 4 302.0 3.12E-04
Hbb-b1 Hemoglobin subunit beta-1 IPI00553333.2 1.5 3 324.0 3.90E-03
Pa2g4 Proliferation-associated protein 2G4 IPI00119305.3 1.47 2 70.1 0.08
Myh8 Myosin-8 IPI00265380.4 1.46 13 750.8 2.74E-04
Vim Vimentin IPI00227299.6 1.42 5 207.5 2.42E-03
Hsp90b1 Endoplasmin IPI00129526.1 1.41 2 158.8 0.02
Hnrnpa3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3
IPI00269661.1 1.39 2 105.2 2.63E-03
Fhl1 four and a half LIM domains protein 1 isoform 2 IPI00776352.1 1.36 8 485.9 2.84E-03
Tpm2  Isoform 1 of Tropomyosin beta chain IPI00123319.1 1.36 4 179.0 0.04
Cryab Alpha-crystallin B chain IPI00138274.1 1.33 3 117.6 1.17E-03
Actn2 Alpha-actinin-2 IPI00331664.3 1.3 2 66.4 0.02
Casq2 Calsequestrin-2 IPI00869462.1 1.29 3 197.9 2.61E-03
Hbb-b2 Hemoglobin subunit beta-2 IPI00316491.4 1.27 5 285.0 0.02
Pdia3 Protein disulfide-isomerase A3 IPI00230108.6 1.27 3 116.2 9.86E-03
Hspa8 Heat shock cognate 71 kDa protein IPI00323357.3 1.25 4 208.1 0.07
Ppid Peptidyl-prolyl cis-trans isomerase D IPI00132966.3 1.25 2 82.2 0.02
Cltc Clathrin heavy chain 1 IPI00169916.11 1.24 4 234.6 1.26E-03




FoldGene name Protein name Accession
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Table 3.3 Proteins down-regulated > 20% with peptide count > 1 in the 
rostral band of LAL from SMA mice compared to littermate controls at P1 
 
  
P4hb Putative uncharacterized protein IPI00122815.3 -2.66 3 111.5 6.29E-05
Pvalb Parvalbumin alpha IPI00230766.4 -2.65 2 90.4 3.72E-05
Rcn3 Reticulocalbin-3 IPI00221798.1 -2.28 2 173.7 1.35E-05
Rps7 40S ribosomal protein S7 IPI00136984.1 -2.15 2 63.7 4.38E-04
Anxa5  Annexin A5 IPI00317309.5 -2.05 2 98.2 8.74E-03
Hist1h1d Histone H1.3 IPI00331597.6 -2.03 4 168.9 0.03
Vcl Vinculin IPI00405227.3 -1.9 2 90.6 1.50E-04
H2afv Histone H2A IPI00320149.2 -1.84 2 79.0 7.81E-05
Serpinh1 serpin H1 precursor IPI00880252.1 -1.72 5 250.8 5.98E-05
Rpl3 60S ribosomal protein L3 IPI00321170.8 -1.72 2 100.3 1.69E-03
Rpl7a-ps3 Putative uncharacterized protein Gm5044 IPI00265107.4 -1.72 2 61.3 1.91E-03
Cct7 T-complex protein 1 subunit eta IPI00331174.5 -1.69 2 49.9 0.04
Pkm2 Isoform M1 Pyruvate kinase isozymes M1/M2 IPI00845840.1 -1.66 5 309.1 2.87E-04
Eef2 Elongation factor 2 IPI00466069.3 -1.64 5 251.4 3.58E-04
Hist1h1c Histone H1.2 IPI00223713.5 -1.64 3 155.1 0.05
Akr1b3 Aldose reductase IPI00223757.4 -1.59 2 67.1 6.41E-05
Pdlim5 Putative uncharacterized protein IPI00467374.1 -1.56 3 142.6 2.90E-06
Flna Isoform 1 Filamin-A IPI00131138.10 -1.5 3 159.7 2.02E-04
Ckap4 Cytoskeleton-associated protein 4 IPI00223047.2 -1.5 3 151.4 8.14E-04
Sept8 Isoform 2 Septin-8 IPI00331497.9 -1.48 2 67.6 1.78E-03
Car3 Carbonic anhydrase 3 IPI00221890.6 -1.46 2 120.7 3.67E-05
Anxa2 Annexin A2 IPI00468203.3 -1.42 6 354.3 6.93E-04
Bin1 Isoform 1 Myc box-dependent-interacting protein 1 IPI00114352.1 -1.41 2 187.0 2.86E-04
Sec23a Protein transport protein Sec23A IPI00123349.2 -1.37 2 77.8 1.21E-03
Myom1 Isoform 2 of Myomesin-1 IPI00281109.3 -1.35 4 186.8 6.96E-04
Trim72 Tripartite motif-containing protein 72 IPI00462157.1 -1.34 3 130.3 1.12E-03
Rpl28;Rpl28-ps1 
60S 
ribosomal protein L28 IPI00222547.6 -1.34 2 59.7 4.53E-03





Glyceraldehyde-3-phosphate dehydrogenase IPI00273646.9 -1.23 8 625.5 4.97E-03
Ppia Peptidyl-prolyl cis-trans isomerase IPI00554989.3 -1.22 4 170.1 0.02
Gpi1 Glucose-6-phosphate isomerase IPI00228633.7 -1.2 4 169.7 1.86E-03
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Figure 3.5 Validation of reduced levels of parvalbumin in muscle from an SMA 
mouse using quantitative immunohistochemistry at P1. (A/B) Representative 
fluorescence micrographs of the rostral band of LAL muscle preparations from an 
SMA mouse and (B) littermate control (A) showing expression levels of parvalbumin. 
Note that the same microscope settings were used (i.e. exposure time and digital 
gain). (C) Bar chart (mean ± SEM) showing a ~ 25% reduction in parvalbumin levels 
in the rostral band of LAL of an SMA mouse compared to a littermate control (n=4 
measurement areas, N=1 mouse per genotype). Scale bar = 10 µm. 
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To identify any functional clustering of proteins found to have modified expression 
levels in the rostral band of LAL of severe SMA mice, a systems level analysis of the 
proteomics data was performed using Ingenuity Pathway Analysis software. This 
software incorporates information extracted by experts from the published scientific 
literature, allowing analysis of candidate proteins with respect to their known roles in 
biological functions (Wishart et al. 2010). 83 out of the 97 proteins identified were 
listed in this software and therefore available for data mining of the existing 
published literature to determine potential functional clustering. This analysis 
revealed that many of the proteins with modified expression profiles in muscle from 
severe SMA mice are reported to regulate muscle function and pathology (table 3.4). 
For example, the functional cluster most significantly changed in SMA muscle 
contained proteins known to contribute to skeletal and muscular disorders: 44 of the 
proteins changed in severe SMA muscle (53% of the total list) have links to these 
disorders, 6 of which also directly contribute to myopathies (table 3.4). Similarly, 
modifications were observed in clusters of proteins contributing to cell death 
pathways and morphological development (table 3.4). A different analysis at the 
systems level also highlighted disruption of two protein-interaction networks 
(identified by known direct or indirect interactions between individual proteins) 
implicated in development and function of the skeletal and muscular systems (figure 
3.6). Green nodes represent proteins up-regulated in severe SMA mice compared to 
littermate controls, red nodes represent down-regulated proteins, and grey nodes 
represent proteins in the software-defined interaction network that were not 
identified by, or were found to be unchanged in, the proteomics dataset.  The protein 
interaction network shown in figure 3.6A represents 27 out of the total of 35 proteins 
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that were changed in SMA mice. In figure 3.6B 30 out of a total of 35 proteins were 




Figure 3.6 Identification of two protein-interaction networks with altered 
expression in muscle from pre-symptomatic SMA mice (P1).  (A/B) Ingenuity 
pathway analysis of the rostral band of LAL proteomics data from SMA and wild-
type littermate controls at P1 identified two protein-interaction networks significantly 
disrupted in SMA muscle. Both interaction networks were reported by the analysis 
software to be involved in “skeletal and muscular system development and function”. 
Green nodes represent proteins that are increased in SMA mice, and red nodes 
represent proteins that are decreased compared to littermate controls. Grey nodes 
represent proteins in the software-defined interaction network that were not 
identified by or were found to be unchanged in the proteomics dataset. A normal line 
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Table 3.4 Systems level analysis of functional pathway changes in the rostral 
band of LAL muscle in SMA mice at P1 
 
  





skeletal and muscular disorder 44 53.0 2.31E-08 ACTA1, ACTB, ACTN2, ALB, ANXA2, ANXA5, APOA1, 
ATP5C1, BIN1, CA3, CASQ2, CKAP4, CLTC, CRYAB, DES, 
EEF2, EEF1G, FH, FHL1, FLNA, GPI, HNRNPA1, HNRNPA3, 
HSP90B1, HSPA8, HSPB1, LGALS1, MDH1, MYH8, MYL1, 
MYOM1, MYOM2, NONO, PDIA3, PFKM, PGK1, PKM2, 
PPIA, PVALB, RPL3, RPL32, TNNC2, TPM2, VIM
tumorigenesis 41 49.4 5.12E-06 ACTB, ACTC1, AFP, ALB, ANXA2, ANXA5, APOA1, ATP5C1, 
CA3, CKM, CRYAB, CSRP3, DCN, EIF4A1, FH, FLNA, 
FSCN1, GPI, HBB, HBD, HNRNPA1, HNRNPK, HSP90B1, 
HSPA8, HSPB1, LGALS1, MDH1, MYH8, MYLPF, P4HB, 
PA2G4, PGK1, PKM2, PPIA, SPTBN1, TNNC2, TPM1, TPM2, 
VDAC2, VIM, YWHAG
cell death 29 34.9 9.60E-04 ACTB, ACTC1, AFP, ALB, APOA1, BIN1, CCT7, CCT8, 
CRYAB, DCN, FLNA, GPI, HIST1H1C, HNRNPA1, HSPA8, 
HSPB1, LGALS1, MDH1, NME2, P4HB, PA2G4, PDIA3, 
PKM2, PPIA, PPID, TF, TPM1, VCL, VDAC2
inflammatory disorder 29 34.9 2.32E-02 ACO2, ACTA1, ACTB, ALB, ANXA5, APOA1, CA3, CLTC, 
CRYAB, EEF2, EEF1G, GPI, HBD, HNRNPA1, HNRNPA3, 
HNRNPK, HSP90B1, HSPA8, LGALS1, NONO, P4HB, PDIA3, 
PGK1, PPID, RPL32, TF, TPM2, VDAC2, VIM
growth of cells 24 28.9 1.18E-04 ACTB, AKR1B1, ALB, ANXA2, ATP5B, BIN1, CA3, CCT7, 
CRYAB, DCN, DES, EIF4A1, HNRNPA1, HNRNPK, LGALS1, 
NME2, PA2G4, PDIA3, PGK1, PKM2, SERPINH1, TF, TPM1, 
TPM2
cardiovascular disorder 24 28.9 2.01E-02 ACTA1, ACTC1, ACTN2, ALB, ANXA2, ANXA5, APOA1, BIN1, 
CA3, CASQ2, CKAP4, CKM, CRYAB, CS, CSRP3, DES, 
FHL1, GPI, MYH8, PPIA, SPTBN1, TPM1, VCL, VIM
proliferation of cells 23 27.7 1.10E-02 AFP, AKR1B1, ANXA2, APOA1, BIN1, CLTC, CRYAB, DCN, 
FHL1, FSCN1, GPI, HNRNPK, HSP90B1, LGALS1, NME2, 
PA2G4, PGK1, PPIA, SPTAN1, SPTBN1, TF, VIM, YWHAG
connective tissue disorder 21 25.3 1.38E-02 ACTA1, ALB, ANXA5, APOA1, CLTC, CRYAB, EEF2, EEF1G, 
FLNA, GPI, HNRNPA1, HNRNPA3, HSP90B1, HSPA8, 
LGALS1, NONO, PDIA3, PGK1, RPL32, TPM2, VIM
developmental disorder 15 18.1 9.47E-04 ACTC1, ALB, APOA1, CA3, CASQ2, CRYAB, CSRP3, DES, 
FLNA, HBB, MYOM1, SEC23A, TF, TPM1, VCL
progressive motor neuropathy 15 18.1 8.09E-03 ACTB, ANXA2, ANXA5, CA3, CRYAB, FH, HSPB1, MDH1, 
MYOM1, PDIA3, PDLIM5, PGK1, PVALB, RPL3, VIM
contraction of muscle 14 16.9 6.26E-12 ACTA1, ACTC1, ACTN2, ANXA6, CASQ2, CRYAB, DES, 
MYL1, MYLPF, MYOM1, MYOM2, TNNC2, TPM1, TPM2
cell movement 13 15.7 5.28E-03 ACTB, ANXA2, APOA1, FLNA, FSCN1, GPI, HSPB1, 
LGALS1, PA2G4, PPIA, TPM1, VCL, VIM
formation of filaments 10 12.0 1.07E-05 ACTA1, ACTC1, DES, FHL1, GPI, MYOM1, SERPINH1, 
TPM1, TPM2, VIM
metabolic process of 
carbohydrate
10 12.0 2.40E-04 AKR1B1, APOA1, CKM, CRYAB, CS, GPI, PFKM, PGK1, 
PKM2, PYGM
modification of protein 10 12.0 2.73E-02 APOA1, CCT7, CRYAB, HSPA8, LGALS1, P4HB, PDIA3, 
PPIA, PPID, SPTBN1
developmental process of 
muscle
9 10.8 5.75E-05 ACTC1, CRYAB, CSRP3, DES, HSP90B1, MYLPF, PKM2, 
TPM1, VCL
metabolism of protein 9 10.8 1.78E-02 EEF2, EIF4A1, FLNA, HNRNPK, HSPB1, RPL3, RPL6, RPL8, 
RPL32
binding of normal cells 7 8.4 2.97E-03 ANXA2, ANXA5, APOA1, CKAP4, DCN, PDIA3, VCL
myopathy 6 7.2 3.73E-05 ACTA1, BIN1, CRYAB, DES, FHL1, TPM2
proliferation of connective 
tissue cells
6 7.2 6.64E-03 DCN, GPI, LGALS1, PA2G4, PGK1, TF
modification of mRNA 5 6.0 1.38E-03 ALB, EIF4A1, HBB, HNRNPA1, NONO
development of cytoskeleton 5 6.0 2.66E-03 ACTB, DES, FLNA, FSCN1, TPM1
degradation of DNA 5 6.0 4.05E-03 ALB, BIN1, CRYAB, HNRNPA1, HSPB1
phosphorylation of protein 5 6.0 3.13E-02 APOA1, LGALS1, PDIA3, PPIA, SPTBN1
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3.2.4 Evidence for increased apoptotic cell death in SMA muscle 
The finding that 35% of the proteins submitted for functional clustering analysis 
contribute to cell death pathways (table 3.4) was of particular interest given that 
apoptotic cell death has previously been reported in SMA muscle (Fidzianska et al. 
1990; Tews and Goebel 1997; Guettier-Sigrist et al. 2002; Stathas et al. 2008; Dachs 
et al. 2011). Indeed, several of the protein expression changes identified in the rostral 
band of LAL of severe SMA mice have previously been implicated in activation of 
apoptotic and non-apoptotic cell death pathways (e.g. VDAC2) (Yagoda et al. 2007; 
Yamagata et al. 2009). I investigated whether markers of cell death were increased in 
the rostral band of LAL of severe SMA mice using immunohistochemistry. The 
muscle was labelled for phospho-histone H2AX (H2AX), which is a sensitive marker 
of DNA damage during the early stages of cell death (Plesca et al. 2008; Wen et al. 
2010). Cell nuclei in the LAL were stained with TOPRO-3. The LALs were 
examined using a confocal microscope (63 x magnification). Twenty fields of view 
per muscle (N=3 mice per genotype) were examined and the number of nuclei were 
scored with H2AX staining. A distinction was made between no H2AX labelling, 
moderate accumulation and intense H2AX labelling. In severe SMA mice an 
increased number of cells per mm2 was observed that showed an accumulation of 
H2AX protein around the cell nucleus (figure 3.7; *P<0.05, unpaired, two tailed t-
test). This was not observed in the littermate controls. This suggests an elevated level 
of cell death in muscle from severe SMA mice. Thus, at least some of the protein 
expression changes identified in the rostral band of LAL of SMA mice (e.g. cell 
death proteins; see table 3.4) were contributing directly to biological pathways 
regulating muscle responses to low SMN levels in vivo. 
	  






Figure 3.7 Increased levels of cell death in the rostral band of LAL from SMA 
mice. (A) Representative fluorescence micrographs of the rostral band of LAL from 
SMA mice (bottom panels) and control littermates (top panels) 
immunohistochemically labelled with the cell death marker H2AX (green). Nuclei 
were labelled with TOPRO-3 (red). Almost all muscle nuclei in control mice showed 
no, or weak, H2AX labelling, whereas strong H2AX labelling was easily identified in 
SMA muscles. Images were taken with identical settings on the confocal microscope. 
(B) Bar chart (mean ± SEM) showing a significant increase in the number of cells 
with intense H2AX labelling in the rostral band of LAL of SMA mice compared to 
littermate control (*P<0.05, unpaired, two tailed t-test, N=3 mice per genotype). 
Scale bar = 10 µm.  
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3.2.5 Changes in the molecular composition of skeletal muscle in SMA mice 
are distinct from those elicited following acute or chronic denervation 
The proteomics analysis in this chapter was carried out to examine changes in 
muscle due to low levels of SMN and to exclude changes that are caused by 
denervation occurring as a result of degeneration of the lower motor neurons. To 
confirm that the molecular changes observed in this proteomic screen of SMA 
muscle were different from molecular changes as a result of acute or chronic 
denervation caused by sub-clinical motor neuron pathology, a literature search was 
performed on proteomics studies of chronically denervated muscle (>1 week 
following nerve injury; figure 3.8). I found three papers that showed molecular 
changes in skeletal muscle due to chronic denervation. In figure 3.8 proteins are 
highlighted that were identified in my proteomic screen and protein levels were 
compared to what was found in the literature. The profile of expression changes 
observed in the rostral band of LAL from severe SMA mice was clearly distinct from 
those modified following denervation (figure 3.8) (Li et al. 2005; Sun et al. 2006; 
Sato et al. 2009). For example parvalbumin was decreased in muscle from SMA 
mice but was increased in muscle from rat after denervation (Sato et al. 2009). Beta- 
enolase and triosephosphate-isomerase-1 were both unchanged in SMA muscle, 
however they were shown to be changed due to chronic denervation in muscle 
(figure 3.8).   
 
As the previous molecular studies of denervated muscle were all performed on 
chronically denervated muscle, I also quantified expression levels of two proteins 
significantly altered in SMA muscle, voltage-dependent anion-selective channel 
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protein 2 (hereafter referred to as VDAC2) and parvalbumin in acutely denervated 
tissue. The sciatic nerve in wild-type mice from one leg was lesioned (a ~1 mm 
section of nerve was removed to ensure complete transection) and the denervated 
flexor digitorum brevis (FDB) muscles were isolated from the hind-foot 24 hours 
later and compared to the muscles from the uninjured leg (surgery was performed in 
collaboration with Laura Comley). Morphological evaluation of neuromuscular 
junctions confirmed complete denervation in all muscles examined (examined using 
a fluorescent microscope, no images were taken). However, western blot results 
show that levels of both VDAC2 and parvalbumin remained unchanged (figure 3.9; 
N=3 mice, P>0.05; unpaired, two tailed t-test), confirming that the changes I found 
in the proteomics analysis were specific to muscle due to low levels of SMN and 










Figure 3.8 Molecular pathology of SMA skeletal muscle is molecularly distinct 
from changes elicited following chronic denervation. Comparison of expression 
profiles of individual proteins identified in SMA muscle, with expression changes 
observed in chronically denervated rodent muscle. Note that the molecular profile of 
SMA muscle was distinct from that in denervated muscle. NC, no change; NR, not 







Figure 3.9 Molecular pathology of SMA skeletal muscle is molecularly distinct 
from changes elicited following acute denervation. Bar chart (mean ± SEM) 
showing expression levels of VDAC2 and Parvalbumin in mouse FDB muscles 
without (control) or 24h after (denervated) sciatic nerve lesion. Neither protein 
showed a significant change in expression in denervated muscle (N=3 mice; 
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3.2.6 Molecular pathology of muscle is recapitulated in SMA patients 
Having found that intrinsic molecular changes were present in muscle from pre-
symptomatic severe SMA mice, I wanted to address the question of whether or not 
these changes were also present in skeletal muscle from SMA patients. Quantitative 
fluorescent western blotting was performed on SMA patient quadriceps femoris 
muscle biopsies, to establish expression levels of VDAC2 and parvalbumin (figure 
3.10). Biopsies were obtained from type II/III SMA patients (aged between 3 and 25 
years old; see table 2.1 and 2.2 for more details on the samples), with genetic 
diagnosis of SMA confirmed by a homozygous deletion of the SMN1 gene. Three 
roughly age-matched control samples (aged between 17 and 27 years old), 
genetically confirmed to have no mutations in the SMN1 gene, were used for 
comparison. First it was confirmed that SMN protein expression levels were indeed 
significantly decreased in SMA patient samples compared to control samples (figure 
3.10A/B). As expected, there is variability in SMN levels observed in the patients, as 
the patients were diagnosed with either type II or type III SMA. Quantitative western 
blotting revealed that both VDAC2 and parvalbumin showed similar alterations in 
expression levels to those previously observed in severe SMA mice: VDAC2 was 
significantly up-regulated more than three fold in SMA patient muscle (figure 3.10C; 
*P<0.05; unpaired, two-tailed t-test) and parvalbumin was significantly down-
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Figure 3.10 Molecular modifications are also present in skeletal muscle from 
SMA patients. (A) Representative fluorescent western blots on quadriceps femoris 
biopsies from SMA patients (type II or type III; aged between 3 and 25 years old) 
and non-SMA controls showing levels of SMN, beta-V-tubulin (loading control), 
VDAC2 and parvalbumin. (B-D) Bar charts showing expression levels of SMN, 
VDAC2 and parvalbumin in SMA patient biopsies compared to controls. Data are 
shown for individual patients (black and white bars to the left of the hashed line) as 
well as mean ± SEM for each genotype (right of the line). (B) SMN levels were 
significantly decreased in SMA patients (*P<0.05; unpaired, two-tailed t-test), (C) 
VDAC2 levels were significantly increased (*P<0.05; unpaired, two-tailed t-test). (D) 
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3.2.7 Molecular pathology of skeletal muscle is reversed by treatment with 
the FDA-approved histone deacetylase inhibitor, SAHA  
The finding that levels of full-length SMN protein produced by the SMN2 gene can 
be modulated by small molecules and drugs has raised the possibility of a therapy for 
SMA. For example, epigenetic modulation using histone deacetylase inhibitors 
(HDACi) appears to be successful (Wirth et al. 2006), with the HDACi SAHA (also 
known as Vorinostat or Zolinza) elevating full-length SMN protein levels in SMA 
mouse models in vivo, resulting in a 30 % increase in mean survival and amelioration 
of muscle fiber size shrinkage (Riessland et al. 2010). To examine whether HDAC 
inhibitors are capable of directly targeting molecular changes in muscle during SMA, 
expression levels of VDAC2, parvalbumin and the cell death marker H2AX were 
examined in skeletal muscle from SMA mice treated with SAHA.  
 
For these experiments a milder SMA mouse model was used (Taiwanese SMA mice) 
with a new breeding protocol (Smn-/-;SMN2tg/tg x Smn-/+) (Riessland et al. 2010) to 
generate affected SMA mice that survive until 10 days postnatal on a congenic 
FVB/N genetic background. The slightly longer life-span of this model makes it 
easier for testing potential therapeutic agents than the more severe SMA mouse 
model (Riessland et al. 2010). First it was confirmed that molecular pathological 
changes similar to those observed in severe SMA mice were also present in untreated 
late-symptomatic (P10) Taiwanese SMA mice and in other muscle groups. As 
expected, SMN protein levels in the gastrocnemius muscle were reduced to around 
25 % of those in littermate controls (figure 3.11B; ***P< 0.001; ANOVA with 
Tukey’s post hoc test). VDAC2 levels were increased (figure 3.11C; *P< 0.05) and 
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parvalbumin levels were decreased (figure 3.11D; ***P< 0.001) in Taiwanese SMA 
mice, and increased cell death was confirmed by an increase in levels of H2AX 
(figure 3.9E; ***P< 0.001). Importantly, it has previously been demonstrated that 
neuronal pathology is present in the gastrocnemius (muscle from the hind limb of the 
mouse) of Taiwanese SMA mice at P10 (including denervation of muscle fibers) 
(Riessland et al. 2010). Thus, the molecular changes initially observed in the rostral 
band of LAL muscle of severe SMA mice at P1 in the absence of neuronal pathology 
were also present in anatomically distinct muscles susceptible to denervation in SMA. 
 
Taiwanese SMA mice and littermate controls were treated with SAHA from birth via 
oral administration of 25 mg/kg SAHA twice daily (Riessland et al. 2010). For 
control experiments, mice were dosed with Dimethyl sulfoxide (DMSO) alone. As 
previously reported (Riessland et al. 2010), SAHA treatment significantly increased 
SMN protein expression levels in the gastrocnemius (figure 3.9). I confirm here that 
SMN levels were increased two fold in SMA mice treated with SAHA compared to 
SMA mice treated with DMSO alone (figure 3.11; N=5 SMA mice, N=4 SMA + 
SAHA; *P>0.05, ANOVA with Tukey’s post hoc test). Importantly, SAHA 
treatment significantly ameliorated SMN-induced changes in levels of VDAC2 and 
parvalbumin. VDAC2 showed a 1.25 fold decrease after treatment with SAHA as 
compared to DMSO treated SMA mice. The SAHA treated SMA mice showed 
similar levels of VDAC2 when compared with control mice (figure 3.11C; N=5 
control mice, N=5 SMA mice, N=4 SMA + SAHA; *P>0.05, **P>0.01, ANOVA 
with Tukey’s post hoc test).  Parvalbumin levels were increased two fold in SMA 
mice after treatment with SAHA as compared to DMSO treated SMA mice (figure 
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3.11D; N=5 control mice, N=5 SMA mice, N=4 SMA + SAHA; **P>0.01, 
***P>0.001, ANOVA with Tukey’s post hoc test). Interestingly, as well as rescue of 
VDAC2 and parvalbumin, SAHA treatment also significantly decreased the level of 
the cell death marker H2AX, to similar levels observed in control mice (figure 
3.11E; N=5 control mice, N=5 SMA mice, N=4 SMA + SAHA; ***P>0.001, 
ANOVA with Tukey’s post hoc test). These results suggest a potential treatment 
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Figure 3.11 Reversal of SMA-induced molecular pathology of skeletal muscle 
by treatment with the histone deacetylase inhibitor (HDACi) SAHA. (A) 
Representative fluorescent western blots on gastrocnemius muscle from Taiwanese 
SMA mice (SMA), littermate controls (Control) and SAHA-treated Taiwanese SMA 
mice (SMA + SAHA) at P10 showing levels of SMN, beta-V-tubulin (loading control), 
VDAC2, parvalbumin and H2AX. (B-E) Bar charts (mean ± SEM) showing 
expression levels of SMN, VDAC2, parvalbumin and H2AX. (B) SMN levels were 
significantly decreased in Taiwanese SMA mice compared with controls (***P< 
0.001; ANOVA with Tukey’s post hoc test) and were significantly increased in SMA 
mice treated with SAHA (*P< 0.05). (C) VDAC2 levels were significantly increased in 
SMA mice (*P< 0.05) and decreased with SAHA treatment (**P< 0.01), returning to 
levels observed in littermate controls. (D) Parvalbumin levels were significantly 
decreased in SMA mice (***P< 0.001) but were increased with SAHA treatment 
(**P< 0.01), restoring them to 75% of those found in healthy control muscle. (E) 
H2AX levels were significantly increased in SMA mice (***P< 0.001) but were 
decreased with SAHA treatment (***P< 0.001), restoring them to those found in 
healthy control muscle. n=19 independent measurements from N=5 mice (Control), 
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3.3 Discussion 
 
3.3.1 Overview of results 
In this chapter molecular pathology of skeletal muscle has been identified and 
characterised with the use of a label-free proteomic technique in an established 
mouse model of severe SMA. The protein changes that were identified were present 
during the earliest stages of disease (at P1) and occurred in the absence of any 
detectable degeneration of lower motor neurons. The expression levels of two 
proteins, VDAC2 and parvalbumin, identified with the proteomic screen were 
validated in a different mouse model of SMA and in a different muscle and showed 
the same robust up-regulation of VDAC2 and down-regulation of parvalbumin. In 
addition, changed expression levels were also confirmed in human muscle biopsies. 
Interestingly, molecular pathology of skeletal muscle was ameliorated in mice 
treated with the FDA-approved HDAC inhibitor SAHA. These findings therefore 
provide significant experimental support for the hypothesis that SMN-induced 
changes in skeletal muscle cannot solely be attributed to motor neuron degeneration. 
In addition, the molecular changes that were identified in SMA muscle were distinct 
from those reported in chronically or acutely denervated muscle.  
 
3.3.2 Muscle is an important pathological target in SMA 
Several other studies have supported the proposal that muscle is affected and may 
contribute to SMA pathogenesis. For example, a recent study has shown that satellite 
cells (muscle stem cells) located between the sarcolemma and the basal lamina, are 
accumulated in hind limbs of severe SMA mice and undergo premature 
differentiation. This led to reduced myofiber number and average size of the muscle 
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fibers (Hayhurst et al. 2012). In addition, cultured satellite cells from SMA mice fail 
to form multinucleated myotubes efficiently (Hayhurst et al. 2012). Other in vitro 
studies support this data and have shown that muscle cells derived from SMA 
patients can inhibit neuronal outgrowth and development when co-cultured with 
wild-type healthy motor neurons (Henderson et al. 1987; Braun et al. 1995; Guettier-
Sigrist et al. 2002). In addition, a study showed that myotubes from human SMA 
fetuses also revealed a delay in growth and maturation in vitro (Martinez-Hernandez 
et al. 2009). Moreover, fibroblast growth factor (FGF) signalling in muscle can 
ameliorate SMN-associated abnormalities at the neuromuscular junction in 
Drosophila (Sen et al. 2011) and increased levels of insulin-like growth factor (IGF-
1) in muscle modulates SMA phenotype in mice (Bosch-Marce et al. 2011). In 
addition, studies of SMN protein expression and localization have identified the 
SMN complex in muscle from both mice and Drosophila, as well as in C2C12 cells 
in vitro (Shafey et al. 2005; Rajendra et al. 2007; Walker et al. 2008). Taken 
together, these findings suggest that SMN levels are critical for the establishment and 
maintenance of molecular homeostasis in skeletal muscle. The findings in this 
chapter fit in with these earlier studies and add valuable additional insights as it is the 
first in vivo study on the role of muscle in SMA with the ability to rule out 
denervation-induced changes. In addition, the experimental design used in this study 
generated a reliable list of proteins that could lead to other hypothesis in the role for 
muscle in SMA. To summarize, direct disruption of muscle resulting from low levels 
of SMN is likely to be a significant contributor to SMA pathogenesis, alongside 
pathological changes in motor neurons. 
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3.3.3 Proteins identified are known to be involved in other neuromuscular 
diseases 
Interestingly, many of the proteins identified by the proteomic screen as being 
altered in skeletal muscle during SMA have previously been implicated in other 
neuromuscular diseases where intrinsic muscle pathology occurs. For example, 
decorin is associated with modified proliferation and differentiation of myogenic 
cells in x-linked muscular dystrophy (Abe et al. 2009) and reticulocalbin 1 
expression is altered in dystrophic muscles (Zhang et al. 2006). Galectin 1 has been 
implicated in myoblast differentiation, skeletal muscle development and muscle 
regeneration (Svensson and Tagerud 2009; Grossi et al. 2011). Similarly, proteins 
such as serpin H1 (a.k.a. HSP47) and vinculin, through its interaction with dysferlin, 
have been implicated in muscle fiber repair and maintenance of the muscle 
membrane respectively (Higuchi et al. 2007; de Morree et al. 2010). Thus, the 
proteins that are identified as having altered expression profiles in SMA muscle are 
consistent with those that might be expected to regulate intrinsic muscular pathology 
based on findings from other neuromuscular disorders. 
 
3.3.4 Widespread protein changes in muscles of SMA mouse models and 
SMA patients 
Two proteins of particular interest in the context of this study were VDAC2 and 
parvalbumin. Both showed modified expression levels in skeletal muscle across two 
different mouse models of SMA as well as in muscle biopsies from SMA patients, 
and both proteins responded significantly to SAHA treatment. This confirms that the 
changes identified in the rostral band of LAL are not specific changes in this 
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particular muscle but are widespread changes in muscles of SMA mouse models and 
very interestingly also in human muscle.  
 
VDAC2 is a mitochondrial protein associated with formation of channels in the 
mitochondrial outer membrane, responsible for regulating cell death pathways and 
calcium signalling (Cheng et al. 2003; Roy et al. 2009; Subedi et al. 2011). It is also 
a core component of the muscle response to aging (O'Connell and Ohlendieck 2009) 
and has been implicated in early pathogenic events occurring in the mdx mouse 
model of muscular dystrophy (Massa et al. 2000). Parvalbumin is a cytosolic calcium 
buffer in muscle, breakdown of which similarly contributes to muscular dystrophy 
(Gailly 2002; Rome 2006).  
 
Since both VDAC2 and parvalbumin are involved in calcium signalling, a disruption 
in calcium homeostasis might play a role in muscle pathology in SMA mice. 
Abnormal calcium homeostasis has been suggested to play an important role in 
skeletal muscle degeneration in muscular dystrophy (Shin et al. 2013). Mechanisms 
suggested by which elevated level of calcium causes muscle wasting in muscular 
dystrophy could be either through activation of calcium-dependent proteases such as 
calpains which eventually lead to the degradation of muscle proteins and necrosis 
(Goll et al. 2003), or by modulating the activity of calcineurin/nuclear factor of 
activated T-cells (NFAT) pathway (Hogan et al. 2003), or by acting as important 
secondary messengers that trigger intracellular responses such as excitation-
contraction (E–C) coupling and activation of various signalling pathways (Gailly 
2002).  
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3.3.5 Evidence of increased levels of cell death in muscle of SMA mice 
The observation of increased levels of the cell death marker H2AX is confirming 
earlier studies. Studies have suggested that cell death may be increased in muscle 
during SMA. DNA fragmentation with DNA strand breaks and up-regulated levels of 
Bax were observed in muscle of SMA patients (Tews and Goebel 1996; Tews and 
Goebel 1997).  However, those observations could not rule out that cell death in 
muscle was occurring as a secondary effect of the degenerating motor neurons. In 
this chapter it has been ruled out that cell death in muscle is a secondary effect of 
motor neuron pathology, since the muscle I used has been confirmed to have normal 
innervation and no motor neuron degeneration. 
 
3.3.6 HDAC inhibitors revers altered molecular composition of skeletal 
muscle in SMA 
Finally, the finding that the altered molecular composition of skeletal muscle in 
SMA is reversible using the HDACi SAHA highlights the potential to treat SMN-
induced muscle changes using small molecules and drugs. SAHA has been shown to 
penetrate into a range of tissues following administration - including the nervous 
system and muscle (Hockly et al. 2003; Hahnen et al. 2006; Riessland et al. 2010) - 
and is approved for use in humans by the FDA in the US. SAHA is a second 
generation HDACi, so it is likely that future generations will have even higher 
specificity and potency, increasing their attractiveness for use in SMA patients. The 
findings here suggest that attempts to develop better HDACi that specifically target 
SMN levels in skeletal muscle would likely lead to effective therapeutic options for 
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SMA. Testing other currently available HDACi for the potential to rescue muscle 
pathology in vivo will also be an important next step.   
 
The current data do not allow me to ascertain whether raised SMN levels in muscle 
induced by SAHA also have a secondary impact on pathological changes occurring 
in other cell types (e.g. motor neurons), due to systemic delivery of the HDACi 
(Riessland et al. 2010). Thus, the potential for a causal relationship between the 
rescue of pathological changes occurring in muscle in SAHA treated SMA mice and 
the reduction in pathology of motor neurons previously reported (Riessland et al. 
2010) remains untested and warrants further investigation. Nevertheless, the findings 
in this chapter show that intrinsic pathological changes in muscle are a significant 
feature of SMA, regardless of their possible secondary impact on other cell types. 
Taken together, this study suggests that the most effective SMA therapeutics will 
probably need to be directed at both muscle and motor neurons. 
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Chapter 4  





Disease progression, as well as symptom severity, can vary significantly between 
individual patients with SMA, largely dependent upon the copy number of the near-
identical SMN2 gene (Swoboda et al. 2005; Lorson et al. 2010). A higher copy 
number of SMN2 correlates with a milder phenotype. Similarly, disease-modifying 
genes are known to exist that can influence the severity of a patient’s condition 
(Oprea et al. 2008).  
 
A clearer understanding of the underlying genetics of SMA has led to potentially 
exciting pre-clinical breakthroughs over the past few years, with several therapeutic 
approaches revealing significant benefits in animal models of the disease. For 
example, experiments using gene therapy approaches to restore SMN1 expression 
have yielded impressive amelioration in neuromuscular dysfunction and large 
increases in the lifespan of mice with SMA (Bevan et al. 2010; Foust et al. 2010; 
Valori et al. 2010; Dominguez et al. 2011). Other approaches aimed at increasing the 
amount of SMN protein produced by the SMN2 gene by promoter activation or 
reduction of alternative splicing of SMN2 exon 7 have also shown therapeutic benefit 
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in animal models (Brichta et al. 2003; Oskoui and Kaufmann 2008; Thurmond et al. 
2008). As a result, there is a growing desire to undertake clinical trials in human 
patient cohorts in order to evaluate the potential benefits of these therapeutic 
approaches. However, performing clinical trials in cohorts of young patients (and in 
the case of severe forms of SMA, neonatal patients) brings with it a range of 
technical problems (Swoboda et al. 2007).  
 
In order to improve the reliability and effectiveness of SMA clinical trials, robust 
biomarkers are required. Firstly, biomarkers are needed to allow accurate monitoring 
of disease activity and to predict disease progression in human patients (Kobayashi et 
al. 2013). Secondly, biomarkers are required to provide more accurate measures of 
the responses of individual patients and groups of patients to a new treatment or 
therapeutic approach (Guest et al. 2013). Several different approaches have 
previously been employed in an attempt to identify biomarkers for SMA in both 
mouse models and patient cohorts, incorporating a range of physical, functional and 
molecular readouts (Crawford et al. 2012; El-Khodor et al. 2012; Finkel et al. 2012; 
Kobayashi et al. 2013). However, robust biomarkers for SMA have yet to be 
identified. 
 
Since I showed in the previous chapter that muscle is intrinsically affected in SMA, I 
investigated here whether biomarkers could be identified in this tissue. Proteomics 
technologies have recently been highlighted as a potentially powerful tool for 
biomarker discovery (Guest et al. 2013). In this study, I have utilized a state-of-the-
art, label-free proteomics approach to identify individual proteins in the 
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neuromuscular system of SMA mice that report directly on disease status. By 
comparing the protein composition of skeletal muscle in SMA mice at a pre-
symptomatic time-point (data from chapter 3) with the muscle proteome at a late-
symptomatic time-point, I identified increased expression of both stress protein-70 
(GRP75/mortalin; hereafter referred to as GRP75) and calreticulin as robust 
indicators of disease progression in SMA mice. I show that these potential protein 
biomarkers were similarly modified across different mouse models of SMA, across 
multiple different skeletal muscles, and were also measurable from skin biopsies. 
Furthermore, initial investigation of GRP75 and calreticulin levels in human muscle 
biopsies suggested that they were detectable and measurable by western blot.  
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4.2 Results 
	  
4.2.1 Label-free proteomics analysis reveals a list of 23 putative biomarkers 
of disease status in skeletal muscle from severe SMA mice  
In order to identify potential new protein biomarkers capable of reporting directly on 
the progress of disease in SMA, I utilized unbiased, label-free proteomics 
technologies to compare the proteome of a pathologically affected tissue in SMA 
(skeletal muscle) at early- and late-symptomatic stages of the disease. Given the 
difficulty in obtaining human muscle samples at different time points for such an 
experiment, these initial proteomic screens were performed in the levator auris 
longus (LAL) of an established mouse model of SMA (the severe SMA mouse;  
Smn-/-;SMN2 (Monani et al. 2000)). The mouse LAL muscle is composed of two 
distinct muscle bands that are differentially affected in SMA mice: a caudal band that 
undergoes severe neuromuscular denervation and a rostral band that has minimal 
denervation but intrinsic muscular pathology (for more details on this see chapter 3, 
section 3.2.1 and 3.2.2). In order to obtain a pathologically homogeneous tissue 
sample for proteomics analysis, I chose to selectively examine the larger rostral band 
of the muscle. 
 
The rostral band of LAL muscle was dissected from severe SMA mice and littermate 
controls (Smn+/+;SMN2) at postnatal day one (P1; pre/early-symptomatic) and 
postnatal day five (P5; post-symptomatic; N=9 mice per genotype, per time-point) 
and proteins were extracted for mass-spectrometry analysis. The raw mass-
spectrometry data from both P1 and P5 comparisons was uploaded to Progenesis 
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label-free software for further analyses. The progenesis output data from P1 mice 
was previously analysed using the IPI mouse database and was published (Mutsaers 
et al. 2011). However, since then the IPI database does not update anymore and 
therefore I switched to using the Swiss-Prot database. For the current study, to allow 
direct comparison with the P5 data, the P1 raw data was re-analysed in parallel with 
the P5 data. For a detailed description of the proteomic analysis see results chapter 3 
section 3.2.3. Data from P1 tissue were analysed separately from data obtained from 
P5 tissue, but were compared afterwards in excel.  
 
I identified 540 proteins in the P5 dataset (figure 4.1, left column). A filtering 
protocol was then applied for subsequent stringent positive identification of proteins, 
with only those proteins identified by two or more unique peptides taken forward for 
further analysis. Proteins that were either up- or down-regulated >20% in SMA 
muscle compared to controls were considered to have an altered expression profile 
(figure 4.1, middle column). To be considered as a putative biomarker, I was looking 
to identify proteins whose expression levels were unchanged in SMA muscle at P1 
(pre/early-symptomatic), but were significantly changed at P5 (late-symptomatic). I 
therefore took the list of all proteins with modified expression in SMA mice at P5 
compared to controls, and searched for expression data for the same proteins in the 
P1 comparison dataset. Any proteins found to have altered expression at both P5 and 
P1 were considered to be unsuitable as a biomarker and were therefore removed 
from the candidate list (figure 4.1, right column). This filtering of data resulted in the 
identification of 14 candidate biomarker proteins that were up-regulated in severe 
SMA mouse muscle at P5 but not at P1 (table 4.1, figure 4.2A) and 9 proteins that 
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were down-regulated in severe SMA mouse muscle at P5 but not at P1 (table 4.2, 
figure 4.2B).  
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Figure 4.1 Filtering of proteomics data. The Scatter plot is showing the process of 
filtering undertaken on the raw proteomics data in order to generate a final list of 23 
proteins modified in SMA mouse skeletal muscle at P5, but unchanged at P1. The 
left column shows all proteins identified by the Progenesis label-free proteomics 
software (n=540 proteins in total) in control and SMA (KO) mouse LAL muscle at P5, 
with the relative expression levels between samples represented as a ratio 
(KO/Control). The red bars indicate the 20% cut off threshold for being up-regulated 
or down-regulated in SMA mice compared to controls. The middle column shows 
the proteins remaining in the P5 dataset following filtering (e.g. that were either up- 
or down-regulated by > 20% and were identified by at least 2 peptides (n=245 
proteins in total)). The right column shows those proteins that were identified as 
being changed in SMA mouse skeletal muscle at P5, but that were unchanged in 
comparable muscle samples at P1 (n=23 proteins in total). 
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Figure 4.2 Identification of putative protein biomarkers for SMA in skeletal 
muscle from severe SMA mice. (A) Graph showing all 14 proteins that were 
unchanged at P1 in severe SMA mouse LAL muscle compared to littermate controls, 
but had increased levels >20% at P5. (B) Graph showing all 9 proteins that were 
unchanged at P1 in severe SMA mouse LAL muscle compared to littermate controls, 
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Table 4.1 Proteins unchanged at P1 but increased >20% at P5 in the rostral band of 





Table 4.2 Proteins unchanged at P1 but decreased >20% at P5 in the rostral band 





Accession number Protein name Peptide count Peptides used for quantitationConfidence score Anova (p)* Fold change at P1 Fold change at P5
G6PI_MOUSE Glucose-6-phosphate isomerase 8 6 245.68 6.92E-06 1.03 1.98
GRP75_MOUSE Stress-70 protein 5 3 170.83 5.59E-04 1.02 1.82
TBB5_MOUSE Tubulin beta-5 chain 14 2 639.05 3.69E-05 1.02 1.80
PLEC1_MOUSE Plectin-1 48 21 879.72 4.67E-06 1.18 1.63
THIL_MOUSE Acetyl-CoA acetyltransferase 9 7 448.39 2.95E-04 1.09 1.59
CALR_MOUSE Calreticulin 4 3 83.76 2.08E-03 1.12 1.51
AATM_MOUSE Aspartate aminotransferase 12 7 443.54 1.50E-04 1.17 1.50
THIM_MOUSE 3-ketoacyl-CoA thiolase 16 12 473.14 1.16E-03 1.02 1.41
ANXA2_MOUSE Annexin A2 12 10 729.11 1.28E-03 1.04 1.33
PURA1_MOUSE Adenylosuccinate synthetase isozyme 1 7 5 247.24 1.19E-03 1.09 1.30
S10AB_MOUSE Protein S100-A11 2 2 166.21 2.78E-02 1.01 1.25
HBB2_MOUSE Hemoglobin subunit beta-2 12 6 702.27 1.51E-03 1.01 1.23
LMNA_MOUSE Lamin-A/C 13 7 567.31 2.19E-04 1.16 1.21
VIME_MOUSE Vimentin 20 12 776.2 3.50E-04 1.17 1.21
Accession Protein name Peptide count Peptides used for quantitationConfidence score Anova (p)* Fold change at P1 Fold change at P5
RRBP1_MOUSE Ribosome-binding protein 1 9 3 60.23 1.97E-05 1.12 -6.59
TPM1_MOUSE Tropomyosin alpha-1 chain 17 6 652.67 6.87E-06 1.09 -4.02
ACTN2_MOUSE Alpha-actinin-2 27 15 1413.57 1.82E-04 1.12 -1.65
TCPB_MOUSE T-complex protein 1 subunit beta 8 3 162.09 2.07E-03 1.12 -1.52
POSTN_MOUSE Periostin 5 3 142.66 7.55E-04 1.01 -1.44
HS90A_MOUSE Heat shock protein HSP 90-alpha 10 3 326.05 7.71E-04 1.01 -1.42
HS90B_MOUSE Heat shock protein HSP 90-beta 17 8 600.51 6.45E-05 1.11 -1.42
RTN4_MOUSE Reticulon-4 8 5 123.82 1.69E-02 1.16 -1.27
NB5R3_MOUSE NADH-cytochrome b5 reductase 3 4 3 65.43 3.90E-05 1.05 -1.26
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4.2.2 Validation of putative protein biomarkers in the rostral band of levator 
auris longus  
In order to validate the list of candidate biomarkers generated by this proteomics 
analysis, I obtained more tissue from SMA mice and littermate controls for western 
blot validation. I selected a subset of proteins for validation in the rostral band of 
LAL. I selected two proteins based on the magnitude of their expression change and 
the availability of suitable antibodies for western blotting as well as their expression 
pattern in different tissues (i.e. not muscle-specific, but widely expressed). Stress-
protein 70 (GRP75) and calreticulin showed both an increased expression (1.8 and 
1.5 fold respectively) in SMA mice.  
 
Western blots performed on protein extracts from the rostral band of LAL showed an 
increased trend for both GRP75 and calreticulin expression (figure 4.3; N=2 mice per 
genotype). Because the severe SMA mice were only P5 when they were sacrificed 
and the rostral band of LAL is a very small muscle, not much protein could be 
extracted from it. Therefore I used the Taiwanese SMA mice for the rest of my 
experiments and also to determine whether similar changes in protein levels could be 
detected in a genetically distinct mouse model of SMA.  
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Figure 4.3 Validation of GRP75 and calreticulin in the rostral band of LAL of 
severe SMA mice compared to control. (A) Bar chart (mean ± SEM) showing a 
trend towards an increased expression of GRP75 in the rostral band of the LAL 
(N=2 mice per genotype). (B) Bar chart  (mean ± SEM) showing a trend towards an 
increased expression of calreticulin.  
 
 
4.2.3 Validation of putative protein biomarkers in the Taiwanese mouse 
model of SMA 
For further validation I used a different skeletal muscle, the gastrocnemius, from the 
Taiwanese SMA mice to examine whether the changes were not specific to the 
rostral band of LAL. The gastrocnemius muscle is located in the hind limb of the 
mouse. I selected two more proteins for validation: T-complex protein 1 subunit beta 
(TCPB) which was decreased by 1.5 fold and ribosome-binding protein 1 (RRBP1), 
which was decreased by 6.6 fold in the proteomics data from severe SMA mice 
(table 4.2).  
 
Levels of TCP1, GRP75 and Calreticulin were measured in the gastrocnemius 
muscle of Taiwanese SMA mice and littermate controls at a mid/late-symptomatic 
time-point (P9; figure 4.4A). Levels of TCPB were unchanged in the SMA mice 
compared to controls (figure 4.4B; N=3 mice per genotype; P>0.05, two-tailed, 
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unpaired t-test), thereby failing to validate the original proteomics data in the severe 
mouse model of SMA. However, in contrast, levels of both GRP75 and Calreticulin 
were significantly increased in the Taiwanese SMA mouse muscle, showing that the 
changes in these proteins were conserved between severe and Taiwanese SMA mice, 
as well as between the LAL and gastrocnemius muscle (figure 4.4B/C; **P<0.01, 
***P<0.001 unpaired, two-tailed t-test). RRBP1 could not be detected with western 
blot. Both TCPB and RRBP1 were excluded from further experiments as these 
proteins failed to function as potential biomarkers.  
 
 
Figure 4.4 Validation of calreticulin and GRP75 as potential biomarkers in a 
different muscle from a genetically distinct SMA mouse model. (A) 
Representative fluorescent western blots on gastrocnemius muscle from Taiwanese 
SMA mice (KO) and littermate controls at P9 (mid/late-symptomatic) showing levels 
of TCPB, GRP75, calreticulin and Ponceau (loading control).(B-D) Bar charts (mean 
± SEM) showing expression levels of TCPB, GRP75 and calreticulin in control and 
Taiwanese SMA mice (KO) at P9. (B) TCPB levels showed no difference in 
expression levels in SMA mice compared with controls (N=3 mice per genotype; 
P>0.05; unpaired, two-tailed t-test). (C) GRP75 levels were significantly increased in 
Taiwanese SMA mice compared with controls (**P<0.01; unpaired, two-tailed t-test). 
(D) Calreticulin levels were also significantly increased in Taiwanese SMA mice 
compared with controls (***P<0.001; unpaired, two-tailed t-test). 
 
	  
	   102	  
4.2.4 Preliminary investigation suggests that levels of GRP75 and calreticulin 
are increased in SMA patient muscle biopsies  
Next, I wanted to establish whether the increased levels of GRP75 and calreticulin, 
observed to correlate with disease progression in SMA mouse models, were also 
measureable in skeletal muscle from SMA patients. Therefore, levels of GRP75 and 
calreticulin were examined using quantitative fluorescent western blotting on human 
muscle biopsy samples obtained through EuroBioBank (for more details see chapter 
2 materials and methods). Biopsies were obtained from the quadriceps femoris (large 
muscle group covering the front and sides of the thigh) from three type II/III SMA 
patients (aged between 3 and 25 years old, for more details see table 2.1 and 2.2). All 
three patients had a genetic diagnosis of SMA confirmed by a homozygous deletion 
of the SMN1 gene. Three roughly age-matched control samples (aged between 15 
and 27 years old) were also obtained, genetically confirmed to have no mutations in 
the SMN1 gene.  
 
Levels of both GRP75 and calreticulin could be readily identified and showed a trend 
towards increased levels in SMA patients compared to controls (figure 4.5). GRP75 
levels increased on average by 50% compared to controls, although the considerable 
variability between individuals and low sample size meant that this different did not 
reach statistical significance (figure 4.5B; N=3 samples per group; P>0.05, unpaired, 
two-tailed t-test). Calreticulin levels were significantly increased in the SMA patient 
biopsies, on average by 50% compared to controls (figure 4.5C; N=3 samples per 
group; *P<0.05, unpaired, two-tailed t-test), however there was still considerable 
variability between individuals. Whilst these experiments only represent an initial 
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attempt to measure GRP75 and calreticulin levels in patient muscle biopsies, and are 
limited by the very small sample size, these preliminary investigations suggest that 
both GRP75 and calreticulin may potentially represent accessible protein biomarkers 
in skeletal muscle conserved between mouse models and patients. 
 
 
Figure 4.5 There is a trend towards increased expression levels of GRP75 and 
calreticulin in muscle biopsies from SMA patients. (A) Representative 
fluorescent western blots on quadriceps femoris muscle biopsy samples from an 
SMA patient (type II/III) and an age-matched non-SMA control showing levels of 
GRP75, calreticulin and Ponceau (loading control). (B-C) Bar charts showing 
expression levels of GRP75 and calreticulin in SMA patient muscle biopsies 
compared with controls. Data are shown for each individual patient (black and white 
bars to the left of the hashed line; error bars show variability between two 
independent measurements taken from that individual’s biopsy) as well as a pooled 
mean for each group (right of the line; ± SEM; n=6 measurements for each group, 
two independent measurements from each patient biopsy). (B) GRP75 levels 
showed a trend towards increased expression in SMA patients, but this difference 
did not reach statistical significance (P>0.05; unpaired, two-tailed t-test). (C) 
Calreticulin levels were significantly increased in SMA patient muscle (*P<0.05; 
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4.2.5 Altered levels of GRP75 and calreticulin can be detected in skin 
biopsies from SMA mice 
My analyses of GRP75 and calreticulin levels in skeletal muscle from SMA mouse 
models (supported by preliminary investigations of SMA patient tissue), suggested 
that these two proteins may potentially represent robust protein biomarkers for SMA. 
However, obtaining muscle biopsies from patients is an invasive procedure that is 
not ideal for repeated analyses of protein levels during a clinical trial, especially in 
small children. As a result, the availability of biomarker proteins in more 
peripherally accessible tissue (such as skin and/or blood) would make it much easier 
to obtain quick, repeated tissue samples for monitoring purposes. 
 
Therefore, the next question to ask was whether GRP75 and calreticulin could be 
reliably identified and measured in skin and blood. Analysis of expression datasets 
(www.biogps.org) confirmed that both GRP75 and calreticulin are known to be 
expressed in skin and whole blood extracts. To establish whether these proteins were 
detectable in skin and blood samples from a mouse model, western blots were 
performed for both of these proteins on samples taken from Taiwanese SMA mice 
and littermate controls at P9. Only calreticulin could be detected in whole blood and 
showed a significant increase in expression levels in SMA mice (figure 4.6; N=3 
mice per genotype; **P<0.01, unpaired, two-tailed t-test).  
 
However, both proteins were expressed in skin samples, with their levels being 
significantly increased in SMA mice compared to controls (figure 4.7). Thus, both 
GRP75 and calreticulin were readily identifiable in skin biopsies, with the alterations 
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in their levels in skin closely matching alterations previously observed in skeletal 
muscle (figure 4.7B/C; N=3 mice per genotype; **P<0.01, ***P<0.001, unpaired, 
two-tailed t-test). Since only calreticulin could be detected in whole blood samples I 




Figure 4.6 Validation of calreticulin levels in blood samples. Representative 
fluorescent western blots on blood samples from Taiwanese SMA mice (KO) and 
controls at P9 showing levels of calreticulin and Ponceau (N=3 mice per genotype). 
The bar chart (mean ± SEM) shows a significant increase in the levels of calreticulin 








Figure 4.7 Validation of GRP75 and calreticulin in skin samples from 
Taiwanese SMA mice and controls. (A) Representative fluorescent western blots 
on skin tissue from Taiwanese SMA mice (KO) and littermate controls at P9 
(mid/late-symptomatic) showing levels of GRP75, calreticulin and Ponceau (loading 
control). (B/C) Bar charts (mean ± SEM) showing expression levels of GRP75 and 
calreticulin in Taiwanese SMA mice (KO) and controls at P9 (N=3 mice per 
genotype). (B) GRP75 levels were significantly increased in Taiwanese SMA mice 
compared with controls (***P<0.001; unpaired, two-tailed t-test). (C) Calreticulin 
levels were significantly increased in Taiwanese SMA mice compared with controls 
(**P<0.01; unpaired, two-tailed t-test).  
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4.2.6 Levels of GRP75 and calreticulin in skin from Taiwanese SMA mice 
change over time 
I wanted to establish whether GRP75 and calreticulin levels in skin matched the 
temporal profile that was originally identified in the muscle proteomics experiments. 
Therefore, I collected skin samples from Taiwanese SMA mice and littermate 
controls at four different time-points: P1 and P5 (pre-symptomatic), P7 (early-
symptomatic), and P9 (mid/late-symptomatic). Temporal changes in the levels of 
GRP75 and calreticulin showed similar trends in SMA mouse skin, with no 
differences observed at pre/early-symptomatic time-points, but robust increases 
evident after onset of symptoms at postnatal day six (figure 4.8A/B). Thus, the 
temporal expression of GRP75 and calreticulin revealed a very similar profile in skin 
to that previously observed in skeletal muscle. Once again, the robust increases in 
expression correlated with disease progression, confirming that GRP75 and 
calreticulin may potentially represent peripherally accessible protein biomarkers 
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Figure 4.8 Increased levels of calreticulin and GRP75 in skin samples 
correlate with disease progression in SMA mice. (A/B) Time course of GRP75 
and calreticulin expression in skin biopsies from Taiwanese SMA mice (KO) 
compared to controls (Het) (N=3 mice per genotype/time point). Tissue was 
analysed in mice at P1, P5 (both pre/early-symptomatic), P7 (early-symptomatic) 
and P9 (mid/late-symptomatic). (A) There was no increase in GRP75 levels in 
Taiwanese SMA mice until after overt disease onset (at P6). (B) Similarly, there was 




4.2.7 GRP75 and calreticulin respond to treatment with the HDAC inhibitor, 
Trichostatin A 
Finally, I investigated whether GRP75 and calreticulin would respond to treatment 
with the HDAC inhibitor, Trichostatin A (TSA) which has been shown to increase 
SMN levels and ameliorate disease severity in mice (Avila et al. 2007). Taiwanese 
mice were injected with Trichostatin A (TSA; 10 mg/kg) or DMSO alone from the 
day of birth (P1) until postnatal day eight (P8) once daily. Levels of GRP75 and 
calreticulin were measured in both skin and muscle tissue using western blot 
techniques. The SMA mice treated with TSA showed expression levels of GRP75 
similar to levels in muscle tissue from control mice (figure 4.9A/B; N=6 Control 
mice, n=12 independent measurements; N=6 KO, n=12 independent measurements; 
N=5 KO + TSA, n=10 independent measurements, *P<0.05, **P<0.01; one-way 
ANOVA with Tukey’s multiple comparison test). Calreticulin expression did not 
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respond to treatment with TSA (figure 4.9A/C). In skin tissue both GRP75 and 
calreticulin responded to the TSA treatment and showed expression levels similar to 
levels observed in the control mice (figure 4.10; N=6 Control mice, n=12 
independent measurements; N=6 KO, n=12 independent measurements; N=5 KO + 
TSA, n=10 independent measurements, *P<0.05, **P<0.01, ***P<0.001; ANOVA 
with Tukey’s post hoc test). These results suggest that expression levels of GRP75 
and calreticulin reflect on the progression of disease severity and therefore provide 
further evidence that GRP75 and calreticulin (at least in skin samples) could be 
potential biomarkers for treatment in SMA.  
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Figure 4.9 GRP75 respond to treatment with the HDAC inhibitor, Trichostatin 
A (TSA) in muscle samples from Taiwanese SMA mice. (A) Representative 
fluorescent western blots on muscle tissue from SMA mice (KO), SMA mice treated 
with TSA (KO +TSA) and littermate controls at P9 showing levels of GRP75, 
calreticulin and Ponceau (loading control). (B) Bar charts (mean ± SEM) showing 
expression levels for GRP75. Confirming increased levels in KO mice compared to 
control (N=6 Control mice, n=12 independent measurements; N=6 KO, n=12 
independent measurements; N=5 KO + TSA, n=10 independent measurements, 
*P<0.05; one-way ANOVA with Tukey’s multiple comparison test). In addition KO 
mice treated with TSA (KO + TSA) showed a response to treatment and levels were 
similar to control mice (**P<0.01). (C) Bar charts (mean ± SEM) showing expression 
levels for calreticulin. Confirming increased levels in KO mice compared to control 
(*P<0.05; one-way ANOVA with Tukey’s multiple comparison test). However, 
calreticulin did not respond to treatment with TSA (P>0.05). 
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Figure 4.10 GRP75 and calreticulin respond to treatment with the HDAC 
inhibitor, Trichostatin A (TSA) in skin samples from Taiwanese SMA mice. (A) 
Representative fluorescent western blots on skin tissue from SMA mice (KO), SMA 
mice treated with TSA (KO +TSA) and littermate controls at P9 showing levels of 
GRP75, calreticulin and Ponceau (loading control). (B) Bar charts (mean ± SEM) 
showing expression levels for GRP75. Confirming increased levels in KO mice 
compared to control (N=6 Control mice, n=12 independent measurements; N=6 KO, 
n=12 independent measurements; N=5 KO + TSA, n=10 independent 
measurements, ***P<0.001; one-way ANOVA with Tukey’s multiple comparison 
test). In addition KO mice treated with TSA (KO + TSA) showed a response to 
treatment and levels were similar to control mice (*P<0.05). (C) Bar charts (mean ± 
SEM) showing expression levels for calreticulin. Confirming increased levels in KO 
mice compared to control (***P<0.001; one-way ANOVA with Tukey’s multiple 
comparison test). KO mice treated with TSA (KO + TSA) showed a response to 
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4.3 Discussion 
	  
4.3.1 Overview of results 
In this chapter, label-free proteomic technology was used to identify two proteins 
with the potential to act as biomarkers for SMA. The combination of proteomics 
technology with an established mouse model of SMA (where it is possible to 
accurately identify and isolate tissue from animals at different stages of disease) 
revealed that increased levels of GRP75 and calreticulin in skeletal muscle correlated 
with disease progression. Importantly, these potential protein biomarkers were also 
accessible in skin samples from SMA mice, suggesting that they can be monitored 
from easily harvested tissue in clinical trials. A preliminary study on patient muscle 
biopsies suggested that GRP75 and calreticulin were detectable and measurable in 
human tissue.  
 
4.3.2 Proteomics technology could be a powerful tool for biomarker discovery 
The use of label-free proteomics in this study provides further evidence that 
proteomics technologies represent a powerful tool for biomarker discovery (Guest et 
al. 2013). Indeed, proteomics technology has previously been used to screen for 
potential biomarkers in human SMA patients (Finkel et al. 2012; Kobayashi et al. 
2013). Previous studies combining proteomics with animal models of SMA have 
mainly utilized the technology to uncover molecular pathways disrupted downstream 
of SMN (Fuller et al. 2010; Wishart et al. 2010; Mutsaers et al. 2011; Wu et al. 
2011), but the current study demonstrates that similar approaches can be used to 
identify potential protein biomarkers, potentially suitable for future use in the human 
clinical context. In addition, the ability to identify potential protein biomarkers 
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conserved between different mouse models of SMA and SMA patients suggests that 
common biomarkers can be utilized in both pre-clinical testing of new treatments in 
animal models as well as in human clinical trials. 
 
4.3.3 Advantages of SMA mouse models in biomarker identification 
Recently, the first clinical trials have published data on biomarker identification 
using samples from SMA patients and controls. Patients were asked for one visit to 
the clinic and blood and urine samples were collected for proteomics, metabolomics 
and transcriptomics (Crawford et al. 2012; Finkel et al. 2012; Mano et al. 2012; 
Kobayashi et al. 2013). The studies revealed a list of protein changes in plasma, 
however these changes are likely to be downstream from the original disease 
perturbation in SMA, since blood shows normal levels of SMN protein (Finkel et al. 
2012).  
 
One of the key features of a useful biomarker is that it can be tracked over the time 
course of disease. Using a mouse model of SMA gives the opportunity to easily 
collect samples at different time points and monitor the changes in expression levels 
over this time. In this chapter, muscle tissue was used for the initial proteomic screen. 
As this tissue is pathological in SMA it is more likely to show changes that are 
dependent on the loss of SMN, than for example blood. Taking muscle biopsies at 
different time points is difficult to achieve in a patient cohort. In addition all mice 
have an identical background and healthy littermates can be used as controls, which 
eliminates confounding factors. Since many factors can influence the expression 
levels of biomarkers (for example the time of day of the biopsy and differences in 
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diet), it is essential to minimize these confounding factors. After initial screening for 
biomarkers in a mouse model of SMA, these proteins need to be tested in patients to 
validate whether the expression levels are similar.  
 
4.3.4 GRP75 and/or calreticulin as a potential biomarker for SMA 
GRP75 is a member of the Hsp70 family of chaperones, with roles including the 
regulation of energy generation, stress responses, muscle activity, mitochondrial 
activity, and cellular viability (Bhattacharyya et al. 1995; Ornatsky et al. 1995; 
Takahashi et al. 1998). GRP75 has been previously been identified as a possible 
biomarker for cancer and cardiovascular diseases (Deocaris et al. 2009) as well as 
being a potential prognostic factor for neuroblastoma (Hsu et al. 2008). GRP75 (also 
known as HSPA9) has also been implicated in the pathogenesis of other 
neurodegenerative conditions, including Parkinson’s disease (De Mena et al. 2009) 
and Alzheimer’s disease (Osorio et al. 2007) suggesting that it may contribute 
directly to SMA pathogenesis. Nevertheless, it is important to note that biomarkers 
do not need to actively contribute to disease pathogenesis in order to be effective. 
What is critical is that the levels of a biomarker must alter in a temporally traceable 
and predictable manner as an accurate measure of the molecular and physiological 
processes of disease progression.  
 
Calreticulin is a multifunctional protein that has previously been identified as a 
potential biomarker for other diseases. For example, serum levels of calreticulin have 
been shown to increase in patients with rheumatoid arthritis (Ni et al. 2013) and 
increased levels of calreticulin have been reported in breast cancer (Gromov et al. 
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2010; Song et al. 2012), gastric cancer (Chen et al. 2009), and lung cancer (Liu et al. 
2012). Calreticulin has also been identified as a prognostic factor for neuroblastoma 
(Hsu et al. 2005). However, calreticulin has not previously been linked to SMA, and 
whether it is actively involved in disease pathogenesis or not remains unclear. 
Interestingly, calreticulin has been implicated in regulating motor neuron pathology 
in a related motor neuron disease (ALS; (Bernard-Marissal et al. 2012)), suggesting 
that further investigations into its possible contribution to the pathogenesis of SMA 
are warranted.  
 
4.3.5 Preliminary observations in human biopsies 
My preliminary investigation of GRP75 and calreticulin levels in human skeletal 
muscle suggests that these proteins may potentially represent viable biomarkers in 
SMA patients. However, this preliminary investigation represent nothing more than 
an initial demonstration of the ability to detect and measure these proteins in human 
tissue and was hampered by a lack of detailed information from the Biobank 
regarding the actual stage of disease progression each patient was at when the muscle 
biopsy was harvested as well as the very small sample size. As a result, further, 
large-scale studies on patient cohorts will now be required to validate GRP75 and 
calreticulin as robust protein biomarkers for SMA in humans.  
 
4.3.5 Future investigations 
The demonstration in mouse models that increased levels of these proteins correlated 
with increasing disease severity suggests that a study in patients is now warranted. 
Moreover, the finding that these proteins can be tracked in skin samples suggests that 
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the use of skin biopsies might be of more practical use for these studies, reducing the 
need for repeated invasive muscle biopsies. In light of clinical trial design the results 
showing that GRP75 and likely also calreticulin respond to treatment with TSA in a 
mouse model of SMA are very interesting since it suggests that GRP75 and 
calreticulin could be capable of reporting on responsiveness to treatment in 
individuals. Further work is now required to validate these potential protein 
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Chapter 5  
Disruption of ubiquitin homeostasis and  




Despite clear understanding of the genetic causes of SMA, the mechanisms linking 
low levels of SMN to disease pathogenesis remain unclear. SMN protein is known to 
play key roles in several core canonical cellular pathways, including snRNP 
biogenesis and pre-mRNA splicing (Burghes and Beattie 2009). However, attempts 
to link disruptions in RNA processing directly to SMA pathogenesis have proven 
controversial (Zhang et al. 2008; Baumer et al. 2009). The identification of SMN 
protein in neurite processes and neuronal growth cones in vitro (Fan and Simard 
2002) might suggest that SMN fulfils additional roles downstream from, or outside 
of RNA processing pathways in the nucleus and cell body. In addition, mutations in 
genes encoding proteins that are not directly involved in RNA processing can cause 
similar disease phenotypes. Mutations in the UBA1 gene have been identified to 
cause X-linked infantile spinal muscular atrophy (Ramser et al. 2008). 
 
In many neurodegenerative diseases degeneration of the synapse and distal axonal 
compartments precede the death of the cell body (Raff et al. 2002; Wishart et al. 
2006). Why these distal compartments are vulnerable is currently not known. In 
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spinal muscular atrophy, neuromuscular junctions (NMJs) are early pathological 
targets. Synaptic pathology at the NMJ is initiated before the onset of major clinical 
symptoms in a mouse model of SMA (Smn-/-;SMN2) (Murray et al. 2008).   
 
SMN protein is ubiquitously expressed and recent studies indicate that it is not only 
the neuromuscular system that is affected in SMA, also other parts of the nervous 
system tissues have been shown to be affected (for example low levels of SMN have 
been shown to affect the hippocampus (Wishart et al. 2010)) as well as organs, 
including heart (Shababi et al. 2010), vasculature (Somers et al. 2013), liver (Hua et 
al. 2011) and pancreas (Bowerman et al. 2012). This suggests that SMN deficiency 
causes perturbations across a wide range of cells and tissues in SMA, albeit with 
motor neurons being most vulnerable (Sleigh et al. 2011).  
 
In this chapter, I began by investigating whether SMN protein was localized and/or 
altered in the synapse in vivo in the central nervous system of SMA mice compared 
to littermate controls. Secondly, after having confirmed SMN protein expression in 
the synapse and decreased levels in synapses of SMA mice, an iTRAQ proteomics 
screen was performed to investigate the effect of low levels of SMN on protein 
expression levels in the synapse. This led to the identification of other molecular 
pathways downstream of SMN that are targeted in SMA. By using different animal 
models (mouse and zebrafish) novel roles for SMN were revealed in regulating 
ubiquitin homeostasis and β-catenin (CTNNB1, will be referred to as β-catenin 
throughout this thesis) signalling, perturbations in which are likely to contribute to 
the pathogenesis of SMA. 
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5.2 Results 
 
5.2.1 SMN protein is localized to axonal and synaptic compartments of 
neurons in vivo 
Previous results from the lab showed that neuromuscular junctions are early 
pathological targets in SMA (Murray et al. 2008). Motor neuron degeneration was 
observed in SMA mice (Smn-/-;SMN2) at a pre-symptomatic time point (P2) where 
the mice did not show major clinical symptoms (no weight loss or tremor compared 
to littermate controls).  Therefore the first purpose of experiments in this chapter was 
to determine whether SMN protein was present and functional in distal 
compartments of the neuron in vivo. In our lab, it was not possible to isolate 
neuromuscular junctions for biochemical studies, therefore synapses from the brain 
were isolated instead. I chose to isolate synapses from the hippocampus, as it has 
been shown that the hippocampus contains high levels of SMN in a healthy mouse 
brain. In SMA mice the levels are significantly reduced and this causes reduced 
levels of proliferation and neurogenesis as well as modified expression levels of 
proteins that regulate proliferation, migration and developmental processes (Wishart 
et al. 2010).  
 
In order to investigate the presence and role of SMN protein at the synapse, I made 
synaptosomes, which are isolated nerve terminals containing the complete pre-
synaptic terminal, including mitochondria and synaptic vesicles, along with the post-
synaptic membrane and the post-synaptic density. In brief, the hippocampus from 
both sides of the mouse brain was homogenized in a sucrose solution using a 
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homogenizer to help pinching off the synapses from the rest of the cell.  Several 
centrifugation steps were performed to obtain an enriched synaptic fraction and a 
non-synaptic fraction (containing nuclear proteins). To confirm that the 
synaptosomes were pure (no contamination of non-synaptic compartments) protein 
levels for histone H2B (nuclear protein) were checked and were only observed in the 
non-synaptic fraction. Synaptophysin was used as a marker of synaptic vesicles, and 












Figure 5.1 Representative fluorescent western blots showing the purity of 
synaptosome preparations from a wild-type mouse. The purity of the 
synaptosomes was demonstrated by the presence of a nuclear protein (Histone 
H2B) only in the non-synaptic fraction, with complete absence from the two synaptic 
fractions (synaptosomes without mitochondria and synaptic mitochondria). 
Synaptophysin was used as a marker of synaptic vesicles and COX IV was used as 
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Western blot experiments were performed on the synaptic fraction and confirmed 
that SMN protein was present in hippocampal synapses at postnatal day five (P5), 
with levels reduced in SMA mice (Smn-/-;SMN2, N=3 mice) compared to littermate 
wild-type (Smn+/+;SMN2, N=3 mice) and heterozygous (Smn+/-;SMN2, N=3 mice) 
controls (figure 5.2). Note that SMN protein was hardly detectable in synapses 
isolated from SMA mice and was reduced by approximately 50 % in synapses from 




Figure 5.2 Relative expression levels of SMN protein in hippocampal 
synaptosomes. Synaptosomes were made from wild-type mice (WT; 
Smn+/+;SMN2), heterozygous control mice (Het; Smn+/-;SMN2) and SMA mice (KO; 
Smn-/-;SMN2) at post-natal day five, quantified using fluorescent western blot (N=3 
mice per genotype). Note that SMN protein was still present, albeit at very low levels, 
in homozygous SMA mouse synapses, as a result of expression from the human 
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Previous work has shown that mitochondria are dysfunctional in an SMA cell line 
(Acsadi et al. 2009). Therefore an extra centrifugation step was introduced to 
specifically isolate mitochondria from the synapses to investigate whether SMN 
protein was present there. Surprisingly, SMN protein was also present in fractions of 




Figure 5.3 Quantification of SMN protein in subcellular fractions. Subcellular 
fractions were made from whole brain synaptosomes from wild-type mice (N=3 mice 
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Next I investigated whether a binding partner and part of the SMN complex, Gemin5, 
was present in synapses from the hippocampus as well as cerebellum. I used a 
Gemin5 (GEM5C) antibody produced by Glenn Morris’ Lab in Oswestry. In addition 
I compared a commercially available anti SMN antibody (BD SMN) and an anti 
SMN antibody produced by Glenn Morris’ Lab (ManSMN). As shown in figure 5.4, 
both primary antibodies showed SMN expression levels in synapses from both the 
hippocampus and cerebellum of wild-type mice (N=2 mice) when quantified using 
fluorescent western blots. Although the antibodies showed differences in the 
reactivity, both recognized SMN protein in synapses from hippocampus and 
cerebellum. Gemin5 protein was also present in synapses of hippocampus and 
cerebellum (figure 5.4). After the observation that both SMN and Gemin5 were 
present at the synapse a co-immunoprecipitation was performed to investigate 
whether SMN and Gemin5 physically interact in the synapse. Whole synaptosome 
extracts were sent to Glenn Morris’ Lab, where the co-immunoprecipitation was 
carried out. The synaptosome extracts were incubated with SMN, gemin5 or 
neurofilament (as a non-specific control) beads and bound proteins were eluted. The 
blot was developed with anti-SMN antibodies. Only the lanes with SMN or gemin5 
beads show a band for SMN (appendix 1). This result shows that gemin5 retained the 
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Figure 5.4 Gemin5, a binding partner of SMN is present in hippocampal and 
cerebellar synaptosomes. Bar charts (mean ± SEM) are showing protein levels of 
Actin, SMN and Gemin5 in hippocampal and cerebellar synaptosomes from WT 
mice (N=2). Note that two different SMN antibodies have been used, which show 














	   125	  
5.2.2 Assessing the functional consequences of SMN expression in synaptic 
mitochondria 
Given that SMN was found in synaptic mitochondria, and that mitochondrial stress 
has been implicated as a pathological mechanism in cell models of SMA (Acsadi et 
al. 2009), I tested whether mitochondria in synapses from SMA mice were more 
vulnerable to stress than those from control mice by investigating cytochrome C 
release from the mitochondria. Synaptosomes from whole brains of severe SMA 
mice (N=4 mice) and control littermate heterozygous mice (Smn+/-;SMN2, N=8 
mice) were prepared. I used whole brain synaptosomes in this case, to be able to 
obtain enough protein for analysis. The synaptosomes were resuspended in Krebs 
buffer supplemented with Ca2+Cl and left on a rocking platform in a 37 °C incubator 
to induce stress. At different time points (0, 0.5, 1, 2 and 3 hours) a sample was taken 
and RIPA buffer was used to break down the membranes of the synaptosomes and by 
spinning at 20 000 g all membrane bound proteins within the synaptosomes were 
formed into a pellet. The remaining supernatant contained all remaining soluble 
proteins from the synaptic cytosol (synaptosol). Synaptosolic fractionations were 
taken to measure cytochrome C levels using fluorescent quantitative western blotting.  
 
Cytochrome C is a pro-apoptotic protein released by mitochondria into the cytosol in 
response to stress (Liu et al. 1996). The data shown in figure 5.5 revealed that there 
was no difference in the release of cytochrome C following heat-induced stress 
between SMA mice and control mice at any time point (P>0.05; Mann Whitney test 
for each time point). Cytochrome C release was expressed as a percentage of 
maximum release. Maximum release observed in this assay, was between three and 
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four hours. After this time point the levels of cytochrome C were variable and 
dropped, suggesting that the synaptosomes were probably dying. This assay suggests 
that mitochondria in synapses from SMA mice are not more vulnerable than 





Figure 5.5 Ex vivo assay of cytochrome C release from synaptic mitochondria 
in whole brain synaptosomes. Whole brain synaptosomes from severe SMA mice 
(N=4 mice) and control heterozygous mice (SMN+/-;SMN2, N=8) measured by 
quantitative fluorescent western blotting. The graph shows cytochrome C release as 
a percentage of the maximum release (±SEM) for both SMA and heterozygous 
control mice. There was no difference in synaptic mitochondrial vulnerability 
(P>0.05; Mann Whitney test for each time point). 
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5.2.3 SMN protein is required for normal accumulation of β-actin mRNA at 
the synapse 
It has been proposed that SMN protein has a role in the transportation of β-actin 
mRNA to growth cones in vitro (Rossoll et al. 2003). Therefore I investigated 
whether SMN is involved in transportation of β-actin mRNA to the synapse in the 
synaptosomes in vivo. Brain synaptosomes from SMA and heterozygous control 
mice were made and RNA was extracted. The levels of mRNA in SMA mice and 
heterozygous control mice were compared to mRNA levels in wild-type 
synaptosomes. qRT-PCR was performed to test whether there was a difference in the 
amount of β-actin mRNA levels at the synapse in SMA mice and control littermates. 
I used two primer sets, which were designed against different parts of the β-actin 
RNA sequence (for sequences see material and methods chapter). To calculate the 
fold change I applied the equation 2-Δ(ΔCT), where CT (cycle threshold) is defined as 
the number of cycles required for the fluorescent signal to cross the threshold (i.e. to 
exceed background level) (Livak and Schmittgen 2001). In this PCR I did not use a 
housekeeping gene, because most housekeeping genes (for example GAPDH) are 
changed in SMA. Instead, I decided to use the CT value of WT β-actin RNA levels 
as a control.  ΔCT is calculated as CTtarget-CTcontrol. Therefore, in this study ΔCTSMA= 
CTβ-actinSMA-CTβ-actinWT and ΔCTHet = CTβ-actinHET-CTβ-actinWT. The mean of CTWT was 
calculated and subtracted to all ΔCTSMA and ΔCTHet values. The values were then 
named Δ(ΔCT). Then the fold change was calculated by applying the equation 2-
Δ(ΔCT). Figure 5.6 is showing that there was a clear trend towards a reduced level of β-
actin mRNA at the synapse in SMA mice compared to the levels in heterozygous 
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control mice. In addition levels of β-actin mRNA were similar between wild-type 




Figure 5.6 A reduction in β-actin mRNA levels in hippocampal synaptosomes. 
qRT-PCR using two different β-actin primer sets on hippocampal synaptosomes 
from SMA (N=3), heterozygous (N=2) and wild-type mice (N=1). This revealed a 
reduction in β-actin mRNA levels at the synapse in SMA mice. Bar chart shows fold 
change of β-actin mRNA in SMA mice and heterozygous mice as compared to wild-
type mice (mean ± SEM). 
 
 
5.2.4 iTRAQ proteomic screen reveals disruption in synaptic proteome of 
SMA mice 
To gain more insights into the downstream effects of SMN depletion in synaptic 
compartments of the neurons, an unbiased iTRAQ proteomic screen was performed 
to quantify alterations in the molecular composition. P1 synaptosomes were prepared 
from hippocampi from severe SMA and wild-type littermate controls (N=9 mice per 
genotype) for iTRAQ analysis. This age was chosen as the hippocampus develops 
normally and morphological changes appear at late-symptomatic time (P5). 
Therefore changes in protein levels would be due to reduced levels of SMN and not 
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as a consequence of disease progression. Samples were run in duplicate using the 4-
plex system (114 & 116 SMA mice and 115 & 117 control mice). After stringent 
filtering this screen identified 52 out of 150 (35%) unique proteins that had 
expression levels modified by more than 20 % in synapses from SMA mice compare 
to littermate controls (table 5.1 and 5.2).  This indicates a robust disruption of the 
synaptic proteome as a consequence of low levels of SMN protein.  
 
To identify specific molecular pathways and networks disrupted in the synapses of 
the hippocampus of SMA mice, an in silico pathway analysis was undertaken of the 
proteomics data set using Ingenuity Pathway Analysis software. For functional 
clustering analyses, the 52 proteins identified with the iTRAQ screen were uploaded 
in the software, and this revealed significant modifications in a range of pathways. 
The ubiquitination pathway, and UBA1 protein, (table 5.1 and 5.2; the red and purple 
marked proteins, table 5.3) were of special interest in the context of SMA because 
mutations in the gene coding for human UBA1 are sufficient to cause a genetically-
distinct form of the disease, known as X-linked infantile spinal muscular atrophy 
(Ramser et al. 2008). Moreover, ubiquitination pathways are known to regulate 
axonal and synaptic stability (DiAntonio et al. 2001; Korhonen and Lindholm 2004) 
as well as the stability and degradation of SMN protein itself (Chang et al. 2004; 
Burnett et al. 2009; Hsu et al. 2010). Another interesting pathway that was identified 
using this software was the PI3K/AKT signalling pathway. AKT phosphorylates β-
catenin, which increases its transcriptional activity and stimulates cell motility (Fang 
et al. 2007). 
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Table 5.1 Proteins with increased expression > 20 % in P1 synapses from SMA 
mice versus littermate controls 
  
Protein ID Protein name Score Mass Peptide Matches emPAI 
Ratio 
SMA/WT 
IPI00125899.1 Ctnnb1 Catenin beta-1 208 89934 5 0.03 4.21 
IPI00341282.2 Atp5f1 ATP synthase subunit b, mitochondrial 70 32503 3 0.1 3.42 
IPI00116279.3 Cct5 T-complex protein 1 subunit epsilon 65 66527 2 0.1 3.35 
IPI00230427.5 Mif Macrophage migration inhibitory factor 77 13244 2 0.25 2.33 
IPI00120457.1 Fdps Farnesyl pyrophosphate synthase 65 44789 2 0.07 2.21 
IPI00117264.1 Park7 Protein DJ-1 91 22542 2 0.14 2.19 
IPI00130280.1 Atp5a1 ATP synthase subunit alpha, mitochondrial 426 64441 9 0.21 2.09 
IPI00132728.2 Cyc1 Isoform 1 of Cytochrome c1, heme protein, mitochondrial 144 37695 3 0.08 1.98 
IPI00123494.3 Psmd2 26S proteasome non-ATPase regulatory subunit 2 168 108430 3 0.03 1.93 
IPI00407692.3 Atp6v1a Isoform 1 of V-type proton ATPase catalytic subunit A 122 73812 3 0.04 1.77 
IPI00323179.3 Gdi1 Rab GDP dissociation inhibitor alpha 396 55382 8 0.18 1.73 
IPI00313962.3 Uchl1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 296 27614 11 0.24 1.67 
IPI00312527.4 Crmp1 Crmp1 protein 205 79818 7 0.12 1.65 
IPI00555069.3 Pgk1 Phosphoglycerate kinase 1 112 50973 3 0.13 1.64 
IPI00222430.5 Dbi acyl-CoA-binding protein isoform 1 122 17726 3 0.18 1.62 
IPI00321190.1 Psap Sulfated glycoprotein 1 193 68883 5 0.09 1.60 
IPI00221402.7 Aldoa Fructose-bisphosphate aldolase A 77 43678 2 0.07 1.59 
IPI00117896.3 Mapre1 Microtubule-associated protein RP/EB family member 1 69 33627 2 0.09 1.59 
IPI00407130.4 Pkm2 Isoform M2 of Pyruvate kinase isozymes M1/M2 158 63854 7 0.15 1.55 
IPI00120030.1 Crym Mu-crystallin homolog 86 36123 2 0.09 1.54 
IPI00127987.1 Arpc1a Actin-related protein 2/3 complex subunit 1A 76 45628 2 0.07 1.52 
IPI00119113.3 Atp6v1b2 V-type proton ATPase subunit B, brain isoform 299 60171 6 0.05 1.47 
IPI00462072.3 Eno1;Gm5506 Alpha-enolase 146 52497 5 0.26 1.46 
IPI00118899.1 Actn4 Alpha-actinin-4 83 113581 3 0.06 1.46 
IPI00230707.6 Ywhag 14-3-3 protein gamma 925 31050 29 0.79 1.45 
IPI00129685.3 Tpt1 Translationally-controlled tumor protein 155 21725 4 0.15 1.42 
IPI00133903.1 Hspa9 Stress-70 protein, mitochondrial 82 81549 2 0.04 1.42 
IPI00113141.1 Cs Citrate synthase, mitochondrial 774 56023 20 0.18 1.42 
IPI00281011.7 Marcksl1 MARCKS-related protein 176 22948 5 0.3 1.40 
IPI00118821.2 Pafah1b2 Platelet-activating factor acetylhydrolase IB beta 136 27898 3 0.11 1.36 
IPI00624192.3 Dpysl5 Dihydropyrimidinase-related protein 5 207 66659 8 0.15 1.34 
IPI00119762.4 Dclk1 Doublecortin-like protein 150 65687 3 0.05 1.34 
IPI00330804.4 Hsp90aa1 Heat shock protein HSP 90-alpha 145 96806 4 0.07 1.32 
IPI00110684.1 Ppa1 Inorganic pyrophosphatase 91 37425 3 0.08 1.29 
IPI00229080.7 Hsp90ab1 Putative uncharacterized protein 134 94523 5 0.1 1.28 
IPI00110753.1 Tuba1a Tubulin alpha-1A chain 5994 53670 160 3.63 1.26 
IPI00116283.1 Cct3 T-complex protein 1 subunit gamma 43 66349 2 0.1 1.25 
IPI00117348.4 Tuba1b Tubulin alpha-1B chain 5770 53686 153 3.13 1.25 
IPI00405986.3 Epb4.1l1 Erythrocyte protein band 4.1-like 1 81 127928 2 0.02 1.24 
IPI00118986.1 Atp5o;LOC100047429 ATP synthase subunit O, mitochondrial 64 26576 2 0.12 1.22 
IPI00330754.1 Bdh1 D-beta-hydroxybutyrate dehydrogenase, mitochondrial 51 42061 2 0.07 1.21 
!
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Table 5.2 Proteins with decreased expression > 20 % in P1 synapses from SMA 




Table 5.3 Clustering analysis of proteomic data revealing functional pathways 
modified in P1 SMA mouse synapses 
  
Protein ID Protein name Score Mass Peptide Matches emPAI 
Ratio 
SMA/WT 
IPI00123313.1 Uba1 Ubiquitin-like modifier-activating enzyme 1 63 126857 2 0.02 0.43 
IPI00230194.5 Gng2 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 73 9112 2 0.37 0.54 
IPI00121550.3 Atp1b1 Sodium/potassium-transporting ATPase subunit beta-1 66 40182 2 0.08 0.56 
IPI00128973.1 Gap43 Neuromodulin 80 28200 2 0.24 0.65 
IPI00120719.4 Cox5a Cytochrome c oxidase subunit 5A, mitochondrial 78 17472 3 0.4 0.67 
IPI00554989.3 Ppia MCG121511, isoform CRA_b 336 20491 11 1.06 0.71 
IPI00457898.3 Pgam1 Phosphoglycerate mutase 1 157 31666 5 0.1 0.75 
IPI00128986.1 Tagln3 Transgelin-3 69 24645 2 0.13 0.76 
IPI00307837.6 Eef1a1 Elongation factor 1-alpha 1 122 57341 5 0.11 0.79 
IPI00115546.4 
Gnao1 Isoform Alpha-2 of Guanine nucleotide-binding protein G(o) 
alpha 140 44847 4 0.23 0.80 
IPI00308885.6 Hspd1 Isoform 1 of 60 kDa heat shock protein, mitochondrial 750 69014 15 0.05 0.80 
!
Pathway P Value Individual Proteins 
Oxidative Phosphorylation 1.61E-07 Atp5a1, Atp5f1, Atp6v1a, Cox5a, Cyc1, Ppa1 
Protein Ubiquitination 8.59E-06 Hsp90aa1, Hsp90ab1, Hspa9, Hspd1, Psmd2, Uba1, Uchl1 
Glycolysis/Gluconeugensis 1.14E-04 Aldoa, Pgam1, Pgk1, Pkm2 
Purine Metabolism 1.15E-04 Atp1b1, Atp5a1, Atp5f1, Hsp90aa1, Hspd1, Pkm2 
PI3K/AKT signaling 3.64E-04 Ctnnb1, Hsp90aa1, Hsp90ab1, Ywhag 
!
	  
	   132	  
5.2.5 UBA1 levels are also disrupted in the neuromuscular system 
The proteomics screen was performed on tissue from the central nervous system. In 
order to establish whether ubiquitin-dependent pathways were also modified in 
tissues belonging to the neuromuscular system, UBA1 protein levels were examined 
in preparations of spinal cord and skeletal muscle from severe SMA mice at P5. 
UBA1 levels were reduced by 50 % in spinal cord (figure 5.7A) and > 60 % in 
gastrocnemius (figure 5.7B) from SMA mice compared to littermate controls (N=3 
mice per genotype; ***P<0.001 and **P<0.01 unpaired, two-tailed t-test 
respectively). Beta V Tubulin was used as a loading control. This indicates a 
particular susceptibility of the neuromuscular system.  
 
 
Figure 5.7 UBA1 levels are decreased in spinal cord and muscle tissue in SMA 
mice. Bar charts (mean ± SEM) showing significant reduction in levels of UBA1 in 
the spinal cord (A) and skeletal muscle (B) from severe SMA mice at P5, compared 
to littermate controls, quantified using fluorescent western blot (N=3 mice per 
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5.2.6 Disruption of ubiquitin homeostasis directly correlates with SMN levels, 
and is reversible by treatment with Trichostatin A 
Treatment with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) 
elevates SMN protein levels in the spinal cord and muscle, and ameliorates 
neuromuscular and central nervous system synaptic pathology in SMA mice (Avila 
et al. 2007; Ling et al. 2012). TSA treatment was therefore used to establish whether 
perturbations in UBA1 were directly correlated with SMN levels, and to test whether 
changes in UBA1 level was reversible by pharmacological intervention.   
 
As a pilot experiment, SMA and littermate control pups were injected 
subcutaneously over the shoulders, into the loose skin over the neck with TSA (10 
mg/kg) from the day of birth (P1) until P4. A second litter was injected with DMSO 
only. The mice were weighed daily. No difference was observed in the weight 
between TSA injected and DMSO only injected SMA mice (figure 5.8; N=9 Control 
mice, N= 1 SMA mice with DMSO, N= 3 SMA mice with TSA). This could be due 
to the fact that SMN levels were not increased in the TSA injected SMA mice (figure 
5.9; N=9 Control mice, N= 1 SMA mice with DMSO, N= 3 SMA mice with TSA). 
Because subcutaneous injection did not increase the level of SMN protein, a second 
approach was undertaken.  
 
SMA mice and littermate controls were treated with TSA intra-peritoneally (10 
mg/kg daily) and compared with DMSO injected control mice. Again, mice were 
injected from the day of birth (P1) until P4 and were collected at P5. Previous trials 
with TSA were performed in the delta7 SMA mice (Avila et al. 2007; Mentis et al. 
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2011) because of their longer lifespan (14 days). Nevertheless, increased expression 
levels of SMN protein were observed in spinal cord of severe SMA mice treated with 
TSA compared to DMSO treated mice (figure 5.11A/B; N=5 Control mice, N=4 
SMA mice with DMSO, N=3 SMA mice with TSA; *P<0.05, ***P<0.001, ANOVA 
with Tukey’s post-hoc test). Also, levels of UBA1 were significantly increased in 
TSA-treated SMA mice, almost returning to levels found in littermate controls 
(figure 5.11A/C; N=6 Control mice, N=5 SMA mice with DMSO, N=4 SMA mice 
with TSA; **P<0.01, **P<0.01, ANOVA with Tukey’s post-hoc test). SMA mice 
treated with DMSO showed a loss of weight at P5, this was not observed in the SMA 
mice treated with TSA (figure 5.10; N=6 Control mice, N=5 SMA mice with DMSO, 
N=4 SMA mice with TSA; P>0.05, ANOVA with Tukey’s post-hoc test). This 
suggests that perturbations in UBA1 were both highly sensitive to SMN levels and 
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Figure 5.8 No weight gain in SMA mice after subcutaneous injection with TSA. 
Graph showing the weight curve of control mice (N=9), severe SMA mice treated 
with DMSO (N=1) and severe SMA mice treated with TSA subcutaneously (N=3). 




Figure 5.9 SMN levels are not increased after subcutaneous injections of TSA 
in severe SMA mice in spinal cord. (A) Representative fluorescent western blots 
showing levels of SMN in control mice, severe SMA mice treated with DMSO and 
severe SMA mice treated with TSA. Beta V tubulin was used as a loading control. 
(B) Bar charts (mean ± SEM) showing that SMN levels are dramatically decreased 
in SMA mice (N=1) as compared to littermate controls (N=9). Subcutaneous 
injection with TSA in SMA mice does not rescue the levels of SMN protein (N=3). 
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Figure 5.10 Modest increase in weight in SMA mice treated with TSA intra-
peritoneally. Graph showing the weight curve of control mice (N=6), severe SMA 
mice treated with DMSO (N=5) and severe SMA mice treated with TSA (N=4) intra-
peritoneally (P>0.05, ANOVA with Tukey’s post-hoc test). Note that SMA mice 
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Figure 5.11 Intra-peritoneal injection of TSA in severe SMA mice rescues 
levels of SMN and UBA1 in spinal cord. (A) Representative fluorescent western 
blots showing levels of SMN and UBA1 in control mice, severe SMA mice treated 
with DMSO and severe SMA mice treated with TSA. (B) Bar charts (mean ± SEM) 
showing slightly increased levels of SMN in SMA mice after TSA injection (N=5 
Control mice, N=4 SMA mice with DMSO, N=3 SMA mice with TSA; *P<0.05, 
***P<0.001, ANOVA with Tukey’s post-hoc test). (C) Bar charts (mean ± SEM) 
showing rescue of UBA1 levels in SMA mice after an intra-peritoneal injection with 
TSA (N=6 Control mice, N=5 SMA mice with DMSO, N=4 SMA mice with TSA; 
**P<0.01, **P<0.01, ANOVA with Tukey’s post-hoc test). Note that levels are 




5.2.7 Deregulation of UBA1 protein levels leads to accumulation of β-catenin 
in vitro 
UBA1 regulates the first stages of an enzymatic cascade in which ubiquitin 
molecules are ultimately conjugated to target proteins for proteasome degradation. 
Disruption of this cascade is often associated with a failure to degrade target proteins, 
resulting in their accumulation within the cell. Re-examination of the original 
proteomic dataset revealed one notable protein with such an accumulation: β-catenin 
levels were increased more than four fold in SMA mice compared to littermate 
controls (table 5.1).  
 
Β-catenin is a multifunctional protein; it is a central component of the cadherin cell 
adhesion complex (Aberle et al. 1994; Gumbiner 1997), regulating the control of cell 
adhesion and in addition it plays an essential role in various growth factor signal 
transduction pathways (Peifer 1995). One of these pathways is the PI3K/AKT 
signalling pathway (table 5.1 and 5.2; the blue and purple marked proteins, Table 
5.3). PI3K/AKT is an intracellular pathway important in apoptosis. Phosphorylation 
of β-catenin by AKT results in relocation of β-catenin to the nucleus and increases its 
transcriptional activity (Fang et al. 2007).  
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Beta catenin is also a known target of the ubiquitin-proteasome system (Aberle et al. 
1997). Phosphorylation of β-catenin by a multi-protein complex composed of tumor 
suppressor proteins adnomatous polyposis coli (APC), axin, and glycogen synthase 
kinase-3 (GSK3beta) is the trigger for its ubiquitination-dependent proteolysis 
(Peifer et al. 1994; Yost et al. 1996; Aberle et al. 1997; Orford et al. 1997).  
 
To investigate whether accumulation of β-catenin levels in SMA occur as a result of 
low UBA1 levels, I treated cells with a cell-permeable UBA1 inhibitor called UBEI-
41 (Balut et al. 2011) and measured the levels of β-catenin and beta III tubulin (used 
as a loading control). Primary rat hippocampal cultures and NSC-34 motor neuron-
like cell line were treated with 50 µM of this inhibitor for two hours or with DMSO 
alone. Both the primary neurons as well as the NSC34 cells showed a significantly 
increased level of β-catenin when treated with the UBA1 inhibitor compared to cells 
treated with DMSO alone (figure 5.12; ***P<0.001, ANOVA with Tukey’s post hoc 
test; N=12 coverslips DMSO, N=15 UBEI-41 for hippocampal neurons; N=19 
DMSO, N=18 UBEI-41 for NSC-34 cells). Interestingly, a direct comparison of 
responses in the two cell lines revealed significantly higher levels of β-catenin in the 
NSC-34 cells, showing consistency with the enhanced vulnerability of motor neurons 
in SMA (**P<0.01, ANOVA with Tukey’s post hoc test). These results suggest that 
UBA1 (or the whole ubiquitination pathway) is involved in maintaining normal 
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Figure 5.12 Cells show an increased level of β-catenin after treatment with a 
UBA1 inhibitor. Bar charts (mean ± SEM) showing that β-catenin levels are 
increased in primary cultures of rat hippocampal neurons and a motor neuron cell 
line (NSC-34) treated with 50 µM UBEI-41 for two hours (***P<0.001, ANOVA with 
Tukey’s post hoc test; N=12 coverslips DMSO, N=15 UBEI-41 for hippocampal 
neurons; N=19 DMSO, N=18 UBEI-41 for NSC-34 cells). Motor neurons were 
significantly more susceptible than hippocampal neurons (**P<0.01). 
  
 
5.2.8 Deregulation of UBA1 protein levels leads to accumulation of β-catenin 
in zebrafish and can be rescued by inhibition of β-catenin 
Based on the in vitro data, UBEI-41 can be used as a tool to mimic UBA1 inhibition 
and its downstream consequences can be investigated. Therefore a collaboration was 
instigated with C. Becker’s lab at the university of Edinburgh, to investigate whether 
UBA1 loss is directly contributing to disease pathogenesis and, in particular, motor 
neuron pathology in vivo. Zebrafish were treated with UBEI-41. At 10 µM UBEI-41, 
the majority of motor nerve abnormalities observed resulted from aberrant axonal 
branching. At 50 µM, however, only half of the motor nerve abnormalities observed 
!
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were a result of aberrant nerve branching, with the remainder of motor nerves 
revealing a more severe phenotype: short or missing motor axons (appendix 2). 
Importantly, these pathological events have been observed in motor axons in 
zebrafish models of SMA (McWhorter et al. 2003; Oprea et al. 2008).  The study 
performed by McWhorter et al. injected zebrafish embryos with morpholino 
antisense oligonucleotide at the one to four-cell stage to decrease levels of SMN 
protein. After 36 hours there was a 61 % decrease in SMA protein levels and the 
embryos showed defects in motor axon outgrowth and pathfinding during the first 
three days of development (McWhorter et al. 2003) (appendix 3). 
 
Since I showed that β-catenin levels were regulated by UBA1 in vitro, I designed an 
experiment to inhibit β-catenin in zebrafish treated with the UBA1 inhibitor. 
Zebrafish embryos were treated with the UBA1 inhibitor UBEI-41 and subsequently 
exposed to quercetin, a plant-derived flavonoid that robustly inhibits β-catenin 
signalling pathways by disrupting transcriptional activity of the β-catenin–Tcf 
complex (Park et al. 2005; Gelebart et al. 2008; Asuthkar et al. 2012). Treatment of 
zebrafish with motor neuron defects resulting from the addition of 50 µM UBEI-41 
with 25 µM or 50 µM quercetin revealed a dose-dependent rescue of the motor axon 
branching phenotype (appendix 2). Strikingly, in the zebrafish treated with 50 µM 
quercetin, the number of abnormal motor nerves was reduced to that observed in 
control zebrafish not exposed to the UBA1 inhibitor. Motor nerve abnormalities 
induced by inhibition of UBA1 in zebrafish were fully rescued by simultaneous 
inhibition of β-catenin signalling. In addition to the motor nerve disruptions observed, 
it was noted that exposure to UBEI-41 caused dose-dependent alteration of the gross 
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morphology of zebrafish embryos, manifesting as a bent body axis. These deficits 
were also corrected by treatment with quercetin (appendix 2). 
 
5.2.9 Inhibition of β-catenin signalling ameliorates neuromuscular pathology, 
but not systemic pathology in Taiwanese SMA mice 
Next I investigated whether pharmacological inhibition of β-catenin signalling with 
quercetin could have a similar effect on disease phenotype in SMA mice. For this 
drug trial I used the Taiwanese SMA mice (Smn-/-;SMN2tg/0 (Riessland et al. 2010)). 
These mice have a less severe phenotype and the mean survival is 10-11 days 
compared to 5-6 days in the severe SMA mice. Another advance of the Taiwanese 
SMA mice is that the breeding scheme allows 50% of the litter to be SMA mice 
(Smn-/-;SMN2tg/0) and 50 % to be control mice (Smn-/+;SMN2tg/0) (Riessland et al. 
2010).  
 
Quercetin was injected intra-peritoneal daily from the day of birth (P1). Mice were 
killed when they showed a decrease of 10 % in body-weight per day over two 
consecutive days or when the pups looked very ill (i.e. cold and dry skin and were 
not moving). A dose of 100 mg/kg, 50 mg/kg or 10 mg/kg were injected in the pups. 
I found that 100 mg/kg and 50 mg/kg was lethal, therefore I chose to continue with 
the 10 mg/kg dose. A parallel group of mice received injections of DMSO vehicle 
only (same volume as the mice received that were treated with quercetin). The 
treatment had no significant effect on neuromuscular function in SMA mice at pre-
symptomatic ages (the righting test; figure 5.13; P3, N=30 Het DMSO; N=27 KO 
DMSO; N=21 KO quercetin; Kruskal Wallis test with Dunn’s post hoc test). By 
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contrast, quercetin treatment significantly improved the performance of symptomatic 
(P6) SMA mice during this test (the righting test; figure 5.13; P6, N=31 Het DMSO; 
N=28 KO DMSO; N=27 KO quercetin; Kruskal Wallis test with Dunn’s post hoc 
test). Although quercetin treated mice often appeared much healthier than their 
DMSO-treated counterparts at late symptomatic stages (P10; figure 5.14), treatment 
with quercetin did not increase survival (figure 5.15; N=10 mice DMSO; N=13 
quercetin; P=0.9897 Chi-square test). In order to examine the possible causes of 
quercetin failing to ameliorate non-neuromuscular, systemic pathology, I quantified 
β-catenin levels in heart and liver from un-injected Taiwanese SMA mice. 
Surprisingly, β-catenin levels remained unchanged in heart and liver (figure 5.16A; 
N=3 mice per genotype; ***P< 0.001, ANOVA with Tukey’s post-hoc test). 
In contrast, reduced levels of UBA1 were present throughout all tissue and organ 
systems investigated (Figure 5.16B; N=3 mice per genotype; *P<0.05; **P<0.01; 
***P<0.001, ANOVA with Tukey’s post-hoc test). Thus, perturbations in β-catenin 
signalling pathways occurring downstream of disrupted ubiquitin homeostasis were 
restricted to the neuromuscular system, thereby revealing distinct mechanisms 
driving pathology in the neuromuscular system compared to other tissue and organ 
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Figure 5.13 Significant improvement in neuromuscular function (righting test) 
in symptomatic (P6) Taiwanese SMA mice. At P6 Taiwanese SMA (KO) mice 
treated with 10 mg/kg quercetin from birth show an improvement in neuromuscular 
function. Quercetin treatment had no significant effect on basal neuromuscular 
function pre-symptomatically at P3 (Kruskal Wallis test with Dunn’s post hoc test; P3, 
N=30 tests, Het DMSO; N=27 KO DMSO; N=21 KO quercetin; P6, N=31, Het 
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Figure 5.14 Quercetin treated Taiwanese SMA mice look healthier than 
Taiwanese SMA mice treated with DMSO. Taiwanese SMA mouse (left panel) 
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Figure 5.15 No improvement in survival after treatment with quercetin. Survival 
curve for Taiwanese SMA mice treated with 10 mg/kg quercetin (KO Quercetin) 
showing no significant difference compared to DMSO treated mice (P=0.9897 Chi-
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Figure 5.16 Β-catenin and UBA1 levels in spinal cord, liver and heart. (A) 
Levels of β-catenin in spinal cord, liver and heart of Taiwanese SMA mice at P10 
(KO) compared to littermate controls (Het), quantified using fluorescent western blot. 
Β-catenin was significantly increased in the spinal cord, but not in the liver or heart 
(N=3 mice per genotype; ANOVA with Tukey’s post-hoc test). (B) Levels of UBA1 
protein in the spinal cord, liver and heart of Taiwanese SMA mice at P10 (KO) 
compared to littermate controls (Het; normalised to 1), quantified using fluorescent 
western blot (N=3 mice per genotype; *P<0.05; **P<0.01;***P<0.001).This figure 




5.2.10 UCH-L1 enzyme regulates levels of β-catenin 
Another component of the ubiquitination pathway that was significantly changed in 
the proteomic screen was UCH-L1. This enzyme was increased in SMA 
hippocampal synapses by 1.7 fold. To test whether the increased expression of this 
enzyme had an effect on β-catenin levels, I used an UCH-L1 inhibitor to treat rat 
hippocampal neurons in culture (7 days old) and NSC-34 cells and subsequently 
measured the levels of β-catenin and ubiquitin (as a positive control for the 
efficiency of the drug). I tested different concentrations and durations of drug 
treatment. For an optimal effect in the NSC-34 cells the best concentration was 10 
µM and the best time for treatment was three hours. The scatter plots are shown as a 
percentage of the control (figure 5.17; N= 9 coverslips per time point, N= 6 
coverslips per treatment; *P<0.05, **P<0.01, Kruskal-Wallis test with Dunn’s post-
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Ubiquitin levels showed an increased trend over time, with the highest expression at 
three hours, but this did not reach significance (figure 5.18; N= 9 coverslips per time 
point, P>0.05, Kruskal-Wallis test with Dunn’s post-hoc test).  
 
In the rat hippocampal neurons the optimal conditions were a concentration of 5 µM 
for 1 hour. Both β-catenin and ubiquitin levels were increased under these conditions 
(figure 5.19 and 5.20; N = 12 coverslips per time point, *P<0.05, Kruskal-Wallis test 
with Dunn’s post-hoc test). These results suggest that UCH-L1 plays a role in 
maintaining the protein level of β-catenin in the cytoplasm.  
 
UCH-L1 is a complex enzyme as it performs many functions in the ubiquitination 
pathway (Liu et al. 2002). UCH-L1 monomer has a deubiquitinating function, where 
it removes ubiquitin from target proteins and it also stabilizes mono ubiquitin 
(Larsen et al. 1998; Osaka et al. 2003). When it is in its dimer form it ligases 
ubiquitin molecules to each other or to the target protein (Liu et al. 2002; Setsuie and 
Wada 2007).  It is therefore difficult to predict where an UCH-L1 inhibitor will act. 
In these experiments it seems that the ligase function was inhibited, because the 
ubiquitin levels (mono-ubiquitin levels were measured) were increased after 
treatment and so were β-catenin levels. Therefore it is possible that this specific 
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Figure 5.17 Β-catenin levels in NSC-34 cells after treatment with UCH-L1 
inhibitor. NSC-34 cells were treated with 10 µm of UCH-L1 inhibitor for 1/2h, 1h, 2h 
and 3h or with DMSO only (1h). There is a significant increase in β-catenin levels 
after 2h and 3h of treatment. The scatter plots are shown as a percentage of the 
control (N=9 coverslips per time point, **P<0.01, Kruskal-Wallis test with Dunn’s 
post-hoc test). NSC34 cells were treated with different concentrations of UCH-L1 
inhibitor (1 µM, 10 µM and 25 µM) for 1h. (*P<0.05; N=6 coverslips per treatment, 






Figure 5.18 Ubiquitin levels in NSC-34 cells after treatment with UCH-L1 
inhibitor. There is no significant increase in the levels of ubiquitin after 1/2h, 1h, 2h 
or 3h of treatment with 10 µM of UCH-L1 inhibitor. The scatter plots are shown as a 
percentage of the control (N=9 coverslips per time point, P>0.05, Kruskal-Wallis test 
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Figure 5.19 Β-catenin levels in primary hippocampal rat neurons after 
treatment with UCH-L1 inhibitor. Cells were treated with 5 µM UCH-L1 inhibitor 
for 1h, 3h, 6h or with DMSO only for 1h. There is a significant increase in β-catenin 
levels after treatment for 1h, but not after 3h or 6h. The scatter plots are shown as a 
percentage of the control (N=12 coverslips per time point, *P<0.05, Kruskal-Wallis 




Figure 5.20 Ubiquitin levels in primary hippocampal rat neurons after 
treatment with UCH-L1 inhibitor. Cells were treated with 5 µM UCH-L1 inhibitor 
for 1h, 3h, 6h or with DMSO only for 1h. There is a significant increase in ubiquitin 
levels after treatment for 1h, but not after 3h or 6h. The scatter plots are shown as a 
percentage of the control (N=12 coverslips per time point, *P<0.05, Kruskal-Wallis 
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5.2.11 Β-catenin protein levels are increased in muscle biopsies from SMA 
patients 
Finally, levels of β-catenin and UBA1 were measured in muscle biopsies from SMA 
patients and non-SMA controls. I had three SMA patient biopsies. SMA patient 1 
was four years of age and was diagnosed with type II SMA; SMA patient 2 was 25 
years of age and diagnosed with type III SMA; SMA patient 3 was three years of age 
and diagnosed with type II SMA. The control group consisted of samples from 
individuals between 17 and 27 years of age. The controls were all tested for 
mutations or deletions in the SMN1 gene. Although the levels of β-catenin varied 
among the SMA patients, overall there was a significant increase in the level of β-
catenin (figure 5.21; N=3 per group, **P<0.01 two tailed, unpaired t-test). Levels of 
UBA1 varied between the three control samples (figure 5.22). For example there is 
an almost two fold difference in UBA1 levels between control 1 and control 3. Based 
on the control samples, I concluded that it was not possible to measure levels of 
UBA1 in SMA patients, as the control samples were so variable and it would 
therefore not be possible to compare the SMA samples to the control samples.   
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Figure 5.21 Beta-catenin levels are increased in muscle biopsies from SMA 
patients. (A) Representative western blots for β-catenin levels in three control 
muscle samples and three SMA patient samples. (B) Graph showing significantly 
increased levels of β-catenin in muscle biopsies from SMA patients (**P<0.01; two-
tailed, unpaired t-test). 
  
	  





Figure 5.22 UBA1 levels are variable between human control samples. Graph is 
showing that there is variability in UBA1 levels between human control samples. 
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5.3 Discussion 
 
5.3.1 Overview of results 
The experiments described here were initiated to identify pathways downstream of 
SMN that contribute to SMA pathogenesis and have revealed a novel role for SMN 
in regulating ubiquitin homeostasis, mediated largely via interactions with UBA1. In 
addition, this study has identified β-catenin as a downstream target of 
UBA1/ubiquitination pathways in the neuromuscular system, with disruption of β-
catenin pathways in SMA. Pharmacological inhibition of β-catenin signalling using 
quercetin ameliorated neuromuscular pathology in zebrafish and in a mouse model of 
SMA. Whereas disruption of UBA1 was found to occur across a range of neuronal 
and non-neuronal organs in SMA mice, surprisingly, I found that downstream 
disruption of β-catenin was restricted to the neuromuscular system, and was not 
responsible for regulating SMN-dependent pathology in other tissues and organs. 
The findings here provide experimental evidence directly linking SMN protein to the 
regulation of ubiquitin homeostasis and β-catenin signalling in the neuromuscular 
system and also reveal fundamental molecular differences between pathways 
underlying neuromuscular and systemic pathology in SMA. 
 
5.3.2 SMN protein is localized at the synapse and synaptic mitochondria 
In the first part of this chapter it has been shown for the first time that SMN protein 
and one of its binding partners, Gemin5, were present at the synapse in vivo. In SMA 
mice the levels of SMN protein were significantly reduced. Gemin5 is a large 
tryptophan-asparticacid (WD) repeat protein and it binds directly to SMN in the 
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SMN complex (Gubitz et al. 2002; Gubitz et al. 2004). The presence of the multiple 
WD repeats (protein-protein interaction domains) implies that this protein is engaged 
in multiple protein interactions and might serve as a platform for the assembly of 
protein complexes (Gubitz et al. 2004). It has also been shown here that SMN and 
Gemin5 physically interact in the synaptosol. This indicates that the whole SMN 
complex might be present at the synapse and that SMN fulfils the same role as in the 
cell body in snRNP assembly, however it might have additional roles as well. 
 
The data in this chapter supports earlier results where SMN protein was found in 
axons and growth cones in vitro (Fan and Simard 2002; Rossoll et al. 2003). In 
addition, to confirm the presents of SMN protein at the synapse in vivo, a study 
performed in Drosophila, using pan-neuronally driven dSMN-YFP, showed that 
SMN protein was present in pre-synaptic boutons at the NMJ in third instar larvae as 
well as in neuronal cytoplasm and in axons of motor neurons and photoreceptors. As 
a control experiment dSMN-YFP was driven in muscle and this resulted in no 
fluorescent signal in pre-synaptic boutons (this study was performed in collaboration 
with Philip Young at the Universities of Exeter and Plymouth).   
 
Interestingly, SMN protein was also localized to synaptic mitochondria. The results 
from this chapter show that reduced levels of SMN do not have an effect on 
cytochrome C release from mitochondria. This means that synaptic mitochondrial 
mediated apoptosis cannot be a pathologic process in SMA. However, it cannot be 
ruled out that mitochondria have another role in pathology in SMA.  Previous work 
has shown that mitochondria are dysfunctional in an SMA cell line (i.e. NSC-34 cells 
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that were transfected with siRNA to decrease SMN levels; showing 66 % decreased 
levels of SMN protein after 72 hours). In their study they found that ATP levels were 
decreased suggesting that ATP production is decreased. In addition SMN knock-
down resulted in increased mitochondrial membrane potential and increased free 
radical production (Acsadi et al. 2009). Another study showed that the total active 
mitochondrial surface in the presynaptic terminals were reduced with approximately 
50% in the TVA muscle of delta7 SMA mice (Torres-Benito et al. 2011). Contrary to 
the results detailed in this chapter, one other study found that SMN protein localizes 
to microsomes but not to mitochondria (La Bella et al. 2000).  
 
5.3.3 Β-actin accumulation in the synapse is disrupted in a mouse model of 
SMA in vivo 
The results in this chapter suggest that low levels of SMN in the synapse cause 
disruption of the accumulation of β-actin mRNA. Β-actin mRNA is transported from 
the nucleus, where it is synthesized in most cases, to distal compartments of the 
neuron. Actin is pre-dominantly localized in growth cones and plays a major role in 
growth cone movements and neurite growth (Bassell et al. 1998). Previous studies 
report that SMN protein interacts with hnRNP R instead of Gemin2 in the growth 
cone (Rossoll et al. 2002). hnRNP R can bind to β-actin mRNA full length and this 
suggest that SMN, via binding to hnRNP R could be involved in the transportation of 
specific mRNAs in motor axons (Rossoll et al. 2003). Therefore, the results in this 
chapter can not specifically say whether low levels of β-actin mRNA in the synapse 
of SMA mice were caused by transportation failure or translation failure at the 
synapse due to low levels of SMN.  
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Future work would have to be carried out to investigate this question. A co-
immunoprecipitation on protein extracts from a peripheral nerve from SMA and 
control mice for SMN and hnRNP R would reveal whether there is a disruption in 
the binding of SMN to hnRNP R, which would disrupt the transportation of β-actin 
mRNA. 
 
5.3.4 A role for the ubiquitin/proteasome pathway in SMA 
The identification of changes in the synaptic proteome due to low levels of SMN led 
to the identification of changes in the Ubiquitin/proteasome pathway. Although it is 
known that SMN protein interacts with the ubiquitin-proteasome system in order to 
regulate its own stability (Chang et al. 2004; Burnett et al. 2009; Hsu et al. 2010), 
the results in this chapter significantly extends the understanding of the importance 
of these interactions to include a direct role for ubiquitin homeostasis in regulating 
SMA disease pathogenesis. When taken together with human genetic data showing 
that mutations in UBA1 cause similar pathological changes to those found in SMN-
dependent SMA (Ramser et al. 2008), the findings here suggest that perturbations in 
ubiquitin homeostasis, and UBA1 in particular, may represent a common molecular 
pathway underlying neuromuscular pathology across genetically-distinct forms of the 
disease. Moreover, the finding that perturbations in ubiquitin homeostasis in 
response to SMN deficiency, as well as dysregulation of β-catenin downstream of 
perturbations in UBA1, are evolutionarily conserved between mouse and zebrafish 
models, suggests that regulation of ubiquitin homeostasis represents a key biological 
role for SMN. 
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The identification of β-catenin as a key downstream target of ubiquitin pathways 
disrupted in SMA provides mechanistic insights into the pathways through which 
defects in ubiquitin homeostasis are transferred into pathological changes in the 
neuromuscular system. Although these pathways have not previously been linked to 
neuromuscular pathology in SMA, β-catenin signalling pathways are known to play 
an important role in regulating motor neuron differentiation and stability, including 
regulating synaptic structure and function (Murase et al. 2002; Li et al. 2008; Ojeda 
et al. 2011). Interestingly, Li et al. showed that motor neuron differentiation was 
regulated by retrograde signalling through β-catenin from skeletal muscle (Li et al. 
2008). The demonstration of robust amelioration of neuromuscular pathology in 
zebrafish and mouse models of SMA treated with quercetin highlights the fact that β-
catenin pathways in the neuromuscular system are amenable to pharmacological 
targeting in vivo. Thus, targeting β-catenin signalling pathways during the early 
stages of disease may represent an attractive therapeutic option for stabilizing the 
neuromuscular system in SMA, and possibly also related conditions. 
 
The pathway analysis software identified modifications in the PI3K/AKT pathway 
with the most significant change in levels of β-catenin. There are several 
mechanisms that regulate the activation of β-catenin. Β-catenin was originally 
identified as a component of cell-cell adhesion structures where it interacts with e-
cadherin and links e-cadherin to α-catenin, which in turn mediates anchorage of the 
e-cadherin complex to the cortical actin cytoskeleton (Rimm et al. 1995). Β-catenin 
functions also as a component of the canonical Wnt signalling pathway. Activation 
of the Wnt pathway inhibits the phosphorylation of β-catenin (Molenaar et al. 1996; 
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Liu et al. 2002). Stabilized hypophosphorylated β-catenin then translocates to the 
nucleus where it interacts with transcription factors of the TCF/LEF-1 family leading 
to the increased expression of genes, such as MYC and CCND1 (He et al. 1998; 
Shtutman et al. 1999; Tetsu and McCormick 1999). When Wnt signalling is not 
active β-catenin is phosphorylated by GSK-3β, which leads to its degradation by the 
ubiquitin/proteasome system (Aberle et al. 1997). In addition β-catenin translocates 
to the nucleus in response to epidermal growth factor (EGF) stimulation 
(Hoschuetzky et al. 1994). AKT, which is activated downstream from EGF receptor 
signalling, phosphorylates β-catenin at Ser552 in vitro and in vivo. AKT can activate 
β-catenin-TCF/LEF-1 transcriptional activity both by indirect stabilization of β-
catenin through inhibition of GSK-3β and direct phosphorylation of β-catenin, which 
enhances β-catenin nuclear accumulation and it translational activity (Fang et al. 
2007). 
 
Given that β-catenin is such a well-established target for the ubiquitin-proteasome 
system, and the magnitude of changes in β-catenin pathways observed in the 
neuromuscular system in SMA mice, it was surprising to find that quercetin 
treatment did not target systemic pathology in SMA. Our finding that β-catenin 
signalling pathways remained stable in tissues and organs outside the neuromuscular 
system explains the quercetin result, but also served to highlight an underappreciated 
complexity in molecular pathways underlying disease pathogenesis in SMA, 
implicating both β-catenin-dependent and β-catenin-independent pathways. These 
findings add significant additional support to the hypothesis that SMA is a multi-
system disorder. The contribution of non-neuromuscular, systemic pathology, 
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affecting tissues and organs such as the heart, liver, lungs, intestine and vasculature, 
has only recently been fully appreciated in SMA animal models (Hamilton and 
Gillingwater 2013). As a result, several studies have demonstrated that a failure to 
target peripheral tissues and organs minimises the effectiveness of therapeutics (Hua 
et al. 2011; Schreml et al. 2013). Moreover, they further highlight the likely 
requirement to deliver therapeutics targeting either the SMN1 or SMN2 gene 
systemically in order to fully rescue SMA symptoms (Hua et al. 2011). 
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Chapter 6  
A dopamine agonist does not ameliorate 
neuromuscular pathology in a mouse 




In this final chapter I investigated a different potentially interesting drug for 
treatment of SMA. A recent study showed that dopamine released from the brain 
promoted generation of motor neurons in the developing spinal cord in zebrafish 
(Reimer et al. 2013). In addition, dopamine promotes generation of motor neurons in 
the lesioned spinal cord in adult zebrafish (Reimer et al. 2013). Earlier studies had 
already shown that dopamine was important for the development of different tissue. 
In Drosophila, depletion of dopamine during the second instar results in 
developmental abnormalities and lethality (Neckameyer 1996). I investigated 
whether a dopamine-agonist would have a beneficial effect on the disease severity in 
the Taiwanese SMA mice. Since motor neurons degenerate from a very early stage 
of the disease, a dopamine-agonist could have a beneficial effect.  
R(-)-Propylnorapomorphine hydrochloride (NPA) is a potent and selective D2 
dopamine receptor agonist and has been shown to rescue motor neurons after 
reducing dopaminergic input from the brain by morpholino knock down of th1 (rate 
limiting enzyme for dopamine synthesis; (Reimer et al. 2013)) in zebrafish. This 
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suggests that endogenous dopamine is important for the development of motor 
neurons and that it can be substituted by dopaminergic drugs. 
I show here that a daily injection with 10 mg/kg of NPA does not ameliorate 
neuromuscular pathology in SMA, this includes number of axonal inputs and muscle 
fiber diameter.  
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6.2 Results 
 
6.2.1 Treatment with NPA does not increase weight of SMA mice 
R(-)-Propylnorapomorphine hydrochloride (NPA) was kept as a powder in the fridge. 
The drug was dissolved in a solution of sterile saline and 3% DMSO. Taiwanese 
SMA mice and littermate controls were injected with 10 mg/kg NPA from the day of 
birth (P1) until postnatal day 10 (P10). The mice were weighed daily. There was no 
difference observed in weight loss in the SMA mice treated with NPA compared to 
mice treated with DMSO (figure 6.1). Also the mice did not look healthier (i.e. same 





Figure 6.1 No increase in weight in SMA (KO NPA) mice treated with NPA 
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6.2.2 No improvement of neuromuscular pathology in SMA mice treated with 
NPA 
Since it has been shown that injecting dopaminergic drugs rescued motor neurons in 
zebrafish, I hypothesized that this would happen as well in a mouse model of SMA, 
where motor neurons start to degenerate soon after birth. To investigate this I studied 
the neuromuscular junctions (NMJs) from the Levator auris longus (LAL) and 
transversus abdominus (TVA) muscle from NPA treated SMA mice, DMSO treated 
SMA mice and control (Het) mice. If NPA rescues motor neurons this should be 
reflected in an amelioration of NMJ pathology. One way of measuring pathology is 
quantifying the number of axonal inputs on the endplate (figure 6.2A; axonal inputs 
are in green and the motor endplate is labelled in red). In Taiwanese SMA mice there 
is no widespread denervation as seen in the severe SMA mice (Murray et al. 2008), 
but instead these mice show an increased rate of axonal pruning.  
 
An increased rate of axonal pruning was confirmed in the LAL of Taiwanese mice, 
as the number of axonal inputs was significantly decreased in SMA mice (KO) 
compared to littermate controls (Het) (figure 6.2A/B top panel; *P<0.05, **P<0.01, 
ANOVA with Tukey’s post test). However, this pathology was not rescued by 
treatment with NPA (figure 6.2A/B). The TVA was less severely affected in the 
Taiwanese SMA mouse model. The number of axonal inputs in the TVA was not 
significantly different in Taiwanese SMA mice and control littermates, although 
there was a trend towards a smaller number of axonal inputs. As well as in the LAL, 
SMA mice treated with NPA did not show an improvement of axonal input numbers 
(figure 6.2A/B lower panel; P>0.05, ANOVA with Tukey’s post test). 
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Figure 6.2 Neuromuscular pathology is not rescued by treatment with NPA. 
(A) Confocal micrographs showing axons (in green labelled neurofilament) 
innervating endplates on the muscle fiber (in red post-synaptic acetylcholine 
receptors labelled with TRITC-α-BTX) in the Levator auris longus (LAL) and 
transversus abdominus (TVA) of control het mice, SMA mice (KO) and SMA mice 
treated with NPA (KO NPA) at P9. Note that some endplates are innervated by 
more than one axon. (B) Bar charts showing a decreased average axonal input per 
NMJ in SMA (KO) mice compared to littermate controls (Het) in the LAL. This is not 
rescued by treating SMA mice with NPA (N=3 per genotype; *P<0.05, **P<0.01, 
ANOVA with Tukey’s post test). In the TVA there is no difference in average axonal 
input per NMJ between SMA (KO) and control litters (Het) (N=3 per genotype; 
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In addition I investigated whether NPA had an effect on the development of the 
muscle fibers. The diameter of between 30 and 50 muscle fibers per mouse was 
measured in the LAL. I observed a decreased diameter in muscle fibers from SMA 
mice (KO) compared to littermate controls (Het). However, this was not rescued by 
treatment with NPA (figure 6.3A/B; P>0.05, *P<0.05, ANOVA with Tukey’s post 
test).  
Figure 6.3 Treatment with NPA does not rescue muscle fiber diameter in SMA 
mice. (A) Micrographs showing muscle fibers from Control (Het), SMA (KO DMSO) 
and SMA mice treated with NPA (KO NPA). (B) Bar charts (± SEM) showing a 
decreased diameter in SMA (KO) mice compared to littermate control (Het). NPA 
did not rescue the muscle fiber diameter in SMA mice (KO NPA; N=3 mice per 
genotype; P>0.05, *P < 0.05; ANOVA with Tukey’s post test). Scale bar = 30 µm. 
  
	  
	   166	  
6.3 Discussion 
 
6.3.1 Overview of results 
In this chapter I show that the potent and selective D2 dopamine receptor agonist 
NPA does not rescue neuromuscular pathology, such as number of axonal inputs and 
muscle fiber size, in Taiwanese SMA mice. This suggests that dopamine has no 
effect on motor neuron rescue in SMA. However, it has to be noted that I did not 
have a readout that the agonist targeted the receptors and was active. Taken this 
result in a wider perspective, it shows that not all drugs that are given to the SMA 
mice are working. This is in favour of the quercetin trial confirming that what we see 
there is a real result.  
 
6.3.2 Future work 
Dopamine has been identified as a factor influencing neurogenesis in the developing 
brain and adult brain in mice (Popolo et al. 2004; Yang et al. 2008). It has been 
proposed that dopamine acts in part through activating the hedgehog pathway. This 
is the major signalling pathway involved in the developmental generation of motor 
neurons (Lewis and Eisen 2001). In addition it has been shown that the dopaminergic 
neurons that invade the spinal cord during neuronal differentiation are descending 
from the diencephalic dopaminergic neurons (McLean and Fetcho 2004). A recent 
study identified dopamine from the brain as a promoter of the generation of motor 
neurons in the developing spinal cord at the expense of V2 interneurons in zebrafish. 
This has been shown to be important for the motor performance of free-swimming 
larvae (Reimer et al. 2013). SMN protein is highly active during embryonic and 
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early postnatal development of the central nervous system (Gabanella et al. 2005). 
One explanation that I did not observe a rescue with the dopamine receptor agonist 
could be that the administration of the drug was too late. Motor neurons might have 
started degeneration and the rescue was too late.  
In conclusion, the results that I show here are preliminary and further research is 
needed. The drug could be given to pregnant females to investigate whether the 
timing of the drug administration was too late.  A treatment like this has shown to be 
effective in SMA mice where the pregnant female received water with the drug 
(sodium butyrate) ad libitum (Chang et al. 2001). This increased the survival of the 
pups.  In addition it has to be noted that only one dose (10 mg/kg) of the drug was 
used, it might be that a higher dose of the drug is needed. This has not been tested.  
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Chapter 7  
General discussion 
 
7.1 Overview of results 
 
In this thesis four questions have been addressed.  
1. Is there a direct role for skeletal muscle in the pathogenesis of SMA? 
I show here for the first time that there are intrinsic molecular alterations in vivo 
in muscle tissue independent of denervation-induced changes. VDAC2 and 
parvalbumin were two proteins with changed expression identified in different 
muscles between two different mouse models of SMA. In addition the changed 
expression of VDAC2 and parvalbumin was also identified in muscle biopsies 
from SMA patients. Moreover, with the use of functional cluster analysis and 
H2AX labelling, I revealed increased activity of cell death pathways in SMA 
muscle. And finally, I show that the molecular alterations in muscle were rescued 
after treatment with the HDACi SAHA.  
2. Can biomarkers be identified in skeletal muscle? 
GRP75 and calreticulin have been identified as potential biomarkers for SMA in 
skeletal muscle. The expression levels of these two proteins were unchanged at 
pre-symptomatic ages but were increased at late-symptomatic ages. In addition, 
GRP75 and calreticulin were also readily measurable in skin samples and showed 
the same change in expression in SMA mice compared to littermate controls. 
Moreover, levels of GRP75 and calreticulin responded to treatment with the 
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HDAC inhibitor TSA in both muscle and skin and showed expression levels 
similar to that in control mice. Preliminary results suggest that GRP75 and 
calreticulin are detectable and measurable in muscle samples from SMA patients 
and controls. 
3. Can new pathways involved in disease pathogenesis be identified?  
I propose a new role for SMN protein in regulating the ubiquitination pathway, 
mediated largely via interactions with UBA1.  In addition I show that β-catenin is 
a downstream target of the ubiquitination pathway in the neuromuscular system 
and that restoration of β-catenin levels does ameliorate neuromuscular pathology 
in zebrafish and in SMA mice. Interestingly, I found that β-catenin levels were 
not changed in non-neuronal tissue, suggesting that there are fundamental 
molecular differences between pathways underlying neuromuscular and systemic 
pathology in SMA. 
4. Does a dopamine agonist ameliorate SMA phenotype in a mouse model of SMA? 
I show that increasing dopamine levels in the brain does not ameliorate 
neuromuscular pathology in SMA mice. 
 
The work presented here has significantly contributed to the knowledge of disease 
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7.2 The importance of a new role for SMN protein 
 
Although the pathogenesis of SMA has been investigated extensively, and many new 
insights have been gained, the disease mechanism is still not fully understood. SMN 
protein is ubiquitously expressed and it is known to play key roles in generating 
small nuclear ribonucleoproteins (snRNPs) by combining small nuclear RNA 
(snRNA) molecules with Sm proteins, which leads to an impairment of pre-mRNA 
splicing (Liu et al. 1997). An additional role for SMN protein is in the stabilization 
and maturation of the neuromuscular junction. By moving along granules in the 
axons it plays an important role in the transportation of mRNAs in motor neurons 
(Fan and Simard 2002). Β-actin mRNA depends on SMN to be transported to the 
growth cones (Rossoll et al. 2003). This is disrupted in SMA and therefore motor 
neurons have shorter axons and smaller growth cones (Rossoll et al. 2003). Even 
though these roles for SMN are known, it is still not know how low levels of SMN 
cause the neuromuscular system to degenerate in SMA. Therefore additional 
functions of SMN protein are expected. In addition it has becoming increasingly 
clear that other cell types and tissues are also vulnerable to low levels of SMN 
(Hamilton and Gillingwater 2013). The discovery of skeletal muscle pathology in 
this thesis supports the hypothesis that it is not only motor neurons that are affected. 
Importantly, the results in this thesis show muscle pathology independent of 
deneravation induced degeneration of the muscle. Despite the evidence provided in 
this thesis supporting a direct role for SMN in skeletal muscle, the extent to which 
intrinsic skeletal muscle pathology contributes to SMA pathogenesis is still not clear 
and will need further investigation. 
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In addition I identified SMN protein in mitochondria, which could imply that there 
are addition roles for SMN that are not yet discovered. Mitochondria are important 
for intracellular ATP, buffering of intracellular calcium, the generation of 
intracellular free radicals and involvement in the initiation of apoptotic cell death 
(Shaw 2005). Moreover, mitochondrial dysfunction has been suggested to contribute 
to motor neuron injury in an adult form of motor neuron disease, amyotrophic lateral 
sclerosis (ALS). In ALS patients, alterations in the morphology of mitochondria in 
muscle and motor neurons have been identified as well as increased mitochondrial 
volume and calcium levels within motor axon terminals in muscle biopsies (Siklos et 
al. 1996; Beal 2000).  
 
Taken together the identification of new roles for SMN will lead to a better 
understanding of disease pathogenesis in SMA and subsequently to new targets for 
the treatment of SMA. In addition the identification of a new role for SMN in 
regulating the ubiquitination pathway and subsequent β-catenin levels is potentially 
important. The observation that the treatment with the β-catenin inhibitor 
ameliorated the neuromuscular pathology but did not increase the survival of the 
mice, suggested that non-neuronal tissues were not targeted by this treatment. This 
further suggests that not only the neuromuscular system should be targeted but also 
other tissues. Nevertheless, the identification of disruption of the ubiquitination 
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7.3 Proteomics techniques in neuroscience research 
 
The term proteome was first used in 1995 to describe the protein complement of a 
genome. The proteome is much more complex than either the genome or the 
transcriptome (figure 7.1). While it is estimated that the human genome comprises 
between 20 000 and 25 000 genes (number obtained from the international Human 
Genome Sequencing Consortium), the total number of proteins in the human 
proteome is estimated at over 1 million (Jensen 2004). This is because each protein 
can be chemically modified in different ways after translation (post-translation 
modification). A few examples of post-translation modification are phosphorylation, 
glycosylation, ubiquitination and methylation (Lebrilla and Mahal 2009).  
 
Proteomics is the large-scale study of proteins, particularly their structures and 
functions. Proteomics is important because proteins represent the actual functional 
molecules in the cell. When mutations occur in the DNA, it is the proteins that are 
ultimately affected. In addition proteins do not act on their own but interact with 
other proteins and most drugs act on targeting proteins. Therefore I have been 
studying the proteome of different tissues from SMA mice. In chapters three, four 
and five, proteomic techniques were used to get an insight in the molecular changes 
in either muscle (chapter three and four) or synapses (chapter five) in SMA. Both are 
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Figure 7.1 Proteome complexity. This figure illustrates the complexity of the 
proteome. This is mainly due to post-translational modifications. Proteins are the 
functional molecules of the cell and are the main targets for drug treatment. Figure 
obtained from piercenet.com. 	  
 
Proteomics is a well-established technique in neuroscience research. There are two 
main quantitative methods: gel-based, two-dimensional gel electrophoresis (2-DE) 
and the more recently developed, non-gel-based liquid chromatography/mass 
spectrometry (LC/MS)-based profiling. 2-DE has been employed for protein 
separation since 1975 and it enables the separation of complex mixtures of proteins 
according to charge and molecular weight (Gorg et al. 2004). 2-DE gel-based 
methods are robust and reproducible but as a disadvantage labour-intensive. LC/MS 
techniques in contrast, have strength in analysing more complex protein samples and 
have a greater proteome coverage (Bantscheff et al. 2007). Quantitative results can 
be gained using stable isotope labels or label-free methods (Bantscheff et al. 2007; 
Patel et al. 2009).  Isotope labels can be introduced as an internal standard into 
amino acids metabolically, chemically or enzymatically (Gygi et al. 1999). The 
common feature among these proteomic methods is that stable isotopes provide for 
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the quantitation (relative or absolute) of proteins, based upon a well-characterized 
increase in molecular mass in the protein or peptide of interest. For example iTRAQ 
(isobaric Tags for Relative and Absolute Quantitation) proteomics is based on 
covalent labelling of the N-terminus and side chain amines of peptides from protein 
digestions with tags of varying mass, which are then analysed by the mass 
spectrometer. In label-free methods two or more experiments are compared by direct 
mass spectrometric signal intensity for any given peptide (Bantscheff et al. 2007).  
 
Proteomics allow for example to identify molecular difference in healthy versus 
disease tissue or how tissue response to a drug treatment. In SMA and also in other 
neuroscience research fields, proteomic techniques are now more frequently used. A 
few recent examples using iTRAQ proteomics are: a study investigating the possible 
side-effects of valproic acid (VPA) in SMA patient fibroblasts (Fuller et al. 2010) 
and Wishart et al. investigated changes in brain regions in SMA mice and identified 
molecular changes in the hippocampus (Wishart et al. 2010). In addition an in vitro 
study was performed on SMN-deficient embryonic stem cells from severe SMA 
mice and they identified activated cellular stress pathways that cause a dysregulation 
of energy metabolism, protein degradation and cytoskeleton stability (Wu et al. 
2011). In other neuroscience fields, proteomic studies are used to answer similar 
questions. A proteomic study was performed to enable a greater understanding of 
alterations in the presynaptic molecular composition after induction of repeated 
morphine administration (Abul-Husn et al. 2011). This allowed the identification of 
potential therapeutic targets for opiate dependence and addiction. Another example is 
a comparative proteomic study where the researchers tried to establish global effects 
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of motor neuron disease on the proteome of skeletal muscle from the wobbler mouse 
(animal model for motor neuron disease (Staunton et al. 2011)).  
 
In this thesis I have used proteomics to discover molecular alterations in muscle 
tissue from SMA mice, to identify biomarkers, and to identify new molecular 
pathways that are involved in SMA.  This shows that proteomics is a very powerful 
tool and can be used to answer a wide range of questions.  
 
7.4 Ubiquitin pathology in neurodegenerative disease  
 
The ubiquitin-proteasome system is one of the routes of protein and organelle 
clearance in eukaryotic cell (Rubinsztein 2006). Disruptions in this system has been 
linked to several neurodegenerative diseases. Accumulation of ubiquitin conjugates 
and/or inclusion bodies associated with ubiquitin have been reported in for example 
neurofibriallary tangles of Alzheimer’s disease, brainstem Lewy bodies in 
Parkinsons’ disease and also in Bunina bodies in ALS (Alves-Rodrigues et al. 1998; 
Shaw 2005). In the SOD1 mouse (a mouse model for ALS; (Gurney et al. 1994) a 
mutated form of the SOD1 protein forms aggregates in the cytoplasm of motor 
neurons and sometimes in astrocytes. These aggregates seem to form before the 
onset of motor dysfunction (Shaw 2005). The identification of disruption in the 
ubiquitination pathway in SMA mice, might therefore add SMA to the list of 
neurodegenerative disease that involve problems in the clearance and accumulation 
of proteins. The disruption of the ubiquitin pathway resulted in increased levels of β-
catenin in motor neurons and muscle in SMA mice. It is not known if the β-catenin 
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forms aggregates in the cytoplasm and via this way produces cellular toxicity leading 





Taken together, I have shown here potentially new targets for treatment in spinal 
muscular atrophy. First of all, alterations in muscle have been identified independent 
of motor neuron denervation, suggesting that muscle is an important target in disease 
pathology. Secondly, I show that ubiquitin homeostasis and β-catenin signalling is 
disrupted due to low levels of SMN in the neuromuscular system. In addition 
ubiquitin homeostasis is also disrupted in other tissues. These new insights will 
hopefully lead to new discoveries for treatment. And last but not least I identified 
two potential biomarkers in muscle and skin from SMA mice. This will hopefully 
help with the improvement of drug trials/clinical trials for SMA.  
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Appendices 
 
Appendix 1  
 
Co-immunoprecipitation of Gemin5 and SMN 
 
Gemin5 and SMN maintain the ability to physically interact in the synapse. 
Representative bands from an immunoprecipitation experiment where whole 
synaptosome extracts were incubated with SMN, gemin5 or neurofilament (as a 
non-specific control) beads and bound proteins were eluted, subject to separation 
by SDS-PAGE and transferred to nitrocellulose by western blotting. The blot was 
developed with anti-SMN antibodies. All lanes loaded with SDS extracts of beads 
contain a 50 kDa band of mouse Ig heavy chain which reacts with the HRP anti-
mouse Ig used to develop the blot. Only the lanes with SMN or gemin5 beads bound 
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Appendix 2 
 
 Deregulation of UBA1 protein levels leads to accumulation of β-catenin in 
zebrafish and can be rescued by inhibition of β-catenin 
 
Rescue of UBA1-dependent motor axon defects in zebrafish by 
pharmacological inhibition of β-catenin signalling. (A) Representative confocal 
micrographs showing three segments of Tg(hb9:gfp) zebrafish embryos from the 
trunk region. Note the severe branching phenotype of the motor nerves in the UBEI-
41 treated animal. This phenotype was rescued by quercetin treatment. Scale bar = 
30 µm. (B) Dose-dependent increase in numbers of aberrant motor axons in the 
UBEI-41-treated group compared to DMSO controls. This phenotype was rescued 
by quercetin in a dose-dependent manner (DMSO controls n=331 nerves, N=14 
animals; 10 µM UBEI-41 n=258, N=11; 50 µM UBEI-41 n=280, N=12; 50 µM UBEI-
41 + 25 µM Quercetin n=143, N=6; 50 µM UBEI-41 + 50 µM Quercetin n=168, N=7; 
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Kruskal Wallis test with Dunn’s post hoc test). (C) Representative overview images 
showing body axis defects in zebrafish embryos after UBEI-41 treatment compared 
to DMSO control. Note the rescue of this gross phenotype following application of 
50 µM quercetin.  
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Appendix 3  
 




Motor axons/nerves are abnormal in embryos injected with 9 ng of smn MO. 
Figure taken from (McWhorter et al. 2003) to show the comparision with UBA1 
deficient zebrafish. (A/B) Western blot analysis of WT uninjected (lanes 1 and 3), 
control MO–injected (lane 2), and smn MO–injected (9 ng) (lane 4) embryos at 36 h. 
Hu-C, a neuronal marker, is shown as a loading control. Lateral views of whole-
mount embryos labelled with znp1 mAb at 27 (C–E) and 36 h (F–H) in embryos 
injected with control MO (C and F) or smn MO (D, E, G, and H). Truncated motor 
axons/nerves (D and G; black arrowheads) and branched motor axons/nerves (E 
and H; black arrows) occur when Smn protein levels are further reduced. Bars: (C–
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